id	sid	tid	token	lemma	pos
dpc-3630	1	1	dermatology	dermatology	NOUN
dpc-3630	1	2	:	:	PUNCT
dpc-3630	1	3	practical	practical	ADJ
dpc-3630	1	4	and	and	CCONJ
dpc-3630	1	5	conceptual	conceptual	ADJ
dpc-3630	1	6	original	original	ADJ
dpc-3630	1	7	article	article	NOUN
dpc-3630	1	8	|	|	ADV
dpc-3630	1	9	dermatol	dermatol	ADJ
dpc-3630	1	10	pract	pract	NOUN
dpc-3630	1	11	concept	concept	NOUN
dpc-3630	1	12	.	.	PUNCT
dpc-3630	2	1	2024;14(3):e2024103	2024;14(3):e2024103	NUM
dpc-3630	2	2	1	1	NUM
dpc-3630	2	3	prevalence	prevalence	NOUN
dpc-3630	2	4	of	of	ADP
dpc-3630	2	5	multiple	multiple	ADJ
dpc-3630	2	6	sclerosis	sclerosis	NOUN
dpc-3630	2	7	in	in	ADP
dpc-3630	2	8	vitiligo	vitiligo	ADJ
dpc-3630	2	9	patients	patient	NOUN
dpc-3630	2	10	and	and	CCONJ
dpc-3630	2	11	their	their	PRON
dpc-3630	2	12	first	first	ADJ
dpc-3630	2	13	-	-	PUNCT
dpc-3630	2	14	degree	degree	NOUN
dpc-3630	2	15	relatives	relative	NOUN
dpc-3630	2	16	:	:	PUNCT
dpc-3630	2	17	two	two	NUM
dpc-3630	2	18	diseases	disease	NOUN
dpc-3630	2	19	with	with	ADP
dpc-3630	2	20	similarities	similarity	NOUN
dpc-3630	2	21	in	in	ADP
dpc-3630	2	22	pathogenesis	pathogenesis	NOUN
dpc-3630	2	23	and	and	CCONJ
dpc-3630	2	24	treatment	treatment	NOUN
dpc-3630	2	25	mohammadreza	mohammadreza	NOUN
dpc-3630	2	26	kavyani1,2	kavyani1,2	PROPN
dpc-3630	2	27	,	,	PUNCT
dpc-3630	2	28	vahideh	vahideh	PROPN
dpc-3630	2	29	lajevardi1,2	lajevardi1,2	PROPN
dpc-3630	2	30	,	,	PUNCT
dpc-3630	2	31	maryam	maryam	PROPN
dpc-3630	2	32	ghiasi1,2	ghiasi1,2	PROPN
dpc-3630	2	33	,	,	PUNCT
dpc-3630	2	34	maryam	maryam	PROPN
dpc-3630	2	35	daneshpazhooh1,2	daneshpazhooh1,2	PROPN
dpc-3630	2	36	,	,	PUNCT
dpc-3630	2	37	sama	sama	PROPN
dpc-3630	3	1	heidari1,2	heidari1,2	PROPN
dpc-3630	3	2	,	,	PUNCT
dpc-3630	3	3	amir	amir	PROPN
dpc-3630	3	4	teimourpour1,2	teimourpour1,2	PROPN
dpc-3630	3	5	,	,	PUNCT
dpc-3630	3	6	kamran	kamran	PROPN
dpc-3630	3	7	balighi1,2	balighi1,2	PROPN
dpc-3630	3	8	1	1	NUM
dpc-3630	3	9	department	department	NOUN
dpc-3630	3	10	of	of	ADP
dpc-3630	3	11	dermatology	dermatology	NOUN
dpc-3630	3	12	,	,	PUNCT
dpc-3630	3	13	razi	razi	PROPN
dpc-3630	3	14	hospital	hospital	PROPN
dpc-3630	3	15	,	,	PUNCT
dpc-3630	3	16	tehran	tehran	PROPN
dpc-3630	3	17	university	university	PROPN
dpc-3630	3	18	of	of	ADP
dpc-3630	3	19	medical	medical	ADJ
dpc-3630	3	20	sciences	sciences	PROPN
dpc-3630	3	21	,	,	PUNCT
dpc-3630	3	22	tehran	tehran	PROPN
dpc-3630	3	23	,	,	PUNCT
dpc-3630	3	24	iran	iran	PROPN
dpc-3630	3	25	2	2	NUM
dpc-3630	3	26	autoimmune	autoimmune	ADJ
dpc-3630	3	27	bullous	bullous	ADJ
dpc-3630	3	28	diseases	disease	NOUN
dpc-3630	3	29	research	research	NOUN
dpc-3630	3	30	center	center	NOUN
dpc-3630	3	31	,	,	PUNCT
dpc-3630	3	32	razi	razi	PROPN
dpc-3630	3	33	hospital	hospital	PROPN
dpc-3630	3	34	,	,	PUNCT
dpc-3630	3	35	tehran	tehran	PROPN
dpc-3630	3	36	university	university	PROPN
dpc-3630	3	37	of	of	ADP
dpc-3630	3	38	medical	medical	ADJ
dpc-3630	3	39	sciences	sciences	PROPN
dpc-3630	3	40	,	,	PUNCT
dpc-3630	3	41	tehran	tehran	PROPN
dpc-3630	3	42	,	,	PUNCT
dpc-3630	3	43	iran	iran	PROPN
dpc-3630	3	44	key	key	ADJ
dpc-3630	3	45	words	word	NOUN
dpc-3630	3	46	:	:	PUNCT
dpc-3630	3	47	autoimmune	autoimmune	ADJ
dpc-3630	3	48	,	,	PUNCT
dpc-3630	3	49	multiple	multiple	ADJ
dpc-3630	3	50	sclerosis	sclerosis	NOUN
dpc-3630	3	51	,	,	PUNCT
dpc-3630	3	52	neurological	neurological	ADJ
dpc-3630	3	53	,	,	PUNCT
dpc-3630	3	54	prevalence	prevalence	NOUN
dpc-3630	3	55	,	,	PUNCT
dpc-3630	3	56	vitiligo	vitiligo	NOUN
dpc-3630	3	57	citation	citation	NOUN
dpc-3630	3	58	:	:	PUNCT
dpc-3630	3	59	kavyani	kavyani	PROPN
dpc-3630	3	60	m	m	PROPN
dpc-3630	3	61	,	,	PUNCT
dpc-3630	3	62	lajevardi	lajevardi	PROPN
dpc-3630	3	63	v	v	NOUN
dpc-3630	3	64	,	,	PUNCT
dpc-3630	3	65	ghiasi	ghiasi	NOUN
dpc-3630	3	66	m	m	PROPN
dpc-3630	3	67	,	,	PUNCT
dpc-3630	3	68	et	et	PROPN
dpc-3630	3	69	al	al	PROPN
dpc-3630	3	70	.	.	PUNCT
dpc-3630	4	1	prevalence	prevalence	NOUN
dpc-3630	4	2	of	of	ADP
dpc-3630	4	3	multiple	multiple	ADJ
dpc-3630	4	4	sclerosis	sclerosis	NOUN
dpc-3630	4	5	in	in	ADP
dpc-3630	4	6	vitiligo	vitiligo	ADJ
dpc-3630	4	7	patients	patient	NOUN
dpc-3630	4	8	and	and	CCONJ
dpc-3630	4	9	their	their	PRON
dpc-3630	4	10	first	first	ADJ
dpc-3630	4	11	-	-	PUNCT
dpc-3630	4	12	degree	degree	NOUN
dpc-3630	4	13	relatives	relative	NOUN
dpc-3630	4	14	:	:	PUNCT
dpc-3630	4	15	two	two	NUM
dpc-3630	4	16	diseases	disease	NOUN
dpc-3630	4	17	with	with	ADP
dpc-3630	4	18	similarities	similarity	NOUN
dpc-3630	4	19	in	in	ADP
dpc-3630	4	20	pathogenesis	pathogenesis	NOUN
dpc-3630	4	21	and	and	CCONJ
dpc-3630	4	22	treatment	treatment	NOUN
dpc-3630	4	23	.	.	PUNCT
dpc-3630	5	1	dermatol	dermatol	NOUN
dpc-3630	5	2	pract	pract	PROPN
dpc-3630	5	3	concept	concept	NOUN
dpc-3630	5	4	.	.	PUNCT
dpc-3630	6	1	2024;14(3):e2024103	2024;14(3):e2024103	X
dpc-3630	6	2	.	.	X
dpc-3630	6	3	doi	doi	PROPN
dpc-3630	6	4	:	:	PUNCT
dpc-3630	6	5	https://doi.org	https://doi.org	PROPN
dpc-3630	6	6	/10.5826	/10.5826	PROPN
dpc-3630	6	7	/	/	SYM
dpc-3630	6	8	dpc.1403a103	dpc.1403a103	NUM
dpc-3630	6	9	accepted	accept	VERB
dpc-3630	6	10	:	:	PUNCT
dpc-3630	6	11	january	january	PROPN
dpc-3630	6	12	18	18	NUM
dpc-3630	6	13	,	,	PUNCT
dpc-3630	6	14	2024	2024	NUM
dpc-3630	6	15	;	;	PUNCT
dpc-3630	6	16	published	publish	VERB
dpc-3630	6	17	:	:	PUNCT
dpc-3630	7	1	july	july	PROPN
dpc-3630	7	2	2024	2024	NUM
dpc-3630	7	3	copyright	copyright	NOUN
dpc-3630	7	4	:	:	PUNCT
dpc-3630	7	5	©	©	PROPN
dpc-3630	7	6	2024	2024	NUM
dpc-3630	7	7	kavyani	kavyani	NOUN
dpc-3630	7	8	et	et	PROPN
dpc-3630	7	9	al	al	PROPN
dpc-3630	7	10	.	.	PUNCT
dpc-3630	8	1	this	this	PRON
dpc-3630	8	2	is	be	AUX
dpc-3630	8	3	an	an	DET
dpc-3630	8	4	open	open	ADJ
dpc-3630	8	5	-	-	PUNCT
dpc-3630	8	6	access	access	NOUN
dpc-3630	8	7	article	article	NOUN
dpc-3630	8	8	distributed	distribute	VERB
dpc-3630	8	9	under	under	ADP
dpc-3630	8	10	the	the	DET
dpc-3630	8	11	terms	term	NOUN
dpc-3630	8	12	of	of	ADP
dpc-3630	8	13	the	the	DET
dpc-3630	8	14	creative	creative	ADJ
dpc-3630	8	15	commons	common	NOUN
dpc-3630	8	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-3630	8	17	license	license	NOUN
dpc-3630	8	18	(	(	PUNCT
dpc-3630	8	19	by	by	ADP
dpc-3630	8	20	-	-	PUNCT
dpc-3630	8	21	nc-4.0	nc-4.0	NOUN
dpc-3630	8	22	)	)	PUNCT
dpc-3630	8	23	,	,	PUNCT
dpc-3630	8	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-3630	8	25	,	,	PUNCT
dpc-3630	8	26	which	which	PRON
dpc-3630	8	27	permits	permit	VERB
dpc-3630	8	28	unrestricted	unrestricted	ADJ
dpc-3630	8	29	noncommercial	noncommercial	ADJ
dpc-3630	8	30	use	use	NOUN
dpc-3630	8	31	,	,	PUNCT
dpc-3630	8	32	distribution	distribution	NOUN
dpc-3630	8	33	,	,	PUNCT
dpc-3630	8	34	and	and	CCONJ
dpc-3630	8	35	reproduction	reproduction	NOUN
dpc-3630	8	36	in	in	ADP
dpc-3630	8	37	any	any	DET
dpc-3630	8	38	medium	medium	NOUN
dpc-3630	8	39	,	,	PUNCT
dpc-3630	8	40	provided	provide	VERB
dpc-3630	8	41	the	the	DET
dpc-3630	8	42	original	original	ADJ
dpc-3630	8	43	authors	author	NOUN
dpc-3630	8	44	and	and	CCONJ
dpc-3630	8	45	source	source	NOUN
dpc-3630	8	46	are	be	AUX
dpc-3630	8	47	credited	credit	VERB
dpc-3630	8	48	.	.	PUNCT
dpc-3630	9	1	funding	funding	NOUN
dpc-3630	9	2	:	:	PUNCT
dpc-3630	9	3	none	none	NOUN
dpc-3630	9	4	.	.	PUNCT
dpc-3630	10	1	competing	compete	VERB
dpc-3630	10	2	interests	interest	NOUN
dpc-3630	10	3	:	:	PUNCT
dpc-3630	10	4	none	none	NOUN
dpc-3630	10	5	.	.	PUNCT
dpc-3630	11	1	authorship	authorship	NOUN
dpc-3630	11	2	:	:	PUNCT
dpc-3630	11	3	all	all	DET
dpc-3630	11	4	authors	author	NOUN
dpc-3630	11	5	have	have	AUX
dpc-3630	11	6	contributed	contribute	VERB
dpc-3630	11	7	significantly	significantly	ADV
dpc-3630	11	8	to	to	ADP
dpc-3630	11	9	this	this	DET
dpc-3630	11	10	publication	publication	NOUN
dpc-3630	11	11	.	.	PUNCT
dpc-3630	12	1	corresponding	correspond	VERB
dpc-3630	12	2	author	author	NOUN
dpc-3630	12	3	:	:	PUNCT
dpc-3630	12	4	kamran	kamran	PROPN
dpc-3630	12	5	balighi	balighi	PROPN
dpc-3630	12	6	,	,	PUNCT
dpc-3630	12	7	razi	razi	PROPN
dpc-3630	12	8	hospital	hospital	PROPN
dpc-3630	12	9	,	,	PUNCT
dpc-3630	12	10	vahdat	vahdat	NOUN
dpc-3630	12	11	eslami	eslami	PROPN
dpc-3630	12	12	square	square	PROPN
dpc-3630	12	13	,	,	PUNCT
dpc-3630	12	14	tehran	tehran	PROPN
dpc-3630	12	15	,	,	PUNCT
dpc-3630	12	16	iran	iran	PROPN
dpc-3630	12	17	.	.	PUNCT
dpc-3630	13	1	email	email	NOUN
dpc-3630	13	2	:	:	PUNCT
dpc-3630	13	3	kamran.balighi@yahoo.com	kamran.balighi@yahoo.com	X
dpc-3630	13	4	introduction	introduction	NOUN
dpc-3630	13	5	:	:	PUNCT
dpc-3630	13	6	vitiligo	vitiligo	PROPN
dpc-3630	13	7	is	be	AUX
dpc-3630	13	8	a	a	DET
dpc-3630	13	9	common	common	ADJ
dpc-3630	13	10	pigmentation	pigmentation	NOUN
dpc-3630	13	11	disorder	disorder	NOUN
dpc-3630	13	12	manifested	manifest	VERB
dpc-3630	13	13	by	by	ADP
dpc-3630	13	14	white	white	ADJ
dpc-3630	13	15	macules	macule	NOUN
dpc-3630	13	16	and	and	CCONJ
dpc-3630	13	17	patches	patch	NOUN
dpc-3630	13	18	.	.	PUNCT
dpc-3630	14	1	it	it	PRON
dpc-3630	14	2	is	be	AUX
dpc-3630	14	3	accompanied	accompany	VERB
dpc-3630	14	4	by	by	ADP
dpc-3630	14	5	some	some	DET
dpc-3630	14	6	autoimmune	autoimmune	ADJ
dpc-3630	14	7	and	and	CCONJ
dpc-3630	14	8	neurological	neurological	ADJ
dpc-3630	14	9	diseases	disease	NOUN
dpc-3630	14	10	.	.	PUNCT
dpc-3630	15	1	recently	recently	ADV
dpc-3630	15	2	,	,	PUNCT
dpc-3630	15	3	it	it	PRON
dpc-3630	15	4	has	have	AUX
dpc-3630	15	5	been	be	AUX
dpc-3630	15	6	suggested	suggest	VERB
dpc-3630	15	7	that	that	SCONJ
dpc-3630	15	8	multiple	multiple	ADJ
dpc-3630	15	9	sclerosis	sclerosis	NOUN
dpc-3630	15	10	(	(	PUNCT
dpc-3630	15	11	ms	ms	NOUN
dpc-3630	15	12	)	)	PUNCT
dpc-3630	15	13	is	be	AUX
dpc-3630	15	14	more	more	ADV
dpc-3630	15	15	common	common	ADJ
dpc-3630	15	16	in	in	ADP
dpc-3630	15	17	vitiligo	vitiligo	ADJ
dpc-3630	15	18	patients	patient	NOUN
dpc-3630	15	19	and	and	CCONJ
dpc-3630	15	20	that	that	SCONJ
dpc-3630	15	21	they	they	PRON
dpc-3630	15	22	have	have	VERB
dpc-3630	15	23	a	a	DET
dpc-3630	15	24	higher	high	ADJ
dpc-3630	15	25	risk	risk	NOUN
dpc-3630	15	26	of	of	ADP
dpc-3630	15	27	developing	develop	VERB
dpc-3630	15	28	ms	ms	NOUN
dpc-3630	15	29	during	during	ADP
dpc-3630	15	30	their	their	PRON
dpc-3630	15	31	lifetime	lifetime	NOUN
dpc-3630	15	32	.	.	PUNCT
dpc-3630	16	1	objectives	objective	NOUN
dpc-3630	16	2	:	:	PUNCT
dpc-3630	16	3	in	in	ADP
dpc-3630	16	4	this	this	DET
dpc-3630	16	5	study	study	NOUN
dpc-3630	16	6	,	,	PUNCT
dpc-3630	16	7	we	we	PRON
dpc-3630	16	8	aimed	aim	VERB
dpc-3630	16	9	to	to	PART
dpc-3630	16	10	determine	determine	VERB
dpc-3630	16	11	the	the	DET
dpc-3630	16	12	prevalence	prevalence	NOUN
dpc-3630	16	13	of	of	ADP
dpc-3630	16	14	ms	ms	NOUN
dpc-3630	16	15	in	in	ADP
dpc-3630	16	16	patients	patient	NOUN
dpc-3630	16	17	with	with	ADP
dpc-3630	16	18	vitiligo	vitiligo	NOUN
dpc-3630	16	19	and	and	CCONJ
dpc-3630	16	20	their	their	PRON
dpc-3630	16	21	first	first	ADJ
dpc-3630	16	22	-	-	PUNCT
dpc-3630	16	23	degree	degree	NOUN
dpc-3630	16	24	relatives	relative	NOUN
dpc-3630	16	25	and	and	CCONJ
dpc-3630	16	26	compare	compare	VERB
dpc-3630	16	27	it	it	PRON
dpc-3630	16	28	with	with	ADP
dpc-3630	16	29	the	the	DET
dpc-3630	16	30	prevalence	prevalence	NOUN
dpc-3630	16	31	in	in	ADP
dpc-3630	16	32	the	the	DET
dpc-3630	16	33	population	population	NOUN
dpc-3630	16	34	.	.	PUNCT
dpc-3630	17	1	methods	method	NOUN
dpc-3630	17	2	:	:	PUNCT
dpc-3630	17	3	in	in	ADP
dpc-3630	17	4	this	this	DET
dpc-3630	17	5	cross	cross	ADJ
dpc-3630	17	6	-	-	ADJ
dpc-3630	17	7	sectional	sectional	ADJ
dpc-3630	17	8	study	study	NOUN
dpc-3630	17	9	,	,	PUNCT
dpc-3630	17	10	data	datum	NOUN
dpc-3630	17	11	were	be	AUX
dpc-3630	17	12	consecutively	consecutively	ADV
dpc-3630	17	13	collected	collect	VERB
dpc-3630	17	14	from	from	ADP
dpc-3630	17	15	patients	patient	NOUN
dpc-3630	17	16	referred	refer	VERB
dpc-3630	17	17	to	to	ADP
dpc-3630	17	18	razi	razi	PROPN
dpc-3630	17	19	hospital	hospital	PROPN
dpc-3630	17	20	from	from	ADP
dpc-3630	17	21	march	march	PROPN
dpc-3630	17	22	2020	2020	NUM
dpc-3630	17	23	to	to	ADP
dpc-3630	17	24	december	december	PROPN
dpc-3630	17	25	2021	2021	NUM
dpc-3630	17	26	.	.	PUNCT
dpc-3630	18	1	results	result	NOUN
dpc-3630	18	2	:	:	PUNCT
dpc-3630	18	3	seven	seven	NUM
dpc-3630	18	4	hundred	hundred	NUM
dpc-3630	18	5	and	and	CCONJ
dpc-3630	18	6	nine	nine	NUM
dpc-3630	18	7	patients	patient	NOUN
dpc-3630	18	8	with	with	ADP
dpc-3630	18	9	vitiligo	vitiligo	NOUN
dpc-3630	18	10	participated	participate	VERB
dpc-3630	18	11	in	in	ADP
dpc-3630	18	12	this	this	DET
dpc-3630	18	13	study	study	NOUN
dpc-3630	18	14	,	,	PUNCT
dpc-3630	18	15	and	and	CCONJ
dpc-3630	18	16	15	15	NUM
dpc-3630	18	17	reported	report	VERB
dpc-3630	18	18	a	a	DET
dpc-3630	18	19	history	history	NOUN
dpc-3630	18	20	of	of	ADP
dpc-3630	18	21	ms	ms	NOUN
dpc-3630	18	22	(	(	PUNCT
dpc-3630	18	23	2.12	2.12	NUM
dpc-3630	18	24	%	%	NOUN
dpc-3630	18	25	,	,	PUNCT
dpc-3630	18	26	95	95	NUM
dpc-3630	18	27	%	%	NOUN
dpc-3630	18	28	confidence	confidence	NOUN
dpc-3630	18	29	interval	interval	NOUN
dpc-3630	19	1	[	[	X
dpc-3630	19	2	ci	ci	X
dpc-3630	19	3	]	]	X
dpc-3630	19	4	1.06%-3.17	1.06%-3.17	NUM
dpc-3630	19	5	%	%	NOUN
dpc-3630	19	6	)	)	PUNCT
dpc-3630	19	7	.	.	PUNCT
dpc-3630	20	1	this	this	DET
dpc-3630	20	2	rate	rate	NOUN
dpc-3630	20	3	was	be	AUX
dpc-3630	20	4	significantly	significantly	ADV
dpc-3630	20	5	higher	high	ADJ
dpc-3630	20	6	than	than	ADP
dpc-3630	20	7	the	the	DET
dpc-3630	20	8	prevalence	prevalence	NOUN
dpc-3630	20	9	of	of	ADP
dpc-3630	20	10	ms	ms	NOUN
dpc-3630	20	11	in	in	ADP
dpc-3630	20	12	the	the	DET
dpc-3630	20	13	average	average	ADJ
dpc-3630	20	14	population	population	NOUN
dpc-3630	20	15	of	of	ADP
dpc-3630	20	16	tehran	tehran	PROPN
dpc-3630	20	17	(	(	PUNCT
dpc-3630	20	18	p	p	X
dpc-3630	20	19	<	<	X
dpc-3630	20	20	0.001	0.001	NUM
dpc-3630	20	21	)	)	PUNCT
dpc-3630	20	22	.	.	PUNCT
dpc-3630	21	1	of	of	ADP
dpc-3630	21	2	the	the	DET
dpc-3630	21	3	2886	2886	NUM
dpc-3630	21	4	first	first	ADJ
dpc-3630	21	5	degree	degree	NOUN
dpc-3630	21	6	relatives	relative	NOUN
dpc-3630	21	7	of	of	ADP
dpc-3630	21	8	the	the	DET
dpc-3630	21	9	patients	patient	NOUN
dpc-3630	21	10	,	,	PUNCT
dpc-3630	21	11	10	10	NUM
dpc-3630	21	12	had	have	VERB
dpc-3630	21	13	ms	ms	NOUN
dpc-3630	21	14	(	(	PUNCT
dpc-3630	21	15	0.35	0.35	NUM
dpc-3630	21	16	%	%	NOUN
dpc-3630	21	17	,	,	PUNCT
dpc-3630	21	18	95%ci	95%ci	NUM
dpc-3630	21	19	0.13&-0.56	0.13&-0.56	NOUN
dpc-3630	21	20	%	%	NOUN
dpc-3630	21	21	)	)	PUNCT
dpc-3630	21	22	,	,	PUNCT
dpc-3630	21	23	which	which	PRON
dpc-3630	21	24	was	be	AUX
dpc-3630	21	25	higher	high	ADJ
dpc-3630	21	26	than	than	ADP
dpc-3630	21	27	the	the	DET
dpc-3630	21	28	prevalence	prevalence	NOUN
dpc-3630	21	29	of	of	ADP
dpc-3630	21	30	ms	ms	PROPN
dpc-3630	21	31	,	,	PUNCT
dpc-3630	21	32	yet	yet	ADV
dpc-3630	21	33	not	not	PART
dpc-3630	21	34	statistically	statistically	ADV
dpc-3630	21	35	significant	significant	ADJ
dpc-3630	21	36	.	.	PUNCT
dpc-3630	22	1	conclusions	conclusion	NOUN
dpc-3630	22	2	:	:	PUNCT
dpc-3630	22	3	a	a	DET
dpc-3630	22	4	significant	significant	ADJ
dpc-3630	22	5	association	association	NOUN
dpc-3630	22	6	between	between	ADP
dpc-3630	22	7	vitiligo	vitiligo	PROPN
dpc-3630	22	8	and	and	CCONJ
dpc-3630	22	9	ms	ms	PROPN
dpc-3630	22	10	was	be	AUX
dpc-3630	22	11	observed	observe	VERB
dpc-3630	22	12	,	,	PUNCT
dpc-3630	22	13	which	which	PRON
dpc-3630	22	14	should	should	AUX
dpc-3630	22	15	be	be	AUX
dpc-3630	22	16	of	of	ADP
dpc-3630	22	17	clinical	clinical	ADJ
dpc-3630	22	18	and	and	CCONJ
dpc-3630	22	19	therapeutic	therapeutic	ADJ
dpc-3630	22	20	importance	importance	NOUN
dpc-3630	22	21	.	.	PUNCT
dpc-3630	23	1	however	however	ADV
dpc-3630	23	2	,	,	PUNCT
dpc-3630	23	3	the	the	DET
dpc-3630	23	4	prevalence	prevalence	NOUN
dpc-3630	23	5	of	of	ADP
dpc-3630	23	6	ms	ms	NOUN
dpc-3630	23	7	in	in	ADP
dpc-3630	23	8	first	first	ADJ
dpc-3630	23	9	-	-	PUNCT
dpc-3630	23	10	degree	degree	NOUN
dpc-3630	23	11	relatives	relative	NOUN
dpc-3630	23	12	of	of	ADP
dpc-3630	23	13	vitiligo	vitiligo	ADJ
dpc-3630	23	14	patients	patient	NOUN
dpc-3630	23	15	was	be	AUX
dpc-3630	23	16	higher	high	ADJ
dpc-3630	23	17	than	than	ADP
dpc-3630	23	18	the	the	DET
dpc-3630	23	19	average	average	ADJ
dpc-3630	23	20	rate	rate	NOUN
dpc-3630	23	21	,	,	PUNCT
dpc-3630	23	22	yet	yet	ADV
dpc-3630	23	23	not	not	PART
dpc-3630	23	24	statistically	statistically	ADV
dpc-3630	23	25	significant	significant	ADJ
dpc-3630	23	26	.	.	PUNCT
dpc-3630	24	1	abstract	abstract	ADJ
dpc-3630	24	2	2	2	NUM
dpc-3630	24	3	original	original	ADJ
dpc-3630	24	4	article	article	NOUN
dpc-3630	24	5	|	|	ADV
dpc-3630	24	6	dermatol	dermatol	ADJ
dpc-3630	24	7	pract	pract	NOUN
dpc-3630	24	8	concept	concept	NOUN
dpc-3630	24	9	.	.	PUNCT
dpc-3630	25	1	2024;14(3):e2024103	2024;14(3):e2024103	NUM
dpc-3630	25	2	introduction	introduction	NOUN
dpc-3630	25	3	vitiligo	vitiligo	NOUN
dpc-3630	25	4	is	be	AUX
dpc-3630	25	5	the	the	DET
dpc-3630	25	6	most	most	ADV
dpc-3630	25	7	common	common	ADJ
dpc-3630	25	8	chronic	chronic	NOUN
dpc-3630	25	9	acquired	acquire	VERB
dpc-3630	25	10	pigmentation	pigmentation	NOUN
dpc-3630	25	11	disorder	disorder	NOUN
dpc-3630	25	12	with	with	ADP
dpc-3630	25	13	an	an	DET
dpc-3630	25	14	autoimmune	autoimmune	ADJ
dpc-3630	25	15	basis	basis	NOUN
dpc-3630	25	16	.	.	PUNCT
dpc-3630	26	1	it	it	PRON
dpc-3630	26	2	manifests	manifest	VERB
dpc-3630	26	3	as	as	ADP
dpc-3630	26	4	white	white	ADJ
dpc-3630	26	5	macules	macule	NOUN
dpc-3630	26	6	and	and	CCONJ
dpc-3630	26	7	patches	patch	NOUN
dpc-3630	26	8	due	due	ADJ
dpc-3630	26	9	to	to	ADP
dpc-3630	26	10	progressive	progressive	ADJ
dpc-3630	26	11	loss	loss	NOUN
dpc-3630	26	12	of	of	ADP
dpc-3630	26	13	melanocytes	melanocyte	NOUN
dpc-3630	26	14	in	in	ADP
dpc-3630	26	15	various	various	ADJ
dpc-3630	26	16	areas	area	NOUN
dpc-3630	26	17	[	[	X
dpc-3630	26	18	1,2	1,2	NUM
dpc-3630	26	19	]	]	PUNCT
dpc-3630	26	20	.	.	PUNCT
dpc-3630	27	1	the	the	DET
dpc-3630	27	2	latest	late	ADJ
dpc-3630	27	3	estimate	estimate	NOUN
dpc-3630	27	4	of	of	ADP
dpc-3630	27	5	the	the	DET
dpc-3630	27	6	worldwide	worldwide	ADJ
dpc-3630	27	7	prevalence	prevalence	NOUN
dpc-3630	27	8	of	of	ADP
dpc-3630	27	9	vitiligo	vitiligo	NOUN
dpc-3630	27	10	varies	vary	VERB
dpc-3630	27	11	from	from	ADP
dpc-3630	27	12	0.004	0.004	NUM
dpc-3630	27	13	%	%	NOUN
dpc-3630	27	14	to	to	PART
dpc-3630	27	15	2.28	2.28	NUM
dpc-3630	27	16	%	%	NOUN
dpc-3630	27	17	[	[	X
dpc-3630	27	18	3	3	NUM
dpc-3630	27	19	]	]	PUNCT
dpc-3630	27	20	.	.	PUNCT
dpc-3630	28	1	the	the	DET
dpc-3630	28	2	disease	disease	NOUN
dpc-3630	28	3	can	can	AUX
dpc-3630	28	4	occur	occur	VERB
dpc-3630	28	5	at	at	ADP
dpc-3630	28	6	any	any	DET
dpc-3630	28	7	age	age	NOUN
dpc-3630	28	8	and	and	CCONJ
dpc-3630	28	9	in	in	ADP
dpc-3630	28	10	any	any	DET
dpc-3630	28	11	gender	gender	NOUN
dpc-3630	28	12	,	,	PUNCT
dpc-3630	28	13	but	but	CCONJ
dpc-3630	28	14	women	woman	NOUN
dpc-3630	28	15	are	be	AUX
dpc-3630	28	16	more	more	ADV
dpc-3630	28	17	commonly	commonly	ADV
dpc-3630	28	18	treated	treat	VERB
dpc-3630	28	19	[	[	PUNCT
dpc-3630	28	20	4	4	NUM
dpc-3630	28	21	]	]	PUNCT
dpc-3630	28	22	.	.	PUNCT
dpc-3630	29	1	vitiligo	vitiligo	PROPN
dpc-3630	29	2	has	have	AUX
dpc-3630	29	3	been	be	AUX
dpc-3630	29	4	reported	report	VERB
dpc-3630	29	5	to	to	PART
dpc-3630	29	6	be	be	AUX
dpc-3630	29	7	associated	associate	VERB
dpc-3630	29	8	with	with	ADP
dpc-3630	29	9	other	other	ADJ
dpc-3630	29	10	autoimmune	autoimmune	ADJ
dpc-3630	29	11	diseases	disease	NOUN
dpc-3630	29	12	such	such	ADJ
dpc-3630	29	13	as	as	ADP
dpc-3630	29	14	autoimmune	autoimmune	ADJ
dpc-3630	29	15	thyroid	thyroid	NOUN
dpc-3630	29	16	disease	disease	NOUN
dpc-3630	29	17	,	,	PUNCT
dpc-3630	29	18	alopecia	alopecia	NOUN
dpc-3630	29	19	areata	areata	NOUN
dpc-3630	29	20	,	,	PUNCT
dpc-3630	29	21	addison	addison	PROPN
dpc-3630	29	22	disease	disease	PROPN
dpc-3630	29	23	,	,	PUNCT
dpc-3630	29	24	autoimmune	autoimmune	ADJ
dpc-3630	29	25	gastritis	gastritis	NOUN
dpc-3630	29	26	,	,	PUNCT
dpc-3630	29	27	pernicious	pernicious	ADJ
dpc-3630	29	28	anemia	anemia	NOUN
dpc-3630	29	29	,	,	PUNCT
dpc-3630	29	30	psoriasis	psoriasis	NOUN
dpc-3630	29	31	,	,	PUNCT
dpc-3630	29	32	rheumatoid	rheumatoid	VERB
dpc-3630	29	33	arthritis	arthritis	NOUN
dpc-3630	29	34	(	(	PUNCT
dpc-3630	29	35	ra	ra	NOUN
dpc-3630	29	36	)	)	PUNCT
dpc-3630	29	37	,	,	PUNCT
dpc-3630	29	38	systemic	systemic	ADJ
dpc-3630	29	39	lupus	lupus	PROPN
dpc-3630	29	40	erythematosus	erythematosus	NOUN
dpc-3630	29	41	(	(	PUNCT
dpc-3630	29	42	sle	sle	PROPN
dpc-3630	29	43	)	)	PUNCT
dpc-3630	29	44	,	,	PUNCT
dpc-3630	29	45	and	and	CCONJ
dpc-3630	29	46	type	type	NOUN
dpc-3630	29	47	i	i	PRON
dpc-3630	29	48	diabetes	diabete	VERB
dpc-3630	29	49	mellitus	mellitus	NOUN
dpc-3630	29	50	.	.	PUNCT
dpc-3630	30	1	in	in	ADP
dpc-3630	30	2	addition	addition	NOUN
dpc-3630	30	3	,	,	PUNCT
dpc-3630	30	4	changes	change	NOUN
dpc-3630	30	5	in	in	ADP
dpc-3630	30	6	the	the	DET
dpc-3630	30	7	nervous	nervous	ADJ
dpc-3630	30	8	system	system	NOUN
dpc-3630	30	9	have	have	AUX
dpc-3630	30	10	been	be	AUX
dpc-3630	30	11	observed	observe	VERB
dpc-3630	30	12	to	to	ADP
dpc-3630	30	13	some	some	DET
dpc-3630	30	14	degree	degree	NOUN
dpc-3630	30	15	in	in	ADP
dpc-3630	30	16	vitiligo	vitiligo	NOUN
dpc-3630	30	17	,	,	PUNCT
dpc-3630	30	18	such	such	ADJ
dpc-3630	30	19	as	as	ADP
dpc-3630	30	20	dystrophic	dystrophic	ADJ
dpc-3630	30	21	changes	change	NOUN
dpc-3630	30	22	and	and	CCONJ
dpc-3630	30	23	increasing	increase	VERB
dpc-3630	30	24	basement	basement	NOUN
dpc-3630	30	25	membrane	membrane	NOUN
dpc-3630	30	26	thickness	thickness	NOUN
dpc-3630	30	27	of	of	ADP
dpc-3630	30	28	schwann	schwann	PROPN
dpc-3630	30	29	cells	cell	NOUN
dpc-3630	30	30	in	in	ADP
dpc-3630	30	31	cutaneous	cutaneous	ADJ
dpc-3630	30	32	nerves	nerve	NOUN
dpc-3630	30	33	[	[	X
dpc-3630	30	34	5,6	5,6	NUM
dpc-3630	30	35	]	]	PUNCT
dpc-3630	30	36	.	.	PUNCT
dpc-3630	31	1	some	some	DET
dpc-3630	31	2	studies	study	NOUN
dpc-3630	31	3	have	have	AUX
dpc-3630	31	4	shown	show	VERB
dpc-3630	31	5	the	the	DET
dpc-3630	31	6	co	co	NOUN
dpc-3630	31	7	-	-	NOUN
dpc-3630	31	8	occurrence	occurrence	NOUN
dpc-3630	31	9	of	of	ADP
dpc-3630	31	10	vitiligo	vitiligo	NOUN
dpc-3630	31	11	and	and	CCONJ
dpc-3630	31	12	multiple	multiple	ADJ
dpc-3630	31	13	sclerosis	sclerosis	NOUN
dpc-3630	31	14	(	(	PUNCT
dpc-3630	31	15	ms	ms	PROPN
dpc-3630	31	16	)	)	PUNCT
dpc-3630	32	1	[	[	X
dpc-3630	32	2	6,7	6,7	NUM
dpc-3630	32	3	]	]	PUNCT
dpc-3630	32	4	.	.	PUNCT
dpc-3630	33	1	while	while	SCONJ
dpc-3630	33	2	the	the	DET
dpc-3630	33	3	main	main	ADJ
dpc-3630	33	4	pathophysiological	pathophysiological	ADJ
dpc-3630	33	5	pathways	pathway	NOUN
dpc-3630	33	6	of	of	ADP
dpc-3630	33	7	both	both	DET
dpc-3630	33	8	diseases	disease	NOUN
dpc-3630	33	9	are	be	AUX
dpc-3630	33	10	different	different	ADJ
dpc-3630	33	11	,	,	PUNCT
dpc-3630	33	12	they	they	PRON
dpc-3630	33	13	would	would	AUX
dpc-3630	33	14	have	have	VERB
dpc-3630	33	15	similarities	similarity	NOUN
dpc-3630	33	16	in	in	ADP
dpc-3630	33	17	some	some	DET
dpc-3630	33	18	aspects	aspect	NOUN
dpc-3630	33	19	,	,	PUNCT
dpc-3630	33	20	including	include	VERB
dpc-3630	33	21	increased	increase	VERB
dpc-3630	33	22	interferon	interferon	ADJ
dpc-3630	33	23	-	-	PUNCT
dpc-3630	33	24	gamma	gamma	NOUN
dpc-3630	33	25	,	,	PUNCT
dpc-3630	33	26	il17	il17	PROPN
dpc-3630	33	27	,	,	PUNCT
dpc-3630	33	28	oxidative	oxidative	ADJ
dpc-3630	33	29	stress	stress	NOUN
dpc-3630	33	30	,	,	PUNCT
dpc-3630	33	31	and	and	CCONJ
dpc-3630	33	32	il2ra	il2ra	VERB
dpc-3630	33	33	genes	gene	NOUN
dpc-3630	33	34	[	[	X
dpc-3630	33	35	6	6	NUM
dpc-3630	33	36	]	]	PUNCT
dpc-3630	33	37	.	.	PUNCT
dpc-3630	34	1	in	in	ADP
dpc-3630	34	2	addition	addition	NOUN
dpc-3630	34	3	,	,	PUNCT
dpc-3630	34	4	genes	gene	NOUN
dpc-3630	34	5	containing	contain	VERB
dpc-3630	34	6	hladrb1	hladrb1	NOUN
dpc-3630	34	7	and	and	CCONJ
dpc-3630	34	8	hladqb1	hladqb1	NOUN
dpc-3630	34	9	might	might	AUX
dpc-3630	34	10	be	be	AUX
dpc-3630	34	11	responsible	responsible	ADJ
dpc-3630	34	12	for	for	ADP
dpc-3630	34	13	the	the	DET
dpc-3630	34	14	co	co	NOUN
dpc-3630	34	15	-	-	NOUN
dpc-3630	34	16	occurrence	occurrence	NOUN
dpc-3630	34	17	of	of	ADP
dpc-3630	34	18	vitiligo	vitiligo	NOUN
dpc-3630	34	19	and	and	CCONJ
dpc-3630	34	20	ms	ms	NOUN
dpc-3630	34	21	in	in	ADP
dpc-3630	34	22	some	some	DET
dpc-3630	34	23	individuals	individual	NOUN
dpc-3630	34	24	[	[	X
dpc-3630	34	25	6,8	6,8	NUM
dpc-3630	34	26	]	]	PUNCT
dpc-3630	34	27	.	.	PUNCT
dpc-3630	35	1	some	some	DET
dpc-3630	35	2	studies	study	NOUN
dpc-3630	35	3	have	have	AUX
dpc-3630	35	4	investigated	investigate	VERB
dpc-3630	35	5	the	the	DET
dpc-3630	35	6	association	association	NOUN
dpc-3630	35	7	of	of	ADP
dpc-3630	35	8	these	these	DET
dpc-3630	35	9	two	two	NUM
dpc-3630	35	10	,	,	PUNCT
dpc-3630	35	11	most	most	ADJ
dpc-3630	35	12	of	of	ADP
dpc-3630	35	13	which	which	PRON
dpc-3630	35	14	were	be	AUX
dpc-3630	35	15	conducted	conduct	VERB
dpc-3630	35	16	in	in	ADP
dpc-3630	35	17	western	western	ADJ
dpc-3630	35	18	countries	country	NOUN
dpc-3630	35	19	.	.	PUNCT
dpc-3630	36	1	objectives	objective	NOUN
dpc-3630	36	2	due	due	ADP
dpc-3630	36	3	to	to	ADP
dpc-3630	36	4	the	the	DET
dpc-3630	36	5	different	different	ADJ
dpc-3630	36	6	ethnic	ethnic	ADJ
dpc-3630	36	7	,	,	PUNCT
dpc-3630	36	8	genetic	genetic	ADJ
dpc-3630	36	9	,	,	PUNCT
dpc-3630	36	10	and	and	CCONJ
dpc-3630	36	11	environmental	environmental	ADJ
dpc-3630	36	12	factors	factor	NOUN
dpc-3630	36	13	in	in	ADP
dpc-3630	36	14	different	different	ADJ
dpc-3630	36	15	regions	region	NOUN
dpc-3630	36	16	,	,	PUNCT
dpc-3630	36	17	it	it	PRON
dpc-3630	36	18	seems	seem	VERB
dpc-3630	36	19	necessary	necessary	ADJ
dpc-3630	36	20	to	to	PART
dpc-3630	36	21	investigate	investigate	VERB
dpc-3630	36	22	this	this	DET
dpc-3630	36	23	association	association	NOUN
dpc-3630	36	24	in	in	ADP
dpc-3630	36	25	other	other	ADJ
dpc-3630	36	26	areas	area	NOUN
dpc-3630	36	27	.	.	PUNCT
dpc-3630	37	1	in	in	ADP
dpc-3630	37	2	the	the	DET
dpc-3630	37	3	current	current	ADJ
dpc-3630	37	4	study	study	NOUN
dpc-3630	37	5	,	,	PUNCT
dpc-3630	37	6	we	we	PRON
dpc-3630	37	7	aim	aim	VERB
dpc-3630	37	8	to	to	PART
dpc-3630	37	9	report	report	VERB
dpc-3630	37	10	the	the	DET
dpc-3630	37	11	frequency	frequency	NOUN
dpc-3630	37	12	of	of	ADP
dpc-3630	37	13	ms	ms	PROPN
dpc-3630	37	14	in	in	ADP
dpc-3630	37	15	vitiligo	vitiligo	NOUN
dpc-3630	37	16	patients	patient	NOUN
dpc-3630	37	17	and	and	CCONJ
dpc-3630	37	18	their	their	PRON
dpc-3630	37	19	first	first	ADJ
dpc-3630	37	20	-	-	PUNCT
dpc-3630	37	21	degree	degree	NOUN
dpc-3630	37	22	relatives	relative	NOUN
dpc-3630	37	23	referred	refer	VERB
dpc-3630	37	24	to	to	ADP
dpc-3630	37	25	razi	razi	PROPN
dpc-3630	37	26	hospital	hospital	PROPN
dpc-3630	37	27	in	in	ADP
dpc-3630	37	28	tehran	tehran	PROPN
dpc-3630	37	29	,	,	PUNCT
dpc-3630	37	30	iran	iran	PROPN
dpc-3630	37	31	.	.	PUNCT
dpc-3630	38	1	methods	method	NOUN
dpc-3630	38	2	this	this	DET
dpc-3630	38	3	study	study	NOUN
dpc-3630	38	4	was	be	AUX
dpc-3630	38	5	a	a	DET
dpc-3630	38	6	cross	cross	ADJ
dpc-3630	38	7	-	-	ADJ
dpc-3630	38	8	sectional	sectional	ADJ
dpc-3630	38	9	study	study	NOUN
dpc-3630	38	10	approved	approve	VERB
dpc-3630	38	11	by	by	ADP
dpc-3630	38	12	tehran	tehran	PROPN
dpc-3630	38	13	university	university	PROPN
dpc-3630	38	14	of	of	ADP
dpc-3630	38	15	medical	medical	ADJ
dpc-3630	38	16	sciences	science	NOUN
dpc-3630	38	17	.	.	PUNCT
dpc-3630	39	1	the	the	DET
dpc-3630	39	2	population	population	NOUN
dpc-3630	39	3	of	of	ADP
dpc-3630	39	4	the	the	DET
dpc-3630	39	5	study	study	NOUN
dpc-3630	39	6	included	include	VERB
dpc-3630	39	7	vitiligo	vitiligo	NOUN
dpc-3630	39	8	patients	patient	NOUN
dpc-3630	39	9	who	who	PRON
dpc-3630	39	10	were	be	AUX
dpc-3630	39	11	clinically	clinically	ADV
dpc-3630	39	12	reviewed	review	VERB
dpc-3630	39	13	by	by	ADP
dpc-3630	39	14	dermatologists	dermatologist	NOUN
dpc-3630	39	15	at	at	ADP
dpc-3630	39	16	razi	razi	PROPN
dpc-3630	39	17	hospital	hospital	PROPN
dpc-3630	39	18	,	,	PUNCT
dpc-3630	39	19	tehran	tehran	PROPN
dpc-3630	39	20	,	,	PUNCT
dpc-3630	39	21	iran	iran	PROPN
dpc-3630	39	22	,	,	PUNCT
dpc-3630	39	23	between	between	ADP
dpc-3630	39	24	march	march	PROPN
dpc-3630	39	25	2020	2020	NUM
dpc-3630	39	26	and	and	CCONJ
dpc-3630	39	27	december	december	PROPN
dpc-3630	39	28	2021	2021	NUM
dpc-3630	39	29	.	.	PUNCT
dpc-3630	40	1	sampling	sample	VERB
dpc-3630	40	2	was	be	AUX
dpc-3630	40	3	performed	perform	VERB
dpc-3630	40	4	consecutively	consecutively	ADV
dpc-3630	40	5	in	in	ADP
dpc-3630	40	6	the	the	DET
dpc-3630	40	7	general	general	ADJ
dpc-3630	40	8	outpatient	outpatient	NOUN
dpc-3630	40	9	clinic	clinic	NOUN
dpc-3630	40	10	and	and	CCONJ
dpc-3630	40	11	the	the	DET
dpc-3630	40	12	phototherapy	phototherapy	NOUN
dpc-3630	40	13	department	department	PROPN
dpc-3630	40	14	of	of	ADP
dpc-3630	40	15	razi	razi	PROPN
dpc-3630	40	16	hospital	hospital	PROPN
dpc-3630	40	17	.	.	PUNCT
dpc-3630	41	1	informed	inform	VERB
dpc-3630	41	2	consent	consent	NOUN
dpc-3630	41	3	was	be	AUX
dpc-3630	41	4	obtained	obtain	VERB
dpc-3630	41	5	from	from	ADP
dpc-3630	41	6	all	all	DET
dpc-3630	41	7	participants	participant	NOUN
dpc-3630	41	8	,	,	PUNCT
dpc-3630	41	9	data	datum	NOUN
dpc-3630	41	10	were	be	AUX
dpc-3630	41	11	then	then	ADV
dpc-3630	41	12	collected	collect	VERB
dpc-3630	41	13	manually	manually	ADV
dpc-3630	41	14	using	use	VERB
dpc-3630	41	15	a	a	DET
dpc-3630	41	16	questionnaire	questionnaire	NOUN
dpc-3630	41	17	.	.	PUNCT
dpc-3630	42	1	we	we	PRON
dpc-3630	42	2	followed	follow	VERB
dpc-3630	42	3	-	-	PUNCT
dpc-3630	42	4	up	up	ADP
dpc-3630	42	5	patients	patient	NOUN
dpc-3630	42	6	through	through	ADP
dpc-3630	42	7	telephone	telephone	NOUN
dpc-3630	42	8	interviews	interview	NOUN
dpc-3630	42	9	to	to	PART
dpc-3630	42	10	verify	verify	VERB
dpc-3630	42	11	the	the	DET
dpc-3630	42	12	accuracy	accuracy	NOUN
dpc-3630	42	13	of	of	ADP
dpc-3630	42	14	their	their	PRON
dpc-3630	42	15	information	information	NOUN
dpc-3630	42	16	and	and	CCONJ
dpc-3630	42	17	to	to	PART
dpc-3630	42	18	complete	complete	VERB
dpc-3630	42	19	the	the	DET
dpc-3630	42	20	questionnaire	questionnaire	NOUN
dpc-3630	42	21	.	.	PUNCT
dpc-3630	43	1	patients	patient	NOUN
dpc-3630	43	2	who	who	PRON
dpc-3630	43	3	did	do	AUX
dpc-3630	43	4	not	not	PART
dpc-3630	43	5	answer	answer	VERB
dpc-3630	43	6	the	the	DET
dpc-3630	43	7	questions	question	NOUN
dpc-3630	43	8	on	on	ADP
dpc-3630	43	9	ms	ms	NOUN
dpc-3630	43	10	in	in	ADP
dpc-3630	43	11	the	the	DET
dpc-3630	43	12	questionnaire	questionnaire	NOUN
dpc-3630	43	13	and	and	CCONJ
dpc-3630	43	14	did	do	AUX
dpc-3630	43	15	not	not	PART
dpc-3630	43	16	respond	respond	VERB
dpc-3630	43	17	to	to	ADP
dpc-3630	43	18	phone	phone	NOUN
dpc-3630	43	19	calls	call	NOUN
dpc-3630	43	20	were	be	AUX
dpc-3630	43	21	excluded	exclude	VERB
dpc-3630	43	22	from	from	ADP
dpc-3630	43	23	the	the	DET
dpc-3630	43	24	study	study	NOUN
dpc-3630	43	25	.	.	PUNCT
dpc-3630	44	1	the	the	DET
dpc-3630	44	2	questionnaire	questionnaire	NOUN
dpc-3630	44	3	contained	contain	VERB
dpc-3630	44	4	demographic	demographic	ADJ
dpc-3630	44	5	information	information	NOUN
dpc-3630	44	6	of	of	ADP
dpc-3630	44	7	the	the	DET
dpc-3630	44	8	subjects	subject	NOUN
dpc-3630	44	9	,	,	PUNCT
dpc-3630	44	10	including	include	VERB
dpc-3630	44	11	gender	gender	NOUN
dpc-3630	44	12	,	,	PUNCT
dpc-3630	44	13	age	age	NOUN
dpc-3630	44	14	,	,	PUNCT
dpc-3630	44	15	duration	duration	NOUN
dpc-3630	44	16	of	of	ADP
dpc-3630	44	17	the	the	DET
dpc-3630	44	18	disease	disease	NOUN
dpc-3630	44	19	,	,	PUNCT
dpc-3630	44	20	site	site	NOUN
dpc-3630	44	21	of	of	ADP
dpc-3630	44	22	the	the	DET
dpc-3630	44	23	disease	disease	NOUN
dpc-3630	44	24	(	(	PUNCT
dpc-3630	44	25	face	face	NOUN
dpc-3630	44	26	,	,	PUNCT
dpc-3630	44	27	trunk	trunk	NOUN
dpc-3630	44	28	,	,	PUNCT
dpc-3630	44	29	limbs	limb	NOUN
dpc-3630	44	30	,	,	PUNCT
dpc-3630	44	31	and	and	CCONJ
dpc-3630	44	32	genitals	genital	NOUN
dpc-3630	44	33	)	)	PUNCT
dpc-3630	44	34	,	,	PUNCT
dpc-3630	44	35	age	age	NOUN
dpc-3630	44	36	at	at	ADP
dpc-3630	44	37	onset	onset	NOUN
dpc-3630	44	38	of	of	ADP
dpc-3630	44	39	the	the	DET
dpc-3630	44	40	disease	disease	NOUN
dpc-3630	44	41	,	,	PUNCT
dpc-3630	44	42	number	number	NOUN
dpc-3630	44	43	of	of	ADP
dpc-3630	44	44	first	first	ADJ
dpc-3630	44	45	-	-	PUNCT
dpc-3630	44	46	degree	degree	NOUN
dpc-3630	44	47	relatives	relative	NOUN
dpc-3630	44	48	of	of	ADP
dpc-3630	44	49	patients	patient	NOUN
dpc-3630	44	50	(	(	PUNCT
dpc-3630	44	51	including	include	VERB
dpc-3630	44	52	siblings	sibling	NOUN
dpc-3630	44	53	and	and	CCONJ
dpc-3630	44	54	parents	parent	NOUN
dpc-3630	44	55	)	)	PUNCT
dpc-3630	44	56	,	,	PUNCT
dpc-3630	44	57	and	and	CCONJ
dpc-3630	44	58	history	history	NOUN
dpc-3630	44	59	of	of	ADP
dpc-3630	44	60	ms	ms	NOUN
dpc-3630	44	61	in	in	ADP
dpc-3630	44	62	patients	patient	NOUN
dpc-3630	44	63	themselves	themselves	PRON
dpc-3630	44	64	and	and	CCONJ
dpc-3630	44	65	their	their	PRON
dpc-3630	44	66	first	first	ADJ
dpc-3630	44	67	-	-	PUNCT
dpc-3630	44	68	degree	degree	NOUN
dpc-3630	44	69	relatives	relative	NOUN
dpc-3630	44	70	.	.	PUNCT
dpc-3630	45	1	patients	patient	NOUN
dpc-3630	45	2	were	be	AUX
dpc-3630	45	3	divided	divide	VERB
dpc-3630	45	4	into	into	ADP
dpc-3630	45	5	the	the	DET
dpc-3630	45	6	early	early	ADJ
dpc-3630	45	7	-	-	PUNCT
dpc-3630	45	8	onset	onset	NOUN
dpc-3630	45	9	group	group	NOUN
dpc-3630	45	10	(	(	PUNCT
dpc-3630	45	11	≤	≤	NUM
dpc-3630	45	12	12	12	NUM
dpc-3630	45	13	years	year	NOUN
dpc-3630	45	14	old	old	ADJ
dpc-3630	45	15	)	)	PUNCT
dpc-3630	45	16	and	and	CCONJ
dpc-3630	45	17	the	the	DET
dpc-3630	45	18	late	late	ADJ
dpc-3630	45	19	-	-	PUNCT
dpc-3630	45	20	onset	onset	NOUN
dpc-3630	45	21	group	group	NOUN
dpc-3630	45	22	(	(	PUNCT
dpc-3630	45	23	>	>	X
dpc-3630	45	24	12	12	NUM
dpc-3630	45	25	years	year	NOUN
dpc-3630	45	26	old	old	ADJ
dpc-3630	45	27	)	)	PUNCT
dpc-3630	45	28	according	accord	VERB
dpc-3630	45	29	to	to	ADP
dpc-3630	45	30	the	the	DET
dpc-3630	45	31	age	age	NOUN
dpc-3630	45	32	of	of	ADP
dpc-3630	45	33	onset	onset	NOUN
dpc-3630	45	34	[	[	X
dpc-3630	45	35	1,9	1,9	NUM
dpc-3630	45	36	]	]	PUNCT
dpc-3630	45	37	.	.	PUNCT
dpc-3630	46	1	we	we	PRON
dpc-3630	46	2	obtained	obtain	VERB
dpc-3630	46	3	the	the	DET
dpc-3630	46	4	history	history	NOUN
dpc-3630	46	5	of	of	ADP
dpc-3630	46	6	ms	ms	NOUN
dpc-3630	46	7	based	base	VERB
dpc-3630	46	8	on	on	ADP
dpc-3630	46	9	self	self	NOUN
dpc-3630	46	10	-	-	PUNCT
dpc-3630	46	11	reports	report	NOUN
dpc-3630	46	12	and	and	CCONJ
dpc-3630	46	13	had	have	VERB
dpc-3630	46	14	no	no	DET
dpc-3630	46	15	evidence	evidence	NOUN
dpc-3630	46	16	to	to	PART
dpc-3630	46	17	verify	verify	VERB
dpc-3630	46	18	their	their	PRON
dpc-3630	46	19	disease	disease	NOUN
dpc-3630	46	20	.	.	PUNCT
dpc-3630	47	1	statistical	statistical	ADJ
dpc-3630	47	2	analysis	analysis	NOUN
dpc-3630	47	3	we	we	PRON
dpc-3630	47	4	used	use	VERB
dpc-3630	47	5	the	the	DET
dpc-3630	47	6	chi	chi	ADJ
dpc-3630	47	7	-	-	PUNCT
dpc-3630	47	8	square	square	ADJ
dpc-3630	47	9	test	test	NOUN
dpc-3630	47	10	to	to	PART
dpc-3630	47	11	compare	compare	VERB
dpc-3630	47	12	the	the	DET
dpc-3630	47	13	prevalence	prevalence	NOUN
dpc-3630	47	14	of	of	ADP
dpc-3630	47	15	ms	ms	NOUN
dpc-3630	47	16	in	in	ADP
dpc-3630	47	17	the	the	DET
dpc-3630	47	18	population	population	NOUN
dpc-3630	47	19	of	of	ADP
dpc-3630	47	20	the	the	DET
dpc-3630	47	21	study	study	NOUN
dpc-3630	47	22	with	with	ADP
dpc-3630	47	23	the	the	DET
dpc-3630	47	24	prevalence	prevalence	NOUN
dpc-3630	47	25	of	of	ADP
dpc-3630	47	26	ms	ms	NOUN
dpc-3630	47	27	in	in	ADP
dpc-3630	47	28	the	the	DET
dpc-3630	47	29	average	average	ADJ
dpc-3630	47	30	population	population	NOUN
dpc-3630	47	31	,	,	PUNCT
dpc-3630	47	32	based	base	VERB
dpc-3630	47	33	on	on	ADP
dpc-3630	47	34	the	the	DET
dpc-3630	47	35	iranian	iranian	ADJ
dpc-3630	47	36	ms	ms	PROPN
dpc-3630	47	37	society	society	PROPN
dpc-3630	47	38	(	(	PUNCT
dpc-3630	47	39	imss	imss	PROPN
dpc-3630	47	40	)	)	PUNCT
dpc-3630	47	41	records	record	NOUN
dpc-3630	47	42	,	,	PUNCT
dpc-3630	47	43	as	as	SCONJ
dpc-3630	47	44	reported	report	VERB
dpc-3630	47	45	by	by	ADP
dpc-3630	47	46	amini	amini	PROPN
dpc-3630	47	47	et	et	PROPN
dpc-3630	47	48	al	al	PROPN
dpc-3630	48	1	[	[	X
dpc-3630	48	2	10	10	NUM
dpc-3630	48	3	]	]	PUNCT
dpc-3630	48	4	.	.	PUNCT
dpc-3630	49	1	to	to	PART
dpc-3630	49	2	assess	assess	VERB
dpc-3630	49	3	the	the	DET
dpc-3630	49	4	association	association	NOUN
dpc-3630	49	5	between	between	ADP
dpc-3630	49	6	ms	ms	PROPN
dpc-3630	49	7	and	and	CCONJ
dpc-3630	49	8	other	other	ADJ
dpc-3630	49	9	variables	variable	NOUN
dpc-3630	49	10	,	,	PUNCT
dpc-3630	49	11	we	we	PRON
dpc-3630	49	12	used	use	VERB
dpc-3630	49	13	chi	chi	NOUN
dpc-3630	49	14	-	-	PUNCT
dpc-3630	49	15	square	square	ADJ
dpc-3630	49	16	,	,	PUNCT
dpc-3630	49	17	mann	mann	PROPN
dpc-3630	49	18	-	-	PUNCT
dpc-3630	49	19	whitney	whitney	PROPN
dpc-3630	49	20	,	,	PUNCT
dpc-3630	49	21	and	and	CCONJ
dpc-3630	49	22	fisher	fisher	PROPN
dpc-3630	49	23	exact	exact	ADJ
dpc-3630	49	24	tests	test	NOUN
dpc-3630	49	25	,	,	PUNCT
dpc-3630	49	26	as	as	ADP
dpc-3630	49	27	appropriate	appropriate	ADJ
dpc-3630	49	28	.	.	PUNCT
dpc-3630	50	1	p	p	NOUN
dpc-3630	50	2	values	value	NOUN
dpc-3630	50	3	were	be	AUX
dpc-3630	50	4	2	2	NUM
dpc-3630	50	5	-	-	NUM
dpc-3630	50	6	sided	sided	ADJ
dpc-3630	50	7	,	,	PUNCT
dpc-3630	50	8	and	and	CCONJ
dpc-3630	50	9	p	p	NOUN
dpc-3630	50	10	values	value	NOUN
dpc-3630	50	11	of	of	ADP
dpc-3630	50	12	less	less	ADJ
dpc-3630	50	13	than	than	ADP
dpc-3630	50	14	0.05	0.05	NUM
dpc-3630	50	15	were	be	AUX
dpc-3630	50	16	considered	consider	VERB
dpc-3630	50	17	statistically	statistically	ADV
dpc-3630	50	18	significant	significant	ADJ
dpc-3630	50	19	.	.	PUNCT
dpc-3630	51	1	all	all	DET
dpc-3630	51	2	tests	test	NOUN
dpc-3630	51	3	were	be	AUX
dpc-3630	51	4	performed	perform	VERB
dpc-3630	51	5	using	use	VERB
dpc-3630	51	6	r	r	NOUN
dpc-3630	51	7	software	software	NOUN
dpc-3630	51	8	,	,	PUNCT
dpc-3630	51	9	version	version	NOUN
dpc-3630	51	10	4.1.2	4.1.2	PROPN
dpc-3630	51	11	.	.	PUNCT
dpc-3630	52	1	results	result	NOUN
dpc-3630	52	2	in	in	ADP
dpc-3630	52	3	this	this	DET
dpc-3630	52	4	study	study	NOUN
dpc-3630	52	5	,	,	PUNCT
dpc-3630	52	6	709	709	NUM
dpc-3630	52	7	vitiligo	vitiligo	NOUN
dpc-3630	52	8	patients	patient	NOUN
dpc-3630	52	9	were	be	AUX
dpc-3630	52	10	studied	study	VERB
dpc-3630	52	11	over	over	ADP
dpc-3630	52	12	21	21	NUM
dpc-3630	52	13	months	month	NOUN
dpc-3630	52	14	between	between	ADP
dpc-3630	52	15	march	march	PROPN
dpc-3630	52	16	2020	2020	NUM
dpc-3630	52	17	and	and	CCONJ
dpc-3630	52	18	december	december	PROPN
dpc-3630	52	19	2021	2021	NUM
dpc-3630	52	20	.	.	PUNCT
dpc-3630	53	1	328	328	NUM
dpc-3630	53	2	(	(	PUNCT
dpc-3630	53	3	46.26	46.26	NUM
dpc-3630	53	4	%	%	NOUN
dpc-3630	53	5	)	)	PUNCT
dpc-3630	53	6	were	be	AUX
dpc-3630	53	7	female	female	ADJ
dpc-3630	53	8	and	and	CCONJ
dpc-3630	53	9	381	381	NUM
dpc-3630	53	10	(	(	PUNCT
dpc-3630	53	11	53.74	53.74	NUM
dpc-3630	53	12	%	%	NOUN
dpc-3630	53	13	)	)	PUNCT
dpc-3630	53	14	were	be	AUX
dpc-3630	53	15	male	male	ADJ
dpc-3630	53	16	.	.	PUNCT
dpc-3630	54	1	the	the	DET
dpc-3630	54	2	mean	mean	ADJ
dpc-3630	54	3	age	age	NOUN
dpc-3630	54	4	of	of	ADP
dpc-3630	54	5	patients	patient	NOUN
dpc-3630	54	6	was	be	AUX
dpc-3630	54	7	35.06	35.06	NUM
dpc-3630	54	8	,	,	PUNCT
dpc-3630	54	9	with	with	ADP
dpc-3630	54	10	a	a	DET
dpc-3630	54	11	range	range	NOUN
dpc-3630	54	12	of	of	ADP
dpc-3630	54	13	2	2	NUM
dpc-3630	54	14	-	-	SYM
dpc-3630	54	15	87	87	NUM
dpc-3630	54	16	years	year	NOUN
dpc-3630	54	17	(	(	PUNCT
dpc-3630	54	18	table	table	NOUN
dpc-3630	54	19	1	1	NUM
dpc-3630	54	20	)	)	PUNCT
dpc-3630	54	21	.	.	PUNCT
dpc-3630	55	1	among	among	ADP
dpc-3630	55	2	the	the	DET
dpc-3630	55	3	vitiligo	vitiligo	NOUN
dpc-3630	55	4	patients	patient	NOUN
dpc-3630	55	5	,	,	PUNCT
dpc-3630	55	6	15	15	NUM
dpc-3630	55	7	(	(	PUNCT
dpc-3630	55	8	2.12	2.12	NUM
dpc-3630	55	9	%	%	NOUN
dpc-3630	55	10	,	,	PUNCT
dpc-3630	55	11	95	95	NUM
dpc-3630	55	12	%	%	NOUN
dpc-3630	55	13	ci:1.06%3.17	ci:1.06%3.17	ADJ
dpc-3630	55	14	%	%	NOUN
dpc-3630	55	15	)	)	PUNCT
dpc-3630	55	16	reported	report	VERB
dpc-3630	55	17	a	a	DET
dpc-3630	55	18	history	history	NOUN
dpc-3630	55	19	of	of	ADP
dpc-3630	55	20	ms	ms	NOUN
dpc-3630	55	21	(	(	PUNCT
dpc-3630	55	22	12	12	NUM
dpc-3630	55	23	male	male	ADJ
dpc-3630	55	24	patients	patient	NOUN
dpc-3630	55	25	and	and	CCONJ
dpc-3630	55	26	3	3	NUM
dpc-3630	55	27	female	female	ADJ
dpc-3630	55	28	ones	one	NOUN
dpc-3630	55	29	)	)	PUNCT
dpc-3630	55	30	.	.	PUNCT
dpc-3630	56	1	of	of	ADP
dpc-3630	56	2	the	the	DET
dpc-3630	56	3	2886	2886	NUM
dpc-3630	56	4	first	first	ADJ
dpc-3630	56	5	-	-	PUNCT
dpc-3630	56	6	degree	degree	NOUN
dpc-3630	56	7	relatives	relative	NOUN
dpc-3630	56	8	of	of	ADP
dpc-3630	56	9	patients	patient	NOUN
dpc-3630	56	10	with	with	ADP
dpc-3630	56	11	vitiligo	vitiligo	NOUN
dpc-3630	56	12	,	,	PUNCT
dpc-3630	56	13	10	10	NUM
dpc-3630	56	14	(	(	PUNCT
dpc-3630	56	15	0.35	0.35	NUM
dpc-3630	56	16	%	%	NOUN
dpc-3630	56	17	,	,	PUNCT
dpc-3630	56	18	95	95	NUM
dpc-3630	56	19	%	%	NOUN
dpc-3630	56	20	ci:0.13%-0.56	ci:0.13%-0.56	NOUN
dpc-3630	56	21	%	%	NOUN
dpc-3630	56	22	)	)	PUNCT
dpc-3630	56	23	had	have	VERB
dpc-3630	56	24	ms	ms	NOUN
dpc-3630	56	25	(	(	PUNCT
dpc-3630	56	26	table	table	NOUN
dpc-3630	56	27	2	2	NUM
dpc-3630	56	28	)	)	PUNCT
dpc-3630	56	29	.	.	PUNCT
dpc-3630	57	1	the	the	DET
dpc-3630	57	2	most	most	ADV
dpc-3630	57	3	commonly	commonly	ADV
dpc-3630	57	4	affected	affect	VERB
dpc-3630	57	5	areas	area	NOUN
dpc-3630	57	6	with	with	ADP
dpc-3630	57	7	depigmented	depigmented	ADJ
dpc-3630	57	8	lesions	lesion	NOUN
dpc-3630	57	9	were	be	AUX
dpc-3630	57	10	the	the	DET
dpc-3630	57	11	limbs	limb	NOUN
dpc-3630	57	12	(	(	PUNCT
dpc-3630	57	13	86	86	NUM
dpc-3630	57	14	%	%	NOUN
dpc-3630	57	15	)	)	PUNCT
dpc-3630	57	16	and	and	CCONJ
dpc-3630	57	17	face	face	NOUN
dpc-3630	57	18	(	(	PUNCT
dpc-3630	57	19	74	74	NUM
dpc-3630	57	20	%	%	NOUN
dpc-3630	57	21	)	)	PUNCT
dpc-3630	57	22	(	(	PUNCT
dpc-3630	57	23	table	table	NOUN
dpc-3630	57	24	3	3	NUM
dpc-3630	57	25	)	)	PUNCT
dpc-3630	57	26	.	.	PUNCT
dpc-3630	58	1	we	we	PRON
dpc-3630	58	2	found	find	VERB
dpc-3630	58	3	no	no	DET
dpc-3630	58	4	significant	significant	ADJ
dpc-3630	58	5	association	association	NOUN
dpc-3630	58	6	between	between	ADP
dpc-3630	58	7	the	the	DET
dpc-3630	58	8	history	history	NOUN
dpc-3630	58	9	of	of	ADP
dpc-3630	58	10	ms	ms	NOUN
dpc-3630	58	11	and	and	CCONJ
dpc-3630	58	12	age	age	NOUN
dpc-3630	58	13	(	(	PUNCT
dpc-3630	58	14	p	p	X
dpc-3630	58	15	=	=	NOUN
dpc-3630	58	16	0.363	0.363	NUM
dpc-3630	58	17	)	)	PUNCT
dpc-3630	58	18	,	,	PUNCT
dpc-3630	58	19	gender	gender	NOUN
dpc-3630	58	20	(	(	PUNCT
dpc-3630	58	21	p	p	NOUN
dpc-3630	58	22	=	=	NOUN
dpc-3630	58	23	0.072	0.072	NUM
dpc-3630	58	24	)	)	PUNCT
dpc-3630	58	25	,	,	PUNCT
dpc-3630	58	26	duration	duration	NOUN
dpc-3630	58	27	of	of	ADP
dpc-3630	58	28	disease	disease	NOUN
dpc-3630	58	29	(	(	PUNCT
dpc-3630	58	30	p	p	NOUN
dpc-3630	58	31	=	=	NOUN
dpc-3630	58	32	0.320	0.320	NUM
dpc-3630	58	33	)	)	PUNCT
dpc-3630	58	34	,	,	PUNCT
dpc-3630	58	35	and	and	CCONJ
dpc-3630	58	36	location	location	NOUN
dpc-3630	58	37	of	of	ADP
dpc-3630	58	38	depigmented	depigmented	ADJ
dpc-3630	58	39	lesions	lesion	NOUN
dpc-3630	58	40	(	(	PUNCT
dpc-3630	58	41	p	p	X
dpc-3630	58	42	>	>	X
dpc-3630	58	43	0.05	0.05	NUM
dpc-3630	58	44	)	)	PUNCT
dpc-3630	58	45	in	in	ADP
dpc-3630	58	46	patients	patient	NOUN
dpc-3630	58	47	with	with	ADP
dpc-3630	58	48	vitiligo	vitiligo	PROPN
dpc-3630	58	49	(	(	PUNCT
dpc-3630	58	50	figures	figure	NOUN
dpc-3630	58	51	1	1	NUM
dpc-3630	58	52	and	and	CCONJ
dpc-3630	58	53	2	2	NUM
dpc-3630	58	54	)	)	PUNCT
dpc-3630	58	55	.	.	PUNCT
dpc-3630	59	1	table	table	NOUN
dpc-3630	59	2	1	1	NUM
dpc-3630	59	3	.	.	PUNCT
dpc-3630	60	1	characteristics	characteristic	NOUN
dpc-3630	60	2	of	of	ADP
dpc-3630	60	3	patients	patient	NOUN
dpc-3630	60	4	age	age	NOUN
dpc-3630	60	5	(	(	PUNCT
dpc-3630	60	6	years	year	NOUN
dpc-3630	60	7	)	)	PUNCT
dpc-3630	60	8	mean	mean	NOUN
dpc-3630	60	9	35.06	35.06	NUM
dpc-3630	60	10	range	range	NOUN
dpc-3630	60	11	2–87	2–87	ADJ
dpc-3630	60	12	gender	gender	NOUN
dpc-3630	60	13	male	male	NOUN
dpc-3630	60	14	,	,	PUNCT
dpc-3630	60	15	n	n	PROPN
dpc-3630	60	16	(	(	PUNCT
dpc-3630	60	17	%	%	INTJ
dpc-3630	60	18	)	)	PUNCT
dpc-3630	60	19	381	381	NUM
dpc-3630	60	20	(	(	PUNCT
dpc-3630	60	21	53.74	53.74	NUM
dpc-3630	60	22	)	)	PUNCT
dpc-3630	60	23	female	female	NOUN
dpc-3630	60	24	,	,	PUNCT
dpc-3630	60	25	n	n	CCONJ
dpc-3630	60	26	(	(	PUNCT
dpc-3630	60	27	%	%	INTJ
dpc-3630	60	28	)	)	PUNCT
dpc-3630	60	29	328	328	NUM
dpc-3630	60	30	(	(	PUNCT
dpc-3630	60	31	46.26	46.26	NUM
dpc-3630	60	32	)	)	PUNCT
dpc-3630	60	33	original	original	ADJ
dpc-3630	60	34	article	article	NOUN
dpc-3630	60	35	|	|	ADV
dpc-3630	60	36	dermatol	dermatol	ADJ
dpc-3630	60	37	pract	pract	NOUN
dpc-3630	60	38	concept	concept	NOUN
dpc-3630	60	39	.	.	PUNCT
dpc-3630	61	1	2024;14(3):e2024103	2024;14(3):e2024103	NUM
dpc-3630	61	2	3	3	NUM
dpc-3630	61	3	of	of	ADP
dpc-3630	61	4	690	690	NUM
dpc-3630	61	5	patients	patient	NOUN
dpc-3630	61	6	,	,	PUNCT
dpc-3630	61	7	144	144	NUM
dpc-3630	61	8	(	(	PUNCT
dpc-3630	61	9	21	21	NUM
dpc-3630	61	10	%	%	NOUN
dpc-3630	61	11	)	)	PUNCT
dpc-3630	61	12	had	have	VERB
dpc-3630	61	13	early	early	ADJ
dpc-3630	61	14	-	-	PUNCT
dpc-3630	61	15	onset	onset	NOUN
dpc-3630	61	16	and	and	CCONJ
dpc-3630	61	17	546	546	NUM
dpc-3630	61	18	(	(	PUNCT
dpc-3630	61	19	79	79	NUM
dpc-3630	61	20	%	%	NOUN
dpc-3630	61	21	)	)	PUNCT
dpc-3630	61	22	had	have	VERB
dpc-3630	61	23	late	late	ADJ
dpc-3630	61	24	-	-	PUNCT
dpc-3630	61	25	onset	onset	NOUN
dpc-3630	61	26	vitiligo	vitiligo	NOUN
dpc-3630	61	27	disease	disease	NOUN
dpc-3630	61	28	.	.	PUNCT
dpc-3630	62	1	the	the	DET
dpc-3630	62	2	prevalence	prevalence	NOUN
dpc-3630	62	3	of	of	ADP
dpc-3630	62	4	ms	ms	NOUN
dpc-3630	62	5	was	be	AUX
dpc-3630	62	6	higher	high	ADJ
dpc-3630	62	7	in	in	ADP
dpc-3630	62	8	the	the	DET
dpc-3630	62	9	late	late	ADJ
dpc-3630	62	10	-	-	PUNCT
dpc-3630	62	11	onset	onset	NOUN
dpc-3630	62	12	group	group	NOUN
dpc-3630	62	13	(	(	PUNCT
dpc-3630	62	14	3.76	3.76	NUM
dpc-3630	62	15	-	-	ADJ
dpc-3630	62	16	fold	fold	ADJ
dpc-3630	62	17	increase	increase	NOUN
dpc-3630	62	18	)	)	PUNCT
dpc-3630	62	19	,	,	PUNCT
dpc-3630	62	20	but	but	CCONJ
dpc-3630	62	21	not	not	PART
dpc-3630	62	22	statistically	statistically	ADV
dpc-3630	62	23	significant	significant	ADJ
dpc-3630	62	24	(	(	PUNCT
dpc-3630	62	25	p	p	X
dpc-3630	62	26	=	=	NOUN
dpc-3630	62	27	0.33	0.33	NUM
dpc-3630	62	28	)	)	PUNCT
dpc-3630	62	29	(	(	PUNCT
dpc-3630	62	30	table	table	NOUN
dpc-3630	62	31	4	4	NUM
dpc-3630	62	32	)	)	PUNCT
dpc-3630	62	33	.	.	PUNCT
dpc-3630	63	1	the	the	DET
dpc-3630	63	2	prevalence	prevalence	NOUN
dpc-3630	63	3	in	in	ADP
dpc-3630	63	4	women	woman	NOUN
dpc-3630	63	5	in	in	ADP
dpc-3630	63	6	the	the	DET
dpc-3630	63	7	early	early	ADJ
dpc-3630	63	8	-	-	PUNCT
dpc-3630	63	9	onset	onset	NOUN
dpc-3630	63	10	group	group	NOUN
dpc-3630	63	11	was	be	AUX
dpc-3630	63	12	higher	high	ADJ
dpc-3630	63	13	than	than	ADP
dpc-3630	63	14	in	in	ADP
dpc-3630	63	15	men	man	NOUN
dpc-3630	63	16	;	;	PUNCT
dpc-3630	63	17	however	however	ADV
dpc-3630	63	18	,	,	PUNCT
dpc-3630	63	19	in	in	ADP
dpc-3630	63	20	the	the	DET
dpc-3630	63	21	late	late	ADJ
dpc-3630	63	22	-	-	PUNCT
dpc-3630	63	23	onset	onset	NOUN
dpc-3630	63	24	group	group	NOUN
dpc-3630	63	25	,	,	PUNCT
dpc-3630	63	26	the	the	DET
dpc-3630	63	27	men	man	NOUN
dpc-3630	63	28	had	have	VERB
dpc-3630	63	29	a	a	DET
dpc-3630	63	30	higher	high	ADJ
dpc-3630	63	31	frequency	frequency	NOUN
dpc-3630	63	32	.	.	PUNCT
dpc-3630	64	1	no	no	DET
dpc-3630	64	2	significant	significant	ADJ
dpc-3630	64	3	differences	difference	NOUN
dpc-3630	64	4	in	in	ADP
dpc-3630	64	5	age	age	NOUN
dpc-3630	64	6	were	be	AUX
dpc-3630	64	7	found	find	VERB
dpc-3630	64	8	between	between	ADP
dpc-3630	64	9	men	man	NOUN
dpc-3630	64	10	and	and	CCONJ
dpc-3630	64	11	women	woman	NOUN
dpc-3630	64	12	.	.	PUNCT
dpc-3630	65	1	conclusions	conclusion	NOUN
dpc-3630	65	2	considering	consider	VERB
dpc-3630	65	3	the	the	DET
dpc-3630	65	4	convergence	convergence	NOUN
dpc-3630	65	5	theory	theory	NOUN
dpc-3630	65	6	,	,	PUNCT
dpc-3630	65	7	previous	previous	ADJ
dpc-3630	65	8	publications	publication	NOUN
dpc-3630	65	9	have	have	AUX
dpc-3630	65	10	pursued	pursue	VERB
dpc-3630	65	11	the	the	DET
dpc-3630	65	12	immunologic	immunologic	ADJ
dpc-3630	65	13	,	,	PUNCT
dpc-3630	65	14	genetic	genetic	ADJ
dpc-3630	65	15	,	,	PUNCT
dpc-3630	65	16	biochemical	biochemical	ADJ
dpc-3630	65	17	,	,	PUNCT
dpc-3630	65	18	and	and	CCONJ
dpc-3630	65	19	neuronal	neuronal	ADJ
dpc-3630	65	20	hypotheses	hypothesis	NOUN
dpc-3630	65	21	as	as	ADP
dpc-3630	65	22	etiologic	etiologic	ADJ
dpc-3630	65	23	factors	factor	NOUN
dpc-3630	65	24	of	of	ADP
dpc-3630	65	25	vitiligo	vitiligo	NOUN
dpc-3630	65	26	[	[	X
dpc-3630	65	27	11	11	NUM
dpc-3630	65	28	]	]	PUNCT
dpc-3630	65	29	.	.	PUNCT
dpc-3630	66	1	years	year	NOUN
dpc-3630	66	2	ago	ago	ADV
dpc-3630	66	3	,	,	PUNCT
dpc-3630	66	4	a	a	DET
dpc-3630	66	5	link	link	NOUN
dpc-3630	66	6	between	between	ADP
dpc-3630	66	7	neural	neural	ADJ
dpc-3630	66	8	and	and	CCONJ
dpc-3630	66	9	melanocytic	melanocytic	ADJ
dpc-3630	66	10	systems	system	NOUN
dpc-3630	66	11	was	be	AUX
dpc-3630	66	12	claimed	claim	VERB
dpc-3630	66	13	.	.	PUNCT
dpc-3630	67	1	this	this	DET
dpc-3630	67	2	theory	theory	NOUN
dpc-3630	67	3	was	be	AUX
dpc-3630	67	4	inspired	inspire	VERB
dpc-3630	67	5	by	by	ADP
dpc-3630	67	6	some	some	DET
dpc-3630	67	7	observations	observation	NOUN
dpc-3630	67	8	,	,	PUNCT
dpc-3630	67	9	such	such	ADJ
dpc-3630	67	10	as	as	ADP
dpc-3630	67	11	the	the	DET
dpc-3630	67	12	dermatome	dermatome	NOUN
dpc-3630	67	13	-	-	PUNCT
dpc-3630	67	14	like	like	ADJ
dpc-3630	67	15	distribution	distribution	NOUN
dpc-3630	67	16	of	of	ADP
dpc-3630	67	17	lesions	lesion	NOUN
dpc-3630	67	18	in	in	ADP
dpc-3630	67	19	some	some	DET
dpc-3630	67	20	segmental	segmental	ADJ
dpc-3630	67	21	vitiligo	vitiligo	NOUN
dpc-3630	67	22	patients	patient	NOUN
dpc-3630	67	23	,	,	PUNCT
dpc-3630	67	24	various	various	ADJ
dpc-3630	67	25	degrees	degree	NOUN
dpc-3630	67	26	of	of	ADP
dpc-3630	67	27	degeneration	degeneration	NOUN
dpc-3630	67	28	of	of	ADP
dpc-3630	67	29	dermal	dermal	ADJ
dpc-3630	67	30	nerves	nerve	NOUN
dpc-3630	67	31	in	in	ADP
dpc-3630	67	32	some	some	DET
dpc-3630	67	33	patients	patient	NOUN
dpc-3630	67	34	with	with	ADP
dpc-3630	67	35	active	active	ADJ
dpc-3630	67	36	vitiligo	vitiligo	NOUN
dpc-3630	67	37	,	,	PUNCT
dpc-3630	67	38	and	and	CCONJ
dpc-3630	67	39	the	the	DET
dpc-3630	67	40	origin	origin	NOUN
dpc-3630	67	41	of	of	ADP
dpc-3630	67	42	melanocytes	melanocyte	NOUN
dpc-3630	67	43	and	and	CCONJ
dpc-3630	67	44	nervous	nervous	ADJ
dpc-3630	67	45	system	system	NOUN
dpc-3630	67	46	cells	cell	NOUN
dpc-3630	67	47	from	from	ADP
dpc-3630	67	48	the	the	DET
dpc-3630	67	49	neural	neural	ADJ
dpc-3630	67	50	crest	crest	NOUN
dpc-3630	68	1	[	[	X
dpc-3630	68	2	12	12	NUM
dpc-3630	68	3	-	-	SYM
dpc-3630	68	4	14	14	NUM
dpc-3630	68	5	]	]	PUNCT
dpc-3630	68	6	.	.	PUNCT
dpc-3630	69	1	some	some	DET
dpc-3630	69	2	studies	study	NOUN
dpc-3630	69	3	have	have	AUX
dpc-3630	69	4	suggested	suggest	VERB
dpc-3630	69	5	that	that	SCONJ
dpc-3630	69	6	neurogenic	neurogenic	ADJ
dpc-3630	69	7	mediators	mediator	NOUN
dpc-3630	69	8	such	such	ADJ
dpc-3630	69	9	as	as	ADP
dpc-3630	69	10	neuropeptides	neuropeptide	NOUN
dpc-3630	69	11	and	and	CCONJ
dpc-3630	69	12	neurotransmitters	neurotransmitter	NOUN
dpc-3630	69	13	play	play	VERB
dpc-3630	69	14	an	an	DET
dpc-3630	69	15	important	important	ADJ
dpc-3630	69	16	role	role	NOUN
dpc-3630	69	17	in	in	ADP
dpc-3630	69	18	the	the	DET
dpc-3630	69	19	development	development	NOUN
dpc-3630	69	20	of	of	ADP
dpc-3630	69	21	cutaneous	cutaneous	ADJ
dpc-3630	69	22	neurogenic	neurogenic	ADJ
dpc-3630	69	23	inflammation	inflammation	NOUN
dpc-3630	69	24	and	and	CCONJ
dpc-3630	69	25	melanocyte	melanocyte	NOUN
dpc-3630	69	26	destruction	destruction	NOUN
dpc-3630	69	27	or	or	CCONJ
dpc-3630	69	28	inhibition	inhibition	NOUN
dpc-3630	69	29	of	of	ADP
dpc-3630	69	30	melanin	melanin	NOUN
dpc-3630	69	31	synthesis	synthesis	NOUN
dpc-3630	69	32	.	.	PUNCT
dpc-3630	70	1	these	these	DET
dpc-3630	70	2	mediators	mediator	NOUN
dpc-3630	70	3	are	be	AUX
dpc-3630	70	4	derived	derive	VERB
dpc-3630	70	5	from	from	ADP
dpc-3630	70	6	cutaneous	cutaneous	ADJ
dpc-3630	70	7	nerve	nerve	NOUN
dpc-3630	70	8	endings	ending	NOUN
dpc-3630	70	9	and	and	CCONJ
dpc-3630	70	10	regulated	regulate	VERB
dpc-3630	70	11	by	by	ADP
dpc-3630	70	12	descending	descend	VERB
dpc-3630	70	13	anti	anti	ADJ
dpc-3630	70	14	-	-	ADJ
dpc-3630	70	15	inflammatory	inflammatory	ADJ
dpc-3630	70	16	neural	neural	ADJ
dpc-3630	70	17	pathways	pathway	NOUN
dpc-3630	71	1	[	[	X
dpc-3630	71	2	12	12	NUM
dpc-3630	71	3	-	-	SYM
dpc-3630	71	4	15	15	NUM
dpc-3630	71	5	]	]	PUNCT
dpc-3630	71	6	.	.	PUNCT
dpc-3630	72	1	based	base	VERB
dpc-3630	72	2	on	on	ADP
dpc-3630	72	3	a	a	DET
dpc-3630	72	4	widely	widely	ADV
dpc-3630	72	5	held	hold	VERB
dpc-3630	72	6	belief	belief	NOUN
dpc-3630	72	7	,	,	PUNCT
dpc-3630	72	8	suffering	suffer	VERB
dpc-3630	72	9	from	from	ADP
dpc-3630	72	10	one	one	NUM
dpc-3630	72	11	autoimmune	autoimmune	ADJ
dpc-3630	72	12	disease	disease	NOUN
dpc-3630	72	13	increases	increase	VERB
dpc-3630	72	14	the	the	DET
dpc-3630	72	15	possibility	possibility	NOUN
dpc-3630	72	16	of	of	ADP
dpc-3630	72	17	occurring	occur	VERB
dpc-3630	72	18	other	other	ADJ
dpc-3630	72	19	autoimmune	autoimmune	ADJ
dpc-3630	72	20	diseases	disease	NOUN
dpc-3630	72	21	in	in	ADP
dpc-3630	72	22	individuals	individual	NOUN
dpc-3630	72	23	and	and	CCONJ
dpc-3630	72	24	within	within	ADP
dpc-3630	72	25	families	family	NOUN
dpc-3630	72	26	through	through	ADP
dpc-3630	72	27	gene	gene	NOUN
dpc-3630	72	28	polymorphism	polymorphism	NOUN
dpc-3630	72	29	[	[	X
dpc-3630	72	30	16,17	16,17	NUM
dpc-3630	72	31	]	]	PUNCT
dpc-3630	72	32	.	.	PUNCT
dpc-3630	73	1	a	a	DET
dpc-3630	73	2	combination	combination	NOUN
dpc-3630	73	3	of	of	ADP
dpc-3630	73	4	genetic	genetic	ADJ
dpc-3630	73	5	,	,	PUNCT
dpc-3630	73	6	environmental	environmental	ADJ
dpc-3630	73	7	,	,	PUNCT
dpc-3630	73	8	and	and	CCONJ
dpc-3630	73	9	random	random	ADJ
dpc-3630	73	10	influences	influence	NOUN
dpc-3630	73	11	will	will	AUX
dpc-3630	73	12	presumably	presumably	ADV
dpc-3630	73	13	make	make	VERB
dpc-3630	73	14	synergy	synergy	NOUN
dpc-3630	73	15	and	and	CCONJ
dpc-3630	73	16	a	a	DET
dpc-3630	73	17	weak	weak	ADJ
dpc-3630	73	18	tolerance	tolerance	NOUN
dpc-3630	73	19	of	of	ADP
dpc-3630	73	20	the	the	DET
dpc-3630	73	21	patient	patient	ADJ
dpc-3630	73	22	own	own	ADJ
dpc-3630	73	23	tissues	tissue	NOUN
dpc-3630	73	24	to	to	PART
dpc-3630	73	25	table	table	VERB
dpc-3630	73	26	2	2	NUM
dpc-3630	73	27	.	.	PUNCT
dpc-3630	73	28	frequency	frequency	NOUN
dpc-3630	73	29	of	of	ADP
dpc-3630	73	30	multiple	multiple	ADJ
dpc-3630	73	31	sclerosis	sclerosis	NOUN
dpc-3630	73	32	in	in	ADP
dpc-3630	73	33	patients	patient	NOUN
dpc-3630	73	34	and	and	CCONJ
dpc-3630	73	35	their	their	PRON
dpc-3630	73	36	first	first	ADJ
dpc-3630	73	37	-	-	PUNCT
dpc-3630	73	38	degree	degree	NOUN
dpc-3630	73	39	relatives	relative	NOUN
dpc-3630	73	40	patients	patient	NOUN
dpc-3630	73	41	n	n	PROPN
dpc-3630	73	42	(	(	PUNCT
dpc-3630	73	43	%	%	INTJ
dpc-3630	73	44	)	)	PUNCT
dpc-3630	73	45	male	male	NOUN
dpc-3630	73	46	12	12	NUM
dpc-3630	73	47	(	(	PUNCT
dpc-3630	73	48	1.69	1.69	NUM
dpc-3630	73	49	)	)	PUNCT
dpc-3630	73	50	female	female	NOUN
dpc-3630	73	51	3	3	NUM
dpc-3630	73	52	(	(	PUNCT
dpc-3630	73	53	0.42	0.42	NUM
dpc-3630	73	54	)	)	PUNCT
dpc-3630	73	55	total	total	NOUN
dpc-3630	73	56	15	15	NUM
dpc-3630	73	57	(	(	PUNCT
dpc-3630	73	58	2.12	2.12	NUM
dpc-3630	73	59	)	)	PUNCT
dpc-3630	73	60	patients	patient	NOUN
dpc-3630	73	61	first	first	ADJ
dpc-3630	73	62	-	-	PUNCT
dpc-3630	73	63	degree	degree	NOUN
dpc-3630	73	64	relatives	relative	NOUN
dpc-3630	73	65	n	n	CCONJ
dpc-3630	73	66	(	(	PUNCT
dpc-3630	73	67	%	%	INTJ
dpc-3630	73	68	)	)	PUNCT
dpc-3630	73	69	10	10	NUM
dpc-3630	73	70	(	(	PUNCT
dpc-3630	73	71	0.35	0.35	NUM
dpc-3630	73	72	)	)	PUNCT
dpc-3630	73	73	table	table	NOUN
dpc-3630	73	74	3	3	NUM
dpc-3630	73	75	.	.	PUNCT
dpc-3630	73	76	frequency	frequency	NOUN
dpc-3630	73	77	of	of	ADP
dpc-3630	73	78	multiple	multiple	ADJ
dpc-3630	73	79	sclerosis	sclerosis	NOUN
dpc-3630	73	80	by	by	ADP
dpc-3630	73	81	depigmented	depigmented	ADJ
dpc-3630	73	82	lesion	lesion	NOUN
dpc-3630	73	83	location	location	NOUN
dpc-3630	73	84	multiple	multiple	ADJ
dpc-3630	73	85	sclerosis	sclerosis	NOUN
dpc-3630	73	86	,	,	PUNCT
dpc-3630	73	87	n	n	PROPN
dpc-3630	73	88	(	(	PUNCT
dpc-3630	73	89	%	%	INTJ
dpc-3630	73	90	)	)	PUNCT
dpc-3630	73	91	pno	pno	NOUN
dpc-3630	73	92	yes	yes	INTJ
dpc-3630	73	93	face	face	NOUN
dpc-3630	73	94	513	513	NUM
dpc-3630	73	95	(	(	PUNCT
dpc-3630	73	96	74.03	74.03	NUM
dpc-3630	73	97	)	)	PUNCT
dpc-3630	73	98	9	9	NUM
dpc-3630	73	99	(	(	PUNCT
dpc-3630	73	100	60	60	NUM
dpc-3630	73	101	)	)	PUNCT
dpc-3630	73	102	0.239	0.239	NUM
dpc-3630	73	103	limb	limb	NOUN
dpc-3630	73	104	601	601	NUM
dpc-3630	73	105	(	(	PUNCT
dpc-3630	73	106	86.72	86.72	NUM
dpc-3630	73	107	)	)	PUNCT
dpc-3630	73	108	14	14	NUM
dpc-3630	73	109	(	(	PUNCT
dpc-3630	73	110	93.33	93.33	NUM
dpc-3630	73	111	)	)	PUNCT
dpc-3630	73	112	0.706	0.706	NUM
dpc-3630	73	113	trunk	trunk	NOUN
dpc-3630	73	114	408	408	NUM
dpc-3630	73	115	(	(	PUNCT
dpc-3630	73	116	58.87	58.87	NUM
dpc-3630	73	117	)	)	PUNCT
dpc-3630	73	118	8	8	NUM
dpc-3630	73	119	(	(	PUNCT
dpc-3630	73	120	53.33	53.33	NUM
dpc-3630	73	121	)	)	PUNCT
dpc-3630	73	122	0.868	0.868	NUM
dpc-3630	73	123	genital	genital	ADJ
dpc-3630	73	124	283	283	NUM
dpc-3630	73	125	(	(	PUNCT
dpc-3630	73	126	40.84	40.84	NUM
dpc-3630	73	127	)	)	PUNCT
dpc-3630	73	128	5	5	NUM
dpc-3630	73	129	(	(	PUNCT
dpc-3630	73	130	33.33	33.33	NUM
dpc-3630	73	131	)	)	PUNCT
dpc-3630	73	132	0.749	0.749	NUM
dpc-3630	73	133	figure	figure	NOUN
dpc-3630	73	134	1	1	NUM
dpc-3630	73	135	.	.	PUNCT
dpc-3630	74	1	history	history	NOUN
dpc-3630	74	2	of	of	ADP
dpc-3630	74	3	multiple	multiple	ADJ
dpc-3630	74	4	sclerosis	sclerosis	NOUN
dpc-3630	74	5	and	and	CCONJ
dpc-3630	74	6	duration	duration	NOUN
dpc-3630	74	7	(	(	PUNCT
dpc-3630	74	8	years	year	NOUN
dpc-3630	74	9	)	)	PUNCT
dpc-3630	74	10	of	of	ADP
dpc-3630	74	11	vitiligo	vitiligo	NOUN
dpc-3630	74	12	(	(	PUNCT
dpc-3630	74	13	p	p	NOUN
dpc-3630	74	14	value	value	NOUN
dpc-3630	74	15	=	=	NOUN
dpc-3630	74	16	0.320	0.320	NUM
dpc-3630	74	17	)	)	PUNCT
dpc-3630	74	18	.	.	PUNCT
dpc-3630	75	1	table	table	NOUN
dpc-3630	75	2	4	4	NUM
dpc-3630	75	3	.	.	PUNCT
dpc-3630	75	4	frequency	frequency	NOUN
dpc-3630	75	5	of	of	ADP
dpc-3630	75	6	multiple	multiple	ADJ
dpc-3630	75	7	sclerosis	sclerosis	NOUN
dpc-3630	75	8	in	in	ADP
dpc-3630	75	9	earlyonset	earlyonset	NOUN
dpc-3630	75	10	and	and	CCONJ
dpc-3630	75	11	late	late	ADJ
dpc-3630	75	12	-	-	PUNCT
dpc-3630	75	13	onset	onset	NOUN
dpc-3630	75	14	groups	group	NOUN
dpc-3630	75	15	n	n	CCONJ
dpc-3630	75	16	(	(	PUNCT
dpc-3630	75	17	%	%	NOUN
dpc-3630	75	18	)	)	PUNCT
dpc-3630	75	19	p	p	X
dpc-3630	75	20	-	-	PUNCT
dpc-3630	75	21	value	value	NOUN
dpc-3630	75	22	early	early	ADJ
dpc-3630	75	23	-	-	PUNCT
dpc-3630	75	24	onset	onset	NOUN
dpc-3630	75	25	0.33	0.33	NUM
dpc-3630	75	26	1	1	NUM
dpc-3630	75	27	(	(	PUNCT
dpc-3630	75	28	0.69	0.69	NUM
dpc-3630	75	29	)	)	PUNCT
dpc-3630	75	30	late	late	ADJ
dpc-3630	75	31	-	-	PUNCT
dpc-3630	75	32	onset	onset	NOUN
dpc-3630	75	33	14	14	NUM
dpc-3630	75	34	(	(	PUNCT
dpc-3630	75	35	2.56	2.56	NUM
dpc-3630	75	36	)	)	PUNCT
dpc-3630	75	37	figure	figure	NOUN
dpc-3630	75	38	2	2	NUM
dpc-3630	75	39	.	.	PUNCT
dpc-3630	75	40	history	history	NOUN
dpc-3630	75	41	of	of	ADP
dpc-3630	75	42	multiple	multiple	ADJ
dpc-3630	75	43	sclerosis	sclerosis	NOUN
dpc-3630	75	44	and	and	CCONJ
dpc-3630	75	45	age	age	NOUN
dpc-3630	75	46	(	(	PUNCT
dpc-3630	75	47	years	year	NOUN
dpc-3630	75	48	)	)	PUNCT
dpc-3630	75	49	of	of	ADP
dpc-3630	75	50	patients	patient	NOUN
dpc-3630	75	51	(	(	PUNCT
dpc-3630	75	52	p	p	NOUN
dpc-3630	75	53	value	value	NOUN
dpc-3630	75	54	=	=	NOUN
dpc-3630	75	55	0.363	0.363	NUM
dpc-3630	75	56	)	)	PUNCT
dpc-3630	75	57	.	.	PUNCT
dpc-3630	76	1	4	4	NUM
dpc-3630	76	2	original	original	ADJ
dpc-3630	76	3	article	article	NOUN
dpc-3630	76	4	|	|	ADV
dpc-3630	76	5	dermatol	dermatol	ADJ
dpc-3630	76	6	pract	pract	NOUN
dpc-3630	76	7	concept	concept	NOUN
dpc-3630	76	8	.	.	PUNCT
dpc-3630	77	1	2024;14(3):e2024103	2024;14(3):e2024103	NUM
dpc-3630	78	1	the	the	DET
dpc-3630	78	2	average	average	ADJ
dpc-3630	78	3	population	population	NOUN
dpc-3630	78	4	(	(	PUNCT
dpc-3630	78	5	4.48	4.48	NUM
dpc-3630	78	6	-	-	ADJ
dpc-3630	78	7	fold	fold	ADJ
dpc-3630	78	8	increase	increase	NOUN
dpc-3630	78	9	,	,	PUNCT
dpc-3630	78	10	p	p	X
dpc-3630	78	11	<	<	X
dpc-3630	78	12	0.001	0.001	NUM
dpc-3630	78	13	)	)	PUNCT
dpc-3630	79	1	[	[	X
dpc-3630	79	2	7	7	NUM
dpc-3630	79	3	]	]	PUNCT
dpc-3630	79	4	.	.	PUNCT
dpc-3630	80	1	in	in	ADP
dpc-3630	80	2	some	some	DET
dpc-3630	80	3	studies	study	NOUN
dpc-3630	80	4	,	,	PUNCT
dpc-3630	80	5	vitiligo	vitiligo	PROPN
dpc-3630	80	6	was	be	AUX
dpc-3630	80	7	also	also	ADV
dpc-3630	80	8	reported	report	VERB
dpc-3630	80	9	as	as	ADP
dpc-3630	80	10	a	a	DET
dpc-3630	80	11	common	common	ADJ
dpc-3630	80	12	comorbid	comorbid	NOUN
dpc-3630	80	13	disease	disease	NOUN
dpc-3630	80	14	in	in	ADP
dpc-3630	80	15	patients	patient	NOUN
dpc-3630	80	16	with	with	ADP
dpc-3630	80	17	ms	ms	PROPN
dpc-3630	80	18	[	[	X
dpc-3630	80	19	16	16	NUM
dpc-3630	80	20	]	]	PUNCT
dpc-3630	80	21	.	.	PUNCT
dpc-3630	81	1	however	however	ADV
dpc-3630	81	2	,	,	PUNCT
dpc-3630	81	3	in	in	ADP
dpc-3630	81	4	many	many	ADJ
dpc-3630	81	5	studies	study	NOUN
dpc-3630	81	6	,	,	PUNCT
dpc-3630	81	7	researchers	researcher	NOUN
dpc-3630	81	8	found	find	VERB
dpc-3630	81	9	no	no	DET
dpc-3630	81	10	significant	significant	ADJ
dpc-3630	81	11	association	association	NOUN
dpc-3630	81	12	between	between	ADP
dpc-3630	81	13	vitiligo	vitiligo	PROPN
dpc-3630	81	14	and	and	CCONJ
dpc-3630	81	15	ms	ms	NOUN
dpc-3630	81	16	[	[	X
dpc-3630	81	17	2,5,9,21,24	2,5,9,21,24	PROPN
dpc-3630	81	18	]	]	X
dpc-3630	81	19	.	.	PUNCT
dpc-3630	82	1	a	a	DET
dpc-3630	82	2	systematic	systematic	ADJ
dpc-3630	82	3	review	review	NOUN
dpc-3630	82	4	and	and	CCONJ
dpc-3630	82	5	meta	meta	ADJ
dpc-3630	82	6	-	-	PUNCT
dpc-3630	82	7	analysis	analysis	NOUN
dpc-3630	82	8	conducted	conduct	VERB
dpc-3630	82	9	by	by	ADP
dpc-3630	82	10	shen	shen	NOUN
dpc-3630	82	11	and	and	CCONJ
dpc-3630	82	12	colleagues	colleague	NOUN
dpc-3630	82	13	found	find	VERB
dpc-3630	82	14	no	no	DET
dpc-3630	82	15	association	association	NOUN
dpc-3630	82	16	between	between	ADP
dpc-3630	82	17	ms	ms	PROPN
dpc-3630	82	18	and	and	CCONJ
dpc-3630	82	19	vitiligo	vitiligo	VERB
dpc-3630	82	20	[	[	X
dpc-3630	82	21	6	6	NUM
dpc-3630	82	22	]	]	PUNCT
dpc-3630	82	23	.	.	PUNCT
dpc-3630	83	1	immunity	immunity	NOUN
dpc-3630	83	2	,	,	PUNCT
dpc-3630	83	3	resulting	result	VERB
dpc-3630	83	4	in	in	ADP
dpc-3630	83	5	an	an	DET
dpc-3630	83	6	autoimmune	autoimmune	ADJ
dpc-3630	83	7	attack	attack	NOUN
dpc-3630	83	8	[	[	X
dpc-3630	83	9	18	18	NUM
dpc-3630	83	10	]	]	PUNCT
dpc-3630	83	11	.	.	PUNCT
dpc-3630	84	1	patients	patient	NOUN
dpc-3630	84	2	with	with	ADP
dpc-3630	84	3	vitiligo	vitiligo	PROPN
dpc-3630	84	4	have	have	VERB
dpc-3630	84	5	a	a	DET
dpc-3630	84	6	higher	high	ADJ
dpc-3630	84	7	prevalence	prevalence	NOUN
dpc-3630	84	8	of	of	ADP
dpc-3630	84	9	autoimmune	autoimmune	ADJ
dpc-3630	84	10	diseases	disease	NOUN
dpc-3630	84	11	such	such	ADJ
dpc-3630	84	12	as	as	ADP
dpc-3630	84	13	autoimmune	autoimmune	ADJ
dpc-3630	84	14	thyroid	thyroid	NOUN
dpc-3630	84	15	disease	disease	NOUN
dpc-3630	84	16	,	,	PUNCT
dpc-3630	84	17	type	type	NOUN
dpc-3630	84	18	i	i	PRON
dpc-3630	84	19	diabetes	diabete	VERB
dpc-3630	84	20	mellitus	mellitus	NOUN
dpc-3630	84	21	,	,	PUNCT
dpc-3630	84	22	pernicious	pernicious	ADJ
dpc-3630	84	23	anemia	anemia	NOUN
dpc-3630	84	24	,	,	PUNCT
dpc-3630	84	25	ra	ra	PROPN
dpc-3630	84	26	,	,	PUNCT
dpc-3630	84	27	sle	sle	PROPN
dpc-3630	84	28	,	,	PUNCT
dpc-3630	84	29	addison	addison	PROPN
dpc-3630	84	30	disease	disease	PROPN
dpc-3630	84	31	,	,	PUNCT
dpc-3630	84	32	and	and	CCONJ
dpc-3630	84	33	guillain	guillain	NOUN
dpc-3630	84	34	-	-	PUNCT
dpc-3630	84	35	barre	barre	NOUN
dpc-3630	84	36	syndrome	syndrome	NOUN
dpc-3630	84	37	[	[	X
dpc-3630	84	38	4	4	NUM
dpc-3630	84	39	]	]	PUNCT
dpc-3630	84	40	.	.	PUNCT
dpc-3630	85	1	it	it	PRON
dpc-3630	85	2	appears	appear	VERB
dpc-3630	85	3	that	that	SCONJ
dpc-3630	85	4	infiltration	infiltration	NOUN
dpc-3630	85	5	of	of	ADP
dpc-3630	85	6	t	t	PROPN
dpc-3630	85	7	-	-	PUNCT
dpc-3630	85	8	cells	cell	NOUN
dpc-3630	85	9	,	,	PUNCT
dpc-3630	85	10	including	include	VERB
dpc-3630	85	11	cd4	cd4	PROPN
dpc-3630	85	12	+	+	PROPN
dpc-3630	85	13	and	and	CCONJ
dpc-3630	85	14	cd8	cd8	PROPN
dpc-3630	85	15	+	+	PROPN
dpc-3630	85	16	t	t	NOUN
dpc-3630	85	17	cells	cell	NOUN
dpc-3630	85	18	,	,	PUNCT
dpc-3630	85	19	plays	play	VERB
dpc-3630	85	20	an	an	DET
dpc-3630	85	21	important	important	ADJ
dpc-3630	85	22	role	role	NOUN
dpc-3630	85	23	in	in	ADP
dpc-3630	85	24	the	the	DET
dpc-3630	85	25	pathogenesis	pathogenesis	NOUN
dpc-3630	85	26	of	of	ADP
dpc-3630	85	27	vitiligo	vitiligo	PROPN
dpc-3630	85	28	and	and	CCONJ
dpc-3630	85	29	ms	ms	PROPN
dpc-3630	85	30	.	.	PROPN
dpc-3630	85	31	besides	besides	PROPN
dpc-3630	85	32	,	,	PUNCT
dpc-3630	85	33	interferon	interferon	ADJ
dpc-3630	85	34	-	-	PUNCT
dpc-3630	85	35	gamma	gamma	NOUN
dpc-3630	85	36	,	,	PUNCT
dpc-3630	85	37	interferon	interferon	ADJ
dpc-3630	85	38	-	-	PUNCT
dpc-3630	85	39	gamma	gamma	NOUN
dpc-3630	85	40	-	-	PUNCT
dpc-3630	85	41	induced	induce	VERB
dpc-3630	85	42	chemokines	chemokine	NOUN
dpc-3630	85	43	,	,	PUNCT
dpc-3630	85	44	and	and	CCONJ
dpc-3630	85	45	il17	il17	PROPN
dpc-3630	85	46	are	be	AUX
dpc-3630	85	47	also	also	ADV
dpc-3630	85	48	potent	potent	ADJ
dpc-3630	85	49	cytokines	cytokine	NOUN
dpc-3630	85	50	in	in	ADP
dpc-3630	85	51	the	the	DET
dpc-3630	85	52	pathway	pathway	NOUN
dpc-3630	85	53	of	of	ADP
dpc-3630	85	54	autoimmunity	autoimmunity	NOUN
dpc-3630	85	55	[	[	X
dpc-3630	85	56	18	18	NUM
dpc-3630	85	57	]	]	PUNCT
dpc-3630	85	58	.	.	PUNCT
dpc-3630	86	1	another	another	DET
dpc-3630	86	2	cytokine	cytokine	NOUN
dpc-3630	86	3	that	that	PRON
dpc-3630	86	4	has	have	AUX
dpc-3630	86	5	recently	recently	ADV
dpc-3630	86	6	been	be	AUX
dpc-3630	86	7	mentioned	mention	VERB
dpc-3630	86	8	as	as	ADP
dpc-3630	86	9	a	a	DET
dpc-3630	86	10	common	common	ADJ
dpc-3630	86	11	component	component	NOUN
dpc-3630	86	12	in	in	ADP
dpc-3630	86	13	the	the	DET
dpc-3630	86	14	pathological	pathological	ADJ
dpc-3630	86	15	pathways	pathway	NOUN
dpc-3630	86	16	of	of	ADP
dpc-3630	86	17	ms	ms	NOUN
dpc-3630	86	18	and	and	CCONJ
dpc-3630	86	19	vitiligo	vitiligo	NOUN
dpc-3630	86	20	is	be	AUX
dpc-3630	86	21	il15	il15	PROPN
dpc-3630	86	22	.	.	PUNCT
dpc-3630	87	1	il15	il15	PROPN
dpc-3630	87	2	plays	play	VERB
dpc-3630	87	3	a	a	DET
dpc-3630	87	4	pro	pro	ADJ
dpc-3630	87	5	inflammatory	inflammatory	ADJ
dpc-3630	87	6	role	role	NOUN
dpc-3630	87	7	,	,	PUNCT
dpc-3630	87	8	inducing	induce	VERB
dpc-3630	87	9	demyelination	demyelination	NOUN
dpc-3630	87	10	and	and	CCONJ
dpc-3630	87	11	increasing	increase	VERB
dpc-3630	87	12	il17	il17	PROPN
dpc-3630	87	13	production	production	NOUN
dpc-3630	87	14	by	by	ADP
dpc-3630	87	15	th	th	NOUN
dpc-3630	87	16	cells	cell	NOUN
dpc-3630	87	17	.	.	PUNCT
dpc-3630	88	1	on	on	ADP
dpc-3630	88	2	the	the	DET
dpc-3630	88	3	other	other	ADJ
dpc-3630	88	4	hand	hand	NOUN
dpc-3630	88	5	,	,	PUNCT
dpc-3630	88	6	in	in	ADP
dpc-3630	88	7	patients	patient	NOUN
dpc-3630	88	8	with	with	ADP
dpc-3630	88	9	relapsing	relapse	VERB
dpc-3630	88	10	-	-	PUNCT
dpc-3630	88	11	remitting	remit	VERB
dpc-3630	88	12	ms	ms	NOUN
dpc-3630	88	13	,	,	PUNCT
dpc-3630	88	14	the	the	DET
dpc-3630	88	15	percentage	percentage	NOUN
dpc-3630	88	16	of	of	ADP
dpc-3630	88	17	il15	il15	PROPN
dpc-3630	88	18	producing	produce	VERB
dpc-3630	88	19	γδ	γδ	ADP
dpc-3630	88	20	-	-	PUNCT
dpc-3630	88	21	t	t	NOUN
dpc-3630	88	22	cells	cell	NOUN
dpc-3630	88	23	is	be	AUX
dpc-3630	88	24	significantly	significantly	ADV
dpc-3630	88	25	more	more	ADV
dpc-3630	88	26	frequent	frequent	ADJ
dpc-3630	88	27	than	than	ADP
dpc-3630	88	28	in	in	ADP
dpc-3630	88	29	normal	normal	ADJ
dpc-3630	88	30	individuals	individual	NOUN
dpc-3630	88	31	,	,	PUNCT
dpc-3630	88	32	and	and	CCONJ
dpc-3630	88	33	il15	il15	PROPN
dpc-3630	88	34	is	be	AUX
dpc-3630	88	35	upregulated	upregulate	VERB
dpc-3630	88	36	during	during	ADP
dpc-3630	88	37	relapses	relapse	NOUN
dpc-3630	88	38	[	[	X
dpc-3630	88	39	19	19	NUM
dpc-3630	88	40	]	]	PUNCT
dpc-3630	88	41	.	.	PUNCT
dpc-3630	89	1	in	in	ADP
dpc-3630	89	2	addition	addition	NOUN
dpc-3630	89	3	,	,	PUNCT
dpc-3630	89	4	il15	il15	PROPN
dpc-3630	89	5	is	be	AUX
dpc-3630	89	6	one	one	NUM
dpc-3630	89	7	of	of	ADP
dpc-3630	89	8	the	the	DET
dpc-3630	89	9	most	most	ADV
dpc-3630	89	10	important	important	ADJ
dpc-3630	89	11	factors	factor	NOUN
dpc-3630	89	12	in	in	ADP
dpc-3630	89	13	the	the	DET
dpc-3630	89	14	maintenance	maintenance	NOUN
dpc-3630	89	15	of	of	ADP
dpc-3630	89	16	skin	skin	NOUN
dpc-3630	89	17	-	-	PUNCT
dpc-3630	89	18	resident	resident	NOUN
dpc-3630	89	19	memory	memory	NOUN
dpc-3630	89	20	t	t	PROPN
dpc-3630	89	21	-	-	PUNCT
dpc-3630	89	22	cells	cell	NOUN
dpc-3630	89	23	which	which	PRON
dpc-3630	89	24	are	be	AUX
dpc-3630	89	25	implicated	implicate	VERB
dpc-3630	89	26	in	in	ADP
dpc-3630	89	27	the	the	DET
dpc-3630	89	28	pathogenesis	pathogenesis	NOUN
dpc-3630	89	29	of	of	ADP
dpc-3630	89	30	vitiligo	vitiligo	NOUN
dpc-3630	89	31	[	[	X
dpc-3630	89	32	20	20	NUM
dpc-3630	89	33	]	]	PUNCT
dpc-3630	89	34	.	.	PUNCT
dpc-3630	90	1	it	it	PRON
dpc-3630	90	2	is	be	AUX
dpc-3630	90	3	also	also	ADV
dpc-3630	90	4	strongly	strongly	ADV
dpc-3630	90	5	suggested	suggest	VERB
dpc-3630	90	6	that	that	SCONJ
dpc-3630	90	7	cellular	cellular	ADJ
dpc-3630	90	8	stress	stress	NOUN
dpc-3630	90	9	(	(	PUNCT
dpc-3630	90	10	including	include	VERB
dpc-3630	90	11	the	the	DET
dpc-3630	90	12	generation	generation	NOUN
dpc-3630	90	13	of	of	ADP
dpc-3630	90	14	misfolded	misfolded	ADJ
dpc-3630	90	15	proteins	protein	NOUN
dpc-3630	90	16	,	,	PUNCT
dpc-3630	90	17	the	the	DET
dpc-3630	90	18	formation	formation	NOUN
dpc-3630	90	19	of	of	ADP
dpc-3630	90	20	ros	ros	PROPN
dpc-3630	90	21	,	,	PUNCT
dpc-3630	90	22	and	and	CCONJ
dpc-3630	90	23	environmental	environmental	ADJ
dpc-3630	90	24	exposures	exposure	NOUN
dpc-3630	90	25	such	such	ADJ
dpc-3630	90	26	as	as	ADP
dpc-3630	90	27	uv	uv	NOUN
dpc-3630	90	28	light	light	NOUN
dpc-3630	90	29	and	and	CCONJ
dpc-3630	90	30	chemicals	chemical	NOUN
dpc-3630	90	31	)	)	PUNCT
dpc-3630	90	32	is	be	AUX
dpc-3630	90	33	involved	involve	VERB
dpc-3630	90	34	in	in	ADP
dpc-3630	90	35	the	the	DET
dpc-3630	90	36	pathway	pathway	NOUN
dpc-3630	90	37	of	of	ADP
dpc-3630	90	38	vitiligo	vitiligo	PROPN
dpc-3630	90	39	and	and	CCONJ
dpc-3630	90	40	ms	ms	NOUN
dpc-3630	90	41	,	,	PUNCT
dpc-3630	90	42	and	and	CCONJ
dpc-3630	90	43	as	as	SCONJ
dpc-3630	90	44	previously	previously	ADV
dpc-3630	90	45	noted	note	VERB
dpc-3630	90	46	,	,	PUNCT
dpc-3630	90	47	inflammation	inflammation	NOUN
dpc-3630	90	48	can	can	AUX
dpc-3630	90	49	be	be	AUX
dpc-3630	90	50	a	a	DET
dpc-3630	90	51	consequence	consequence	NOUN
dpc-3630	90	52	of	of	ADP
dpc-3630	90	53	cellular	cellular	ADJ
dpc-3630	90	54	stress	stress	NOUN
dpc-3630	91	1	[	[	X
dpc-3630	91	2	18	18	NUM
dpc-3630	91	3	]	]	PUNCT
dpc-3630	91	4	.	.	PUNCT
dpc-3630	92	1	on	on	ADP
dpc-3630	92	2	the	the	DET
dpc-3630	92	3	other	other	ADJ
dpc-3630	92	4	hand	hand	NOUN
dpc-3630	92	5	,	,	PUNCT
dpc-3630	92	6	according	accord	VERB
dpc-3630	92	7	to	to	ADP
dpc-3630	92	8	a	a	DET
dpc-3630	92	9	systematic	systematic	ADJ
dpc-3630	92	10	review	review	NOUN
dpc-3630	92	11	by	by	ADP
dpc-3630	92	12	marrie	marrie	PROPN
dpc-3630	92	13	et	et	PROPN
dpc-3630	92	14	al	al	PROPN
dpc-3630	92	15	,	,	PUNCT
dpc-3630	92	16	no	no	DET
dpc-3630	92	17	particular	particular	ADJ
dpc-3630	92	18	increased	increase	VERB
dpc-3630	92	19	risk	risk	NOUN
dpc-3630	92	20	was	be	AUX
dpc-3630	92	21	found	find	VERB
dpc-3630	92	22	between	between	ADP
dpc-3630	92	23	ms	ms	PROPN
dpc-3630	92	24	and	and	CCONJ
dpc-3630	92	25	other	other	ADJ
dpc-3630	92	26	autoimmune	autoimmune	ADJ
dpc-3630	92	27	diseases	disease	NOUN
dpc-3630	92	28	,	,	PUNCT
dpc-3630	92	29	except	except	SCONJ
dpc-3630	92	30	for	for	ADP
dpc-3630	92	31	inflammatory	inflammatory	ADJ
dpc-3630	92	32	bowel	bowel	NOUN
dpc-3630	92	33	disease	disease	NOUN
dpc-3630	92	34	,	,	PUNCT
dpc-3630	92	35	uveitis	uveitis	NOUN
dpc-3630	92	36	,	,	PUNCT
dpc-3630	92	37	and	and	CCONJ
dpc-3630	92	38	pemphigoid	pemphigoid	ADJ
dpc-3630	92	39	.	.	PUNCT
dpc-3630	93	1	these	these	DET
dpc-3630	93	2	diseases	disease	NOUN
dpc-3630	93	3	may	may	AUX
dpc-3630	93	4	be	be	AUX
dpc-3630	93	5	more	more	ADV
dpc-3630	93	6	common	common	ADJ
dpc-3630	93	7	in	in	ADP
dpc-3630	93	8	ms	ms	NOUN
dpc-3630	93	9	due	due	ADP
dpc-3630	93	10	to	to	ADP
dpc-3630	93	11	a	a	DET
dpc-3630	93	12	shared	share	VERB
dpc-3630	93	13	genetic	genetic	ADJ
dpc-3630	93	14	susceptibility	susceptibility	NOUN
dpc-3630	93	15	and	and	CCONJ
dpc-3630	93	16	environmental	environmental	ADJ
dpc-3630	93	17	influences	influence	NOUN
dpc-3630	93	18	(	(	PUNCT
dpc-3630	93	19	table	table	NOUN
dpc-3630	93	20	5	5	NUM
dpc-3630	93	21	)	)	PUNCT
dpc-3630	94	1	[	[	X
dpc-3630	94	2	21	21	NUM
dpc-3630	94	3	]	]	PUNCT
dpc-3630	94	4	.	.	PUNCT
dpc-3630	95	1	vitamin	vitamin	NOUN
dpc-3630	95	2	d	d	NOUN
dpc-3630	95	3	regulates	regulate	VERB
dpc-3630	95	4	melanogenesis	melanogenesis	NOUN
dpc-3630	95	5	and	and	CCONJ
dpc-3630	95	6	immune	immune	ADJ
dpc-3630	95	7	functions	function	NOUN
dpc-3630	95	8	.	.	PUNCT
dpc-3630	96	1	the	the	DET
dpc-3630	96	2	occurrence	occurrence	NOUN
dpc-3630	96	3	of	of	ADP
dpc-3630	96	4	vitiligo	vitiligo	NOUN
dpc-3630	96	5	,	,	PUNCT
dpc-3630	96	6	like	like	ADP
dpc-3630	96	7	many	many	ADJ
dpc-3630	96	8	other	other	ADJ
dpc-3630	96	9	autoimmune	autoimmune	ADJ
dpc-3630	96	10	conditions	condition	NOUN
dpc-3630	96	11	,	,	PUNCT
dpc-3630	96	12	including	include	VERB
dpc-3630	96	13	rheumatoid	rheumatoid	NOUN
dpc-3630	96	14	arthritis	arthritis	NOUN
dpc-3630	96	15	,	,	PUNCT
dpc-3630	96	16	diabetes	diabetes	NOUN
dpc-3630	96	17	mellitus	mellitus	NOUN
dpc-3630	96	18	,	,	PUNCT
dpc-3630	96	19	and	and	CCONJ
dpc-3630	96	20	multiple	multiple	ADJ
dpc-3630	96	21	sclerosis	sclerosis	NOUN
dpc-3630	96	22	,	,	PUNCT
dpc-3630	96	23	may	may	AUX
dpc-3630	96	24	be	be	AUX
dpc-3630	96	25	due	due	ADJ
dpc-3630	96	26	to	to	ADP
dpc-3630	96	27	low	low	ADJ
dpc-3630	96	28	vitamin	vitamin	NOUN
dpc-3630	96	29	d	d	NOUN
dpc-3630	96	30	status	status	NOUN
dpc-3630	96	31	[	[	X
dpc-3630	96	32	22,23	22,23	NOUN
dpc-3630	96	33	]	]	X
dpc-3630	96	34	.	.	PUNCT
dpc-3630	97	1	some	some	DET
dpc-3630	97	2	studies	study	NOUN
dpc-3630	97	3	have	have	AUX
dpc-3630	97	4	shown	show	VERB
dpc-3630	97	5	that	that	SCONJ
dpc-3630	97	6	a	a	DET
dpc-3630	97	7	polymorphism	polymorphism	NOUN
dpc-3630	97	8	in	in	ADP
dpc-3630	97	9	the	the	DET
dpc-3630	97	10	vitamin	vitamin	NOUN
dpc-3630	97	11	d	d	NOUN
dpc-3630	97	12	receptor	receptor	NOUN
dpc-3630	97	13	(	(	PUNCT
dpc-3630	97	14	vdr	vdr	NOUN
dpc-3630	97	15	)	)	PUNCT
dpc-3630	97	16	gene	gene	NOUN
dpc-3630	97	17	increases	increase	VERB
dpc-3630	97	18	the	the	DET
dpc-3630	97	19	risk	risk	NOUN
dpc-3630	97	20	of	of	ADP
dpc-3630	97	21	many	many	ADJ
dpc-3630	97	22	autoimmune	autoimmune	ADJ
dpc-3630	97	23	diseases	disease	NOUN
dpc-3630	97	24	such	such	ADJ
dpc-3630	97	25	as	as	ADP
dpc-3630	97	26	hashimoto	hashimoto	NOUN
dpc-3630	97	27	thyroiditis	thyroiditis	NOUN
dpc-3630	97	28	,	,	PUNCT
dpc-3630	97	29	ibd	ibd	PROPN
dpc-3630	97	30	,	,	PUNCT
dpc-3630	97	31	graves	grave	VERB
dpc-3630	97	32	disease	disease	NOUN
dpc-3630	97	33	,	,	PUNCT
dpc-3630	97	34	ra	ra	PROPN
dpc-3630	97	35	,	,	PUNCT
dpc-3630	97	36	sle	sle	PROPN
dpc-3630	97	37	,	,	PUNCT
dpc-3630	97	38	pbc	pbc	PROPN
dpc-3630	97	39	,	,	PUNCT
dpc-3630	97	40	autoimmune	autoimmune	ADJ
dpc-3630	97	41	hepatitis	hepatitis	PROPN
dpc-3630	97	42	,	,	PUNCT
dpc-3630	97	43	addison	addison	PROPN
dpc-3630	97	44	disease	disease	PROPN
dpc-3630	97	45	,	,	PUNCT
dpc-3630	97	46	vitiligo	vitiligo	PROPN
dpc-3630	97	47	,	,	PUNCT
dpc-3630	97	48	celiac	celiac	ADJ
dpc-3630	97	49	disease	disease	NOUN
dpc-3630	97	50	,	,	PUNCT
dpc-3630	97	51	t1	t1	PROPN
dpc-3630	97	52	dm	dm	PROPN
dpc-3630	97	53	,	,	PUNCT
dpc-3630	97	54	and	and	CCONJ
dpc-3630	97	55	ms	ms	NOUN
dpc-3630	98	1	[	[	X
dpc-3630	98	2	17	17	NUM
dpc-3630	98	3	]	]	PUNCT
dpc-3630	98	4	.	.	PUNCT
dpc-3630	99	1	in	in	ADP
dpc-3630	99	2	the	the	DET
dpc-3630	99	3	current	current	ADJ
dpc-3630	99	4	study	study	NOUN
dpc-3630	99	5	,	,	PUNCT
dpc-3630	99	6	709	709	NUM
dpc-3630	99	7	vitiligo	vitiligo	NOUN
dpc-3630	99	8	patients	patient	NOUN
dpc-3630	99	9	were	be	AUX
dpc-3630	99	10	observed	observe	VERB
dpc-3630	99	11	,	,	PUNCT
dpc-3630	99	12	15	15	NUM
dpc-3630	99	13	of	of	ADP
dpc-3630	99	14	whom	whom	PRON
dpc-3630	99	15	(	(	PUNCT
dpc-3630	99	16	2.12	2.12	NUM
dpc-3630	99	17	%	%	NOUN
dpc-3630	99	18	,	,	PUNCT
dpc-3630	99	19	95	95	NUM
dpc-3630	99	20	%	%	NOUN
dpc-3630	99	21	ci:1.06%-3.17	ci:1.06%-3.17	NOUN
dpc-3630	99	22	%	%	NOUN
dpc-3630	99	23	)	)	PUNCT
dpc-3630	99	24	had	have	VERB
dpc-3630	99	25	ms	ms	NOUN
dpc-3630	99	26	,	,	PUNCT
dpc-3630	99	27	which	which	PRON
dpc-3630	99	28	,	,	PUNCT
dpc-3630	99	29	according	accord	VERB
dpc-3630	99	30	to	to	ADP
dpc-3630	99	31	amini	amini	PROPN
dpc-3630	99	32	et	et	PROPN
dpc-3630	99	33	al	al	PROPN
dpc-3630	99	34	,	,	PUNCT
dpc-3630	99	35	was	be	AUX
dpc-3630	99	36	significantly	significantly	ADV
dpc-3630	99	37	higher	high	ADJ
dpc-3630	99	38	than	than	ADP
dpc-3630	99	39	the	the	DET
dpc-3630	99	40	mean	mean	NOUN
dpc-3630	99	41	of	of	ADP
dpc-3630	99	42	the	the	DET
dpc-3630	99	43	tehran	tehran	NOUN
dpc-3630	99	44	ms	ms	PROPN
dpc-3630	99	45	population	population	PROPN
dpc-3630	99	46	(	(	PUNCT
dpc-3630	99	47	0.184	0.184	NUM
dpc-3630	99	48	%	%	NOUN
dpc-3630	99	49	)	)	PUNCT
dpc-3630	100	1	(	(	PUNCT
dpc-3630	100	2	p	p	X
dpc-3630	100	3	<	<	X
dpc-3630	100	4	0.001	0.001	NUM
dpc-3630	100	5	)	)	PUNCT
dpc-3630	101	1	[	[	X
dpc-3630	101	2	10	10	NUM
dpc-3630	101	3	]	]	PUNCT
dpc-3630	101	4	.	.	PUNCT
dpc-3630	102	1	our	our	PRON
dpc-3630	102	2	results	result	NOUN
dpc-3630	102	3	support	support	VERB
dpc-3630	102	4	the	the	DET
dpc-3630	102	5	hypothesis	hypothesis	NOUN
dpc-3630	102	6	that	that	PRON
dpc-3630	102	7	patients	patient	NOUN
dpc-3630	102	8	with	with	ADP
dpc-3630	102	9	vitiligo	vitiligo	PROPN
dpc-3630	102	10	have	have	VERB
dpc-3630	102	11	a	a	DET
dpc-3630	102	12	higher	high	ADJ
dpc-3630	102	13	tendency	tendency	NOUN
dpc-3630	102	14	to	to	PART
dpc-3630	102	15	get	get	VERB
dpc-3630	102	16	ms	ms	NOUN
dpc-3630	102	17	in	in	ADP
dpc-3630	102	18	their	their	PRON
dpc-3630	102	19	lifetime	lifetime	NOUN
dpc-3630	102	20	.	.	PUNCT
dpc-3630	103	1	however	however	ADV
dpc-3630	103	2	,	,	PUNCT
dpc-3630	103	3	to	to	PART
dpc-3630	103	4	generalize	generalize	VERB
dpc-3630	103	5	this	this	DET
dpc-3630	103	6	conclusion	conclusion	NOUN
dpc-3630	103	7	to	to	ADP
dpc-3630	103	8	the	the	DET
dpc-3630	103	9	general	general	ADJ
dpc-3630	103	10	vitiligo	vitiligo	NOUN
dpc-3630	103	11	population	population	NOUN
dpc-3630	103	12	,	,	PUNCT
dpc-3630	103	13	further	further	ADJ
dpc-3630	103	14	studies	study	NOUN
dpc-3630	103	15	need	need	VERB
dpc-3630	103	16	to	to	PART
dpc-3630	103	17	be	be	AUX
dpc-3630	103	18	conducted	conduct	VERB
dpc-3630	103	19	on	on	ADP
dpc-3630	103	20	a	a	DET
dpc-3630	103	21	larger	large	ADJ
dpc-3630	103	22	scale	scale	NOUN
dpc-3630	103	23	.	.	PUNCT
dpc-3630	104	1	since	since	SCONJ
dpc-3630	104	2	most	most	ADJ
dpc-3630	104	3	of	of	ADP
dpc-3630	104	4	the	the	DET
dpc-3630	104	5	previous	previous	ADJ
dpc-3630	104	6	studies	study	NOUN
dpc-3630	104	7	were	be	AUX
dpc-3630	104	8	conducted	conduct	VERB
dpc-3630	104	9	in	in	ADP
dpc-3630	104	10	western	western	ADJ
dpc-3630	104	11	countries	country	NOUN
dpc-3630	104	12	,	,	PUNCT
dpc-3630	104	13	it	it	PRON
dpc-3630	104	14	is	be	AUX
dpc-3630	104	15	better	well	ADJ
dpc-3630	104	16	to	to	PART
dpc-3630	104	17	conduct	conduct	VERB
dpc-3630	104	18	this	this	DET
dpc-3630	104	19	research	research	NOUN
dpc-3630	104	20	in	in	ADP
dpc-3630	104	21	other	other	ADJ
dpc-3630	104	22	communities	community	NOUN
dpc-3630	104	23	in	in	ADP
dpc-3630	104	24	the	the	DET
dpc-3630	104	25	future	future	NOUN
dpc-3630	104	26	.	.	PUNCT
dpc-3630	105	1	there	there	PRON
dpc-3630	105	2	are	be	VERB
dpc-3630	105	3	some	some	DET
dpc-3630	105	4	studies	study	NOUN
dpc-3630	105	5	that	that	PRON
dpc-3630	105	6	confirm	confirm	VERB
dpc-3630	105	7	our	our	PRON
dpc-3630	105	8	findings	finding	NOUN
dpc-3630	105	9	.	.	PUNCT
dpc-3630	106	1	according	accord	VERB
dpc-3630	106	2	to	to	ADP
dpc-3630	106	3	hadi	hadi	PROPN
dpc-3630	106	4	et	et	PROPN
dpc-3630	106	5	al	al	PROPN
dpc-3630	106	6	,	,	PUNCT
dpc-3630	106	7	patients	patient	NOUN
dpc-3630	106	8	with	with	ADP
dpc-3630	106	9	vitiligo	vitiligo	PROPN
dpc-3630	106	10	had	have	VERB
dpc-3630	106	11	a	a	DET
dpc-3630	106	12	higher	high	ADJ
dpc-3630	106	13	ms	ms	NOUN
dpc-3630	106	14	frequency	frequency	NOUN
dpc-3630	106	15	than	than	ADP
dpc-3630	106	16	table	table	NOUN
dpc-3630	106	17	5	5	NUM
dpc-3630	106	18	.	.	PUNCT
dpc-3630	107	1	the	the	DET
dpc-3630	107	2	prevalence	prevalence	NOUN
dpc-3630	107	3	of	of	ADP
dpc-3630	107	4	autoimmune	autoimmune	ADJ
dpc-3630	107	5	comorbidities	comorbiditie	NOUN
dpc-3630	107	6	in	in	ADP
dpc-3630	107	7	patients	patient	NOUN
dpc-3630	107	8	with	with	ADP
dpc-3630	107	9	multiple	multiple	ADJ
dpc-3630	107	10	sclerosis	sclerosis	NOUN
dpc-3630	107	11	according	accord	VERB
dpc-3630	107	12	to	to	ADP
dpc-3630	107	13	a	a	DET
dpc-3630	107	14	review	review	NOUN
dpc-3630	107	15	conducted	conduct	VERB
dpc-3630	107	16	by	by	ADP
dpc-3630	107	17	marrie	marrie	PROPN
dpc-3630	107	18	et	et	PROPN
dpc-3630	107	19	al	al	PROPN
dpc-3630	108	1	[	[	X
dpc-3630	108	2	21	21	NUM
dpc-3630	108	3	]	]	PUNCT
dpc-3630	108	4	autoimmune	autoimmune	ADJ
dpc-3630	108	5	comorbid	comorbid	NOUN
dpc-3630	108	6	diseases	disease	NOUN
dpc-3630	108	7	prevalence	prevalence	NOUN
dpc-3630	108	8	,	,	PUNCT
dpc-3630	108	9	range	range	NOUN
dpc-3630	108	10	(	(	PUNCT
dpc-3630	108	11	%	%	INTJ
dpc-3630	108	12	)	)	PUNCT
dpc-3630	108	13	gastrointestinal	gastrointestinal	ADJ
dpc-3630	108	14	autoimmune	autoimmune	ADJ
dpc-3630	108	15	hepatitis	hepatitis	PROPN
dpc-3630	108	16	0.06–0.2	0.06–0.2	NUM
dpc-3630	108	17	celiac	celiac	ADJ
dpc-3630	108	18	disease	disease	NOUN
dpc-3630	108	19	0–11.1	0–11.1	VERB
dpc-3630	108	20	inflammatory	inflammatory	ADJ
dpc-3630	108	21	bowel	bowel	NOUN
dpc-3630	108	22	disease	disease	NOUN
dpc-3630	108	23	0.36–4.66	0.36–4.66	NUM
dpc-3630	109	1	a	a	DET
dpc-3630	109	2	primary	primary	ADJ
dpc-3630	109	3	biliary	biliary	NOUN
dpc-3630	109	4	cirrhosis	cirrhosis	NOUN
dpc-3630	109	5	0–0.12	0–0.12	NUM
dpc-3630	109	6	endocrine	endocrine	ADJ
dpc-3630	109	7	adrenocortical	adrenocortical	ADJ
dpc-3630	109	8	insufficiency	insufficiency	NOUN
dpc-3630	109	9	0–0.31	0–0.31	PROPN
dpc-3630	109	10	diabetes	diabetes	NOUN
dpc-3630	109	11	0–9.4	0–9.4	NUM
dpc-3630	110	1	autoimmune	autoimmune	ADJ
dpc-3630	110	2	thyroid	thyroid	NOUN
dpc-3630	110	3	disease	disease	NOUN
dpc-3630	110	4	2.08–10	2.08–10	PROPN
dpc-3630	110	5	a	a	DET
dpc-3630	110	6	eye	eye	NOUN
dpc-3630	110	7	uveitis	uveitis	NOUN
dpc-3630	110	8	0.41–1.95	0.41–1.95	NOUN
dpc-3630	111	1	a	a	DET
dpc-3630	111	2	hair	hair	NOUN
dpc-3630	111	3	and	and	CCONJ
dpc-3630	111	4	skin	skin	NOUN
dpc-3630	111	5	alopecia	alopecia	NOUN
dpc-3630	111	6	areata	areata	ADJ
dpc-3630	111	7	<	<	X
dpc-3630	111	8	1	1	NUM
dpc-3630	111	9	pemphigoid	pemphigoid	NOUN
dpc-3630	111	10	0.08	0.08	NUM
dpc-3630	111	11	a	a	PRON
dpc-3630	111	12	pemphigus	pemphigus	NOUN
dpc-3630	111	13	0.02–0.62	0.02–0.62	NUM
dpc-3630	112	1	psoriasis	psoriasis	NOUN
dpc-3630	112	2	0.39–7.74	0.39–7.74	NUM
dpc-3630	112	3	a	a	DET
dpc-3630	112	4	vitiligo	vitiligo	NOUN
dpc-3630	112	5	0–0.70	0–0.70	NUM
dpc-3630	112	6	connective	connective	ADJ
dpc-3630	112	7	tissue	tissue	NOUN
dpc-3630	112	8	disorders	disorder	NOUN
dpc-3630	112	9	ankylosing	ankylose	VERB
dpc-3630	112	10	spondylitis	spondylitis	NOUN
dpc-3630	112	11	0.12–1.98	0.12–1.98	NUM
dpc-3630	112	12	a	a	DET
dpc-3630	112	13	dermatomyositis	dermatomyositis	PROPN
dpc-3630	112	14	0.03	0.03	NUM
dpc-3630	112	15	polymyositis	polymyositis	PROPN
dpc-3630	112	16	3.33	3.33	NUM
dpc-3630	112	17	polymyalgia	polymyalgia	PROPN
dpc-3630	112	18	rheumatica	rheumatica	NOUN
dpc-3630	112	19	0.12–0.15	0.12–0.15	NUM
dpc-3630	112	20	rheumatoid	rheumatoid	NOUN
dpc-3630	112	21	arthritis	arthritis	NOUN
dpc-3630	112	22	0.30–3.64	0.30–3.64	NUM
dpc-3630	113	1	a	a	DET
dpc-3630	113	2	sjogren	sjogren	NOUN
dpc-3630	113	3	syndrome	syndrome	NOUN
dpc-3630	113	4	0–16.7	0–16.7	NUM
dpc-3630	113	5	systemic	systemic	ADJ
dpc-3630	113	6	lupus	lupus	PROPN
dpc-3630	113	7	erythematosus	erythematosus	NOUN
dpc-3630	113	8	0.14–2.90	0.14–2.90	NUM
dpc-3630	113	9	a	a	DET
dpc-3630	113	10	systemic	systemic	ADJ
dpc-3630	113	11	sclerosis	sclerosis	NOUN
dpc-3630	113	12	0.06–0.85	0.06–0.85	CCONJ
dpc-3630	114	1	wegener	wegener	PROPN
dpc-3630	114	2	granulomatosis	granulomatosis	NOUN
dpc-3630	114	3	0.02–0.03	0.02–0.03	NUM
dpc-3630	114	4	autoimmune	autoimmune	ADJ
dpc-3630	114	5	hematologic	hematologic	NOUN
dpc-3630	114	6	disorders	disorder	NOUN
dpc-3630	114	7	pernicious	pernicious	ADJ
dpc-3630	114	8	anemia	anemia	NOUN
dpc-3630	114	9	0–2.44	0–2.44	NOUN
dpc-3630	114	10	a	a	DET
dpc-3630	114	11	autoimmune	autoimmune	ADJ
dpc-3630	114	12	hemolytic	hemolytic	ADJ
dpc-3630	114	13	anemia	anemia	NOUN
dpc-3630	114	14	0.02–1.11	0.02–1.11	NUM
dpc-3630	114	15	idiopathic	idiopathic	ADJ
dpc-3630	114	16	thrombocytopenic	thrombocytopenic	ADJ
dpc-3630	114	17	purpura	purpura	NOUN
dpc-3630	114	18	0.11–0.13	0.11–0.13	PUNCT
dpc-3630	115	1	others	other	NOUN
dpc-3630	115	2	myasthenia	myasthenia	PROPN
dpc-3630	115	3	gravis	gravis	VERB
dpc-3630	115	4	0–0.56	0–0.56	PROPN
dpc-3630	115	5	a	a	DET
dpc-3630	115	6	guillain	guillain	NOUN
dpc-3630	115	7	-	-	PUNCT
dpc-3630	115	8	barre	barre	NOUN
dpc-3630	115	9	syndrome	syndrome	NOUN
dpc-3630	115	10	0.11–1.66	0.11–1.66	PUNCT
dpc-3630	115	11	a	a	DET
dpc-3630	115	12	a	a	DET
dpc-3630	115	13	comorbidities	comorbiditie	NOUN
dpc-3630	115	14	that	that	PRON
dpc-3630	115	15	had	have	VERB
dpc-3630	115	16	more	more	ADV
dpc-3630	115	17	significant	significant	ADJ
dpc-3630	115	18	prevalence	prevalence	NOUN
dpc-3630	115	19	compared	compare	VERB
dpc-3630	115	20	with	with	ADP
dpc-3630	115	21	the	the	DET
dpc-3630	115	22	normal	normal	ADJ
dpc-3630	115	23	population	population	NOUN
dpc-3630	115	24	in	in	ADP
dpc-3630	115	25	at	at	ADV
dpc-3630	115	26	least	least	ADV
dpc-3630	115	27	one	one	NUM
dpc-3630	115	28	study	study	NOUN
dpc-3630	115	29	.	.	PUNCT
dpc-3630	116	1	original	original	ADJ
dpc-3630	116	2	article	article	NOUN
dpc-3630	116	3	|	|	ADV
dpc-3630	116	4	dermatol	dermatol	ADJ
dpc-3630	116	5	pract	pract	NOUN
dpc-3630	116	6	concept	concept	NOUN
dpc-3630	116	7	.	.	PUNCT
dpc-3630	117	1	2024;14(3):e2024103	2024;14(3):e2024103	NUM
dpc-3630	117	2	5	5	NUM
dpc-3630	117	3	hand	hand	NOUN
dpc-3630	117	4	,	,	PUNCT
dpc-3630	117	5	according	accord	VERB
dpc-3630	117	6	to	to	ADP
dpc-3630	117	7	another	another	DET
dpc-3630	117	8	study	study	NOUN
dpc-3630	117	9	,	,	PUNCT
dpc-3630	117	10	concurrent	concurrent	ADJ
dpc-3630	117	11	autoimmune	autoimmune	ADJ
dpc-3630	117	12	comorbidities	comorbiditie	NOUN
dpc-3630	117	13	in	in	ADP
dpc-3630	117	14	ms	ms	PROPN
dpc-3630	117	15	result	result	NOUN
dpc-3630	117	16	in	in	ADP
dpc-3630	117	17	lower	low	ADJ
dpc-3630	117	18	quality	quality	NOUN
dpc-3630	117	19	of	of	ADP
dpc-3630	117	20	life	life	NOUN
dpc-3630	117	21	,	,	PUNCT
dpc-3630	117	22	brain	brain	NOUN
dpc-3630	117	23	parenchymal	parenchymal	ADJ
dpc-3630	117	24	fraction	fraction	NOUN
dpc-3630	117	25	,	,	PUNCT
dpc-3630	117	26	cortical	cortical	ADJ
dpc-3630	117	27	and	and	CCONJ
dpc-3630	117	28	total	total	ADJ
dpc-3630	117	29	gray	gray	ADJ
dpc-3630	117	30	matter	matter	NOUN
dpc-3630	117	31	,	,	PUNCT
dpc-3630	117	32	and	and	CCONJ
dpc-3630	117	33	magnetization	magnetization	NOUN
dpc-3630	117	34	transfer	transfer	NOUN
dpc-3630	117	35	ratio	ratio	NOUN
dpc-3630	117	36	.	.	PUNCT
dpc-3630	118	1	also	also	ADV
dpc-3630	118	2	,	,	PUNCT
dpc-3630	118	3	it	it	PRON
dpc-3630	118	4	is	be	AUX
dpc-3630	118	5	associated	associate	VERB
dpc-3630	118	6	with	with	ADP
dpc-3630	118	7	a	a	DET
dpc-3630	118	8	higher	high	ADJ
dpc-3630	118	9	rate	rate	NOUN
dpc-3630	118	10	of	of	ADP
dpc-3630	118	11	relapses	relapse	NOUN
dpc-3630	118	12	,	,	PUNCT
dpc-3630	118	13	mortality	mortality	NOUN
dpc-3630	118	14	,	,	PUNCT
dpc-3630	118	15	and	and	CCONJ
dpc-3630	118	16	more	more	ADV
dpc-3630	118	17	physical	physical	ADJ
dpc-3630	118	18	and	and	CCONJ
dpc-3630	118	19	cognitive	cognitive	ADJ
dpc-3630	118	20	impairments	impairment	NOUN
dpc-3630	118	21	[	[	X
dpc-3630	118	22	32	32	NUM
dpc-3630	118	23	]	]	PUNCT
dpc-3630	118	24	.	.	PUNCT
dpc-3630	119	1	these	these	DET
dpc-3630	119	2	comorbidities	comorbiditie	NOUN
dpc-3630	119	3	can	can	AUX
dpc-3630	119	4	affect	affect	VERB
dpc-3630	119	5	many	many	ADJ
dpc-3630	119	6	aspects	aspect	NOUN
dpc-3630	119	7	of	of	ADP
dpc-3630	119	8	an	an	DET
dpc-3630	119	9	ms	ms	NOUN
dpc-3630	119	10	patient	patient	NOUN
dpc-3630	119	11	,	,	PUNCT
dpc-3630	119	12	including	include	VERB
dpc-3630	119	13	diagnosis	diagnosis	NOUN
dpc-3630	119	14	(	(	PUNCT
dpc-3630	119	15	delay	delay	NOUN
dpc-3630	119	16	in	in	ADP
dpc-3630	119	17	diagnosis	diagnosis	NOUN
dpc-3630	119	18	which	which	PRON
dpc-3630	119	19	results	result	VERB
dpc-3630	119	20	in	in	ADP
dpc-3630	119	21	higher	high	ADJ
dpc-3630	119	22	rates	rate	NOUN
dpc-3630	119	23	of	of	ADP
dpc-3630	119	24	disability	disability	NOUN
dpc-3630	119	25	and	and	CCONJ
dpc-3630	119	26	relapse	relapse	NOUN
dpc-3630	119	27	)	)	PUNCT
dpc-3630	119	28	and	and	CCONJ
dpc-3630	119	29	prognosis	prognosis	NOUN
dpc-3630	119	30	(	(	PUNCT
dpc-3630	119	31	higher	high	ADJ
dpc-3630	119	32	mortality	mortality	NOUN
dpc-3630	119	33	and	and	CCONJ
dpc-3630	119	34	lower	low	ADJ
dpc-3630	119	35	quality	quality	NOUN
dpc-3630	119	36	of	of	ADP
dpc-3630	119	37	life	life	NOUN
dpc-3630	119	38	)	)	PUNCT
dpc-3630	119	39	.	.	PUNCT
dpc-3630	120	1	moreover	moreover	ADV
dpc-3630	120	2	,	,	PUNCT
dpc-3630	120	3	the	the	DET
dpc-3630	120	4	management	management	NOUN
dpc-3630	120	5	of	of	ADP
dpc-3630	120	6	clinical	clinical	ADJ
dpc-3630	120	7	and	and	CCONJ
dpc-3630	120	8	socioeconomic	socioeconomic	ADJ
dpc-3630	120	9	burdens	burden	NOUN
dpc-3630	120	10	will	will	AUX
dpc-3630	120	11	be	be	AUX
dpc-3630	120	12	more	more	ADV
dpc-3630	120	13	complex	complex	ADJ
dpc-3630	120	14	[	[	X
dpc-3630	120	15	31,33	31,33	NUM
dpc-3630	120	16	]	]	PUNCT
dpc-3630	120	17	.	.	PUNCT
dpc-3630	121	1	to	to	PART
dpc-3630	121	2	optimize	optimize	VERB
dpc-3630	121	3	ms	ms	PROPN
dpc-3630	121	4	care	care	NOUN
dpc-3630	121	5	,	,	PUNCT
dpc-3630	121	6	physicians	physician	NOUN
dpc-3630	121	7	should	should	AUX
dpc-3630	121	8	consider	consider	VERB
dpc-3630	121	9	the	the	DET
dpc-3630	121	10	impact	impact	NOUN
dpc-3630	121	11	of	of	ADP
dpc-3630	121	12	treatment	treatment	NOUN
dpc-3630	121	13	models	model	NOUN
dpc-3630	121	14	on	on	ADP
dpc-3630	121	15	initiating	initiate	VERB
dpc-3630	121	16	or	or	CCONJ
dpc-3630	121	17	outcomes	outcome	NOUN
dpc-3630	121	18	of	of	ADP
dpc-3630	121	19	some	some	DET
dpc-3630	121	20	comorbidities	comorbiditie	NOUN
dpc-3630	121	21	.	.	PUNCT
dpc-3630	122	1	alemtuzumab	alemtuzumab	NOUN
dpc-3630	122	2	,	,	PUNCT
dpc-3630	122	3	an	an	DET
dpc-3630	122	4	anti	anti	ADJ
dpc-3630	122	5	-	-	ADJ
dpc-3630	122	6	cd52	cd52	ADJ
dpc-3630	122	7	antibody	antibody	NOUN
dpc-3630	122	8	approved	approve	VERB
dpc-3630	122	9	d	d	NOUN
dpc-3630	122	10	for	for	ADP
dpc-3630	122	11	the	the	DET
dpc-3630	122	12	treatment	treatment	NOUN
dpc-3630	122	13	of	of	ADP
dpc-3630	122	14	active	active	ADJ
dpc-3630	122	15	relapsing	relapsing	NOUN
dpc-3630	122	16	-	-	PUNCT
dpc-3630	122	17	remitting	remit	VERB
dpc-3630	122	18	multiple	multiple	ADJ
dpc-3630	122	19	sclerosis	sclerosis	NOUN
dpc-3630	122	20	(	(	PUNCT
dpc-3630	122	21	rrms	rrm	NOUN
dpc-3630	122	22	)	)	PUNCT
dpc-3630	122	23	,	,	PUNCT
dpc-3630	122	24	can	can	AUX
dpc-3630	122	25	trigger	trigger	VERB
dpc-3630	122	26	some	some	DET
dpc-3630	122	27	comorbid	comorbid	NOUN
dpc-3630	122	28	autoimmune	autoimmune	ADJ
dpc-3630	122	29	diseases	disease	NOUN
dpc-3630	122	30	in	in	ADP
dpc-3630	122	31	almost	almost	ADV
dpc-3630	122	32	30	30	NUM
dpc-3630	122	33	%	%	NOUN
dpc-3630	122	34	of	of	ADP
dpc-3630	122	35	treated	treat	VERB
dpc-3630	122	36	patients	patient	NOUN
dpc-3630	122	37	[	[	X
dpc-3630	122	38	32	32	NUM
dpc-3630	122	39	]	]	PUNCT
dpc-3630	122	40	.	.	PUNCT
dpc-3630	123	1	it	it	PRON
dpc-3630	123	2	is	be	AUX
dpc-3630	123	3	been	be	AUX
dpc-3630	123	4	reported	report	VERB
dpc-3630	123	5	some	some	DET
dpc-3630	123	6	ms	ms	PROPN
dpc-3630	123	7	patients	patient	NOUN
dpc-3630	123	8	develop	develop	VERB
dpc-3630	123	9	vitiligo	vitiligo	NOUN
dpc-3630	123	10	months	month	NOUN
dpc-3630	123	11	after	after	ADP
dpc-3630	123	12	treatment	treatment	NOUN
dpc-3630	123	13	with	with	ADP
dpc-3630	123	14	alemtuzumab	alemtuzumab	NOUN
dpc-3630	123	15	[	[	X
dpc-3630	123	16	8,34	8,34	X
dpc-3630	123	17	]	]	X
dpc-3630	123	18	.	.	PUNCT
dpc-3630	124	1	also	also	ADV
dpc-3630	124	2	,	,	PUNCT
dpc-3630	124	3	according	accord	VERB
dpc-3630	124	4	to	to	ADP
dpc-3630	124	5	the	the	DET
dpc-3630	124	6	study	study	NOUN
dpc-3630	124	7	published	publish	VERB
dpc-3630	124	8	in	in	ADP
dpc-3630	124	9	2009	2009	NUM
dpc-3630	124	10	by	by	ADP
dpc-3630	124	11	kocer	kocer	PROPN
dpc-3630	124	12	et	et	PROPN
dpc-3630	124	13	al	al	PROPN
dpc-3630	124	14	,	,	PUNCT
dpc-3630	124	15	in	in	ADP
dpc-3630	124	16	which	which	PRON
dpc-3630	124	17	a	a	DET
dpc-3630	124	18	patient	patient	NOUN
dpc-3630	124	19	presented	present	VERB
dpc-3630	124	20	with	with	ADP
dpc-3630	124	21	vitiligo	vitiligo	NOUN
dpc-3630	124	22	after	after	ADP
dpc-3630	124	23	treatment	treatment	NOUN
dpc-3630	124	24	of	of	ADP
dpc-3630	124	25	her	her	PRON
dpc-3630	124	26	relapsing	relapse	VERB
dpc-3630	124	27	-	-	PUNCT
dpc-3630	124	28	remitting	remit	VERB
dpc-3630	124	29	ms	ms	NOUN
dpc-3630	124	30	with	with	ADP
dpc-3630	124	31	interferon	interferon	NOUN
dpc-3630	124	32	(	(	PUNCT
dpc-3630	124	33	ifn	ifn	PROPN
dpc-3630	124	34	)	)	PUNCT
dpc-3630	124	35	β-1a	β-1a	PROPN
dpc-3630	124	36	.	.	PUNCT
dpc-3630	125	1	the	the	DET
dpc-3630	125	2	ifn	ifn	PROPN
dpc-3630	125	3	β-1a	β-1a	PROPN
dpc-3630	125	4	was	be	AUX
dpc-3630	125	5	terminated	terminate	VERB
dpc-3630	125	6	and	and	CCONJ
dpc-3630	125	7	the	the	DET
dpc-3630	125	8	vitiligo	vitiligo	NOUN
dpc-3630	125	9	lesions	lesion	NOUN
dpc-3630	125	10	improved	improve	VERB
dpc-3630	125	11	within	within	ADP
dpc-3630	125	12	three	three	NUM
dpc-3630	125	13	months	month	NOUN
dpc-3630	126	1	[	[	X
dpc-3630	126	2	35	35	NUM
dpc-3630	126	3	]	]	PUNCT
dpc-3630	126	4	.	.	PUNCT
dpc-3630	127	1	in	in	ADP
dpc-3630	127	2	this	this	DET
dpc-3630	127	3	study	study	NOUN
dpc-3630	127	4	,	,	PUNCT
dpc-3630	127	5	the	the	DET
dpc-3630	127	6	location	location	NOUN
dpc-3630	127	7	of	of	ADP
dpc-3630	127	8	the	the	DET
dpc-3630	127	9	depigmented	depigmente	VERB
dpc-3630	127	10	areas	area	NOUN
dpc-3630	127	11	was	be	AUX
dpc-3630	127	12	not	not	PART
dpc-3630	127	13	precisely	precisely	ADV
dpc-3630	127	14	determined	determine	VERB
dpc-3630	127	15	,	,	PUNCT
dpc-3630	127	16	and	and	CCONJ
dpc-3630	127	17	these	these	DET
dpc-3630	127	18	areas	area	NOUN
dpc-3630	127	19	included	include	VERB
dpc-3630	127	20	only	only	ADV
dpc-3630	127	21	the	the	DET
dpc-3630	127	22	face	face	NOUN
dpc-3630	127	23	,	,	PUNCT
dpc-3630	127	24	trunk	trunk	NOUN
dpc-3630	127	25	,	,	PUNCT
dpc-3630	127	26	limbs	limb	NOUN
dpc-3630	127	27	,	,	PUNCT
dpc-3630	127	28	and	and	CCONJ
dpc-3630	127	29	genitals	genital	NOUN
dpc-3630	127	30	,	,	PUNCT
dpc-3630	127	31	and	and	CCONJ
dpc-3630	127	32	it	it	PRON
dpc-3630	127	33	was	be	AUX
dpc-3630	127	34	not	not	PART
dpc-3630	127	35	specified	specify	VERB
dpc-3630	127	36	in	in	ADP
dpc-3630	127	37	detail	detail	NOUN
dpc-3630	127	38	.	.	PUNCT
dpc-3630	128	1	we	we	PRON
dpc-3630	128	2	had	have	VERB
dpc-3630	128	3	no	no	DET
dpc-3630	128	4	control	control	NOUN
dpc-3630	128	5	group	group	NOUN
dpc-3630	128	6	,	,	PUNCT
dpc-3630	128	7	and	and	CCONJ
dpc-3630	128	8	the	the	DET
dpc-3630	128	9	cases	case	NOUN
dpc-3630	128	10	were	be	AUX
dpc-3630	128	11	not	not	PART
dpc-3630	128	12	matched	match	VERB
dpc-3630	128	13	for	for	ADP
dpc-3630	128	14	age	age	NOUN
dpc-3630	128	15	and	and	CCONJ
dpc-3630	128	16	gender	gender	NOUN
dpc-3630	128	17	with	with	ADP
dpc-3630	128	18	the	the	DET
dpc-3630	128	19	average	average	ADJ
dpc-3630	128	20	population	population	NOUN
dpc-3630	128	21	.	.	PUNCT
dpc-3630	129	1	the	the	DET
dpc-3630	129	2	insufficient	insufficient	ADJ
dpc-3630	129	3	sample	sample	NOUN
dpc-3630	129	4	size	size	NOUN
dpc-3630	129	5	due	due	ADP
dpc-3630	129	6	to	to	ADP
dpc-3630	129	7	the	the	DET
dpc-3630	129	8	pandemic	pandemic	ADJ
dpc-3630	129	9	covid-19	covid-19	PROPN
dpc-3630	129	10	was	be	AUX
dpc-3630	129	11	another	another	DET
dpc-3630	129	12	limitation	limitation	NOUN
dpc-3630	129	13	of	of	ADP
dpc-3630	129	14	this	this	DET
dpc-3630	129	15	examination	examination	NOUN
dpc-3630	129	16	.	.	PUNCT
dpc-3630	130	1	in	in	ADP
dpc-3630	130	2	conclusion	conclusion	NOUN
dpc-3630	130	3	,	,	PUNCT
dpc-3630	130	4	the	the	DET
dpc-3630	130	5	association	association	NOUN
dpc-3630	130	6	between	between	ADP
dpc-3630	130	7	vitiligo	vitiligo	PROPN
dpc-3630	130	8	and	and	CCONJ
dpc-3630	130	9	ms	ms	NOUN
dpc-3630	130	10	appears	appear	VERB
dpc-3630	130	11	to	to	PART
dpc-3630	130	12	be	be	AUX
dpc-3630	130	13	significant	significant	ADJ
dpc-3630	130	14	,	,	PUNCT
dpc-3630	130	15	and	and	CCONJ
dpc-3630	130	16	some	some	DET
dpc-3630	130	17	treatments	treatment	NOUN
dpc-3630	130	18	may	may	AUX
dpc-3630	130	19	target	target	VERB
dpc-3630	130	20	both	both	PRON
dpc-3630	130	21	in	in	ADP
dpc-3630	130	22	the	the	DET
dpc-3630	130	23	future	future	NOUN
dpc-3630	130	24	.	.	PUNCT
dpc-3630	131	1	references	reference	NOUN
dpc-3630	131	2	1	1	NUM
dpc-3630	131	3	.	.	PUNCT
dpc-3630	132	1	elbuluk	elbuluk	PROPN
dpc-3630	132	2	n	n	PROPN
dpc-3630	132	3	,	,	PUNCT
dpc-3630	132	4	ezzedine	ezzedine	PROPN
dpc-3630	132	5	k.	k.	PROPN
dpc-3630	132	6	quality	quality	NOUN
dpc-3630	132	7	of	of	ADP
dpc-3630	132	8	life	life	NOUN
dpc-3630	132	9	,	,	PUNCT
dpc-3630	132	10	burden	burden	NOUN
dpc-3630	132	11	of	of	ADP
dpc-3630	132	12	disease	disease	NOUN
dpc-3630	132	13	,	,	PUNCT
dpc-3630	132	14	co	co	NOUN
dpc-3630	132	15	morbidities	morbidity	NOUN
dpc-3630	132	16	,	,	PUNCT
dpc-3630	132	17	and	and	CCONJ
dpc-3630	132	18	systemic	systemic	ADJ
dpc-3630	132	19	effects	effect	NOUN
dpc-3630	132	20	in	in	ADP
dpc-3630	132	21	vitiligo	vitiligo	NOUN
dpc-3630	132	22	patients	patient	NOUN
dpc-3630	132	23	.	.	PUNCT
dpc-3630	133	1	dermatol	dermatol	NOUN
dpc-3630	133	2	clin	clin	PROPN
dpc-3630	133	3	.	.	PUNCT
dpc-3630	134	1	2017;35(2):117	2017;35(2):117	PROPN
dpc-3630	134	2	-	-	PUNCT
dpc-3630	134	3	128	128	NUM
dpc-3630	134	4	.	.	PUNCT
dpc-3630	135	1	doi	doi	NOUN
dpc-3630	135	2	:	:	PUNCT
dpc-3630	135	3	10.1016	10.1016	NUM
dpc-3630	135	4	/	/	SYM
dpc-3630	135	5	j.det.2016.11.002	j.det.2016.11.002	NOUN
dpc-3630	135	6	.	.	PUNCT
dpc-3630	136	1	pmid	pmid	NOUN
dpc-3630	136	2	:	:	PUNCT
dpc-3630	136	3	28317521	28317521	NUM
dpc-3630	136	4	.	.	PUNCT
dpc-3630	137	1	2	2	X
dpc-3630	137	2	.	.	X
dpc-3630	137	3	alkhateeb	alkhateeb	PROPN
dpc-3630	137	4	a	a	PROPN
dpc-3630	137	5	,	,	PUNCT
dpc-3630	137	6	fain	fain	PROPN
dpc-3630	137	7	pr	pr	PROPN
dpc-3630	137	8	,	,	PUNCT
dpc-3630	137	9	thody	thody	NOUN
dpc-3630	137	10	a	a	NOUN
dpc-3630	137	11	,	,	PUNCT
dpc-3630	137	12	bennett	bennett	PROPN
dpc-3630	137	13	dc	dc	PROPN
dpc-3630	137	14	,	,	PUNCT
dpc-3630	137	15	spritz	spritz	PROPN
dpc-3630	137	16	ra	ra	PROPN
dpc-3630	137	17	.	.	PUNCT
dpc-3630	138	1	epidemiology	epidemiology	NOUN
dpc-3630	138	2	of	of	ADP
dpc-3630	138	3	vitiligo	vitiligo	PROPN
dpc-3630	138	4	and	and	CCONJ
dpc-3630	138	5	associated	associated	ADJ
dpc-3630	138	6	autoimmune	autoimmune	ADJ
dpc-3630	138	7	diseases	disease	NOUN
dpc-3630	138	8	in	in	ADP
dpc-3630	138	9	caucasian	caucasian	ADJ
dpc-3630	138	10	probands	proband	NOUN
dpc-3630	138	11	and	and	CCONJ
dpc-3630	138	12	their	their	PRON
dpc-3630	138	13	families	family	NOUN
dpc-3630	138	14	.	.	PUNCT
dpc-3630	139	1	pigment	pigment	ADJ
dpc-3630	139	2	cell	cell	NOUN
dpc-3630	139	3	res	re	NOUN
dpc-3630	139	4	.	.	PUNCT
dpc-3630	140	1	2003;16(3):208	2003;16(3):208	NUM
dpc-3630	140	2	-	-	SYM
dpc-3630	140	3	214	214	NUM
dpc-3630	140	4	.	.	PUNCT
dpc-3630	141	1	doi	doi	NOUN
dpc-3630	141	2	:	:	PUNCT
dpc-3630	141	3	10.1034	10.1034	NUM
dpc-3630	141	4	/	/	SYM
dpc-3630	141	5	j.1600	j.1600	PROPN
dpc-3630	141	6	-	-	PUNCT
dpc-3630	141	7	0749.2003.00032.x	0749.2003.00032.x	PROPN
dpc-3630	141	8	.	.	PUNCT
dpc-3630	142	1	pmid	pmid	NOUN
dpc-3630	142	2	:	:	PUNCT
dpc-3630	142	3	12753387	12753387	NUM
dpc-3630	142	4	.	.	PUNCT
dpc-3630	143	1	3	3	X
dpc-3630	143	2	.	.	X
dpc-3630	143	3	gandhi	gandhi	PROPN
dpc-3630	143	4	k	k	PROPN
dpc-3630	143	5	,	,	PUNCT
dpc-3630	143	6	ezzedine	ezzedine	PROPN
dpc-3630	143	7	k	k	NOUN
dpc-3630	143	8	,	,	PUNCT
dpc-3630	143	9	anastassopoulos	anastassopoulo	NOUN
dpc-3630	143	10	kp	kp	PROPN
dpc-3630	143	11	,	,	PUNCT
dpc-3630	143	12	et	et	PROPN
dpc-3630	143	13	al	al	PROPN
dpc-3630	143	14	.	.	PUNCT
dpc-3630	144	1	prevalence	prevalence	NOUN
dpc-3630	144	2	of	of	ADP
dpc-3630	144	3	vitiligo	vitiligo	NOUN
dpc-3630	144	4	among	among	ADP
dpc-3630	144	5	adults	adult	NOUN
dpc-3630	144	6	in	in	ADP
dpc-3630	144	7	the	the	DET
dpc-3630	144	8	united	united	PROPN
dpc-3630	144	9	states	states	PROPN
dpc-3630	144	10	.	.	PUNCT
dpc-3630	145	1	jama	jama	PROPN
dpc-3630	145	2	dermatology	dermatology	PROPN
dpc-3630	145	3	.	.	PUNCT
dpc-3630	146	1	2022;158(1):43	2022;158(1):43	NUM
dpc-3630	146	2	-	-	SYM
dpc-3630	146	3	50	50	NUM
dpc-3630	146	4	.	.	PUNCT
dpc-3630	147	1	doi	doi	NOUN
dpc-3630	147	2	:	:	PUNCT
dpc-3630	147	3	10.1001	10.1001	NUM
dpc-3630	147	4	/	/	SYM
dpc-3630	147	5	jamadermatol.2021.4724	jamadermatol.2021.4724	NOUN
dpc-3630	147	6	.	.	PUNCT
dpc-3630	148	1	pmid	pmid	NOUN
dpc-3630	148	2	:	:	PUNCT
dpc-3630	148	3	34787670	34787670	NUM
dpc-3630	148	4	.	.	PUNCT
dpc-3630	149	1	pmcid	pmcid	NOUN
dpc-3630	149	2	:	:	PUNCT
dpc-3630	149	3	pmc8600454	pmc8600454	NOUN
dpc-3630	149	4	.	.	PUNCT
dpc-3630	150	1	4	4	X
dpc-3630	150	2	.	.	NUM
dpc-3630	150	3	rodrigues	rodrigues	PROPN
dpc-3630	150	4	m	m	PROPN
dpc-3630	150	5	,	,	PUNCT
dpc-3630	150	6	ezzedine	ezzedine	PROPN
dpc-3630	150	7	k	k	NOUN
dpc-3630	150	8	,	,	PUNCT
dpc-3630	150	9	hamzavi	hamzavi	PROPN
dpc-3630	150	10	i	i	PRON
dpc-3630	150	11	,	,	PUNCT
dpc-3630	150	12	pandya	pandya	PROPN
dpc-3630	150	13	ag	ag	PROPN
dpc-3630	150	14	,	,	PUNCT
dpc-3630	150	15	harris	harris	PROPN
dpc-3630	150	16	je	je	PROPN
dpc-3630	150	17	,	,	PUNCT
dpc-3630	150	18	group	group	PROPN
dpc-3630	150	19	vw	vw	PROPN
dpc-3630	150	20	.	.	PUNCT
dpc-3630	151	1	new	new	ADJ
dpc-3630	151	2	discoveries	discovery	NOUN
dpc-3630	151	3	in	in	ADP
dpc-3630	151	4	the	the	DET
dpc-3630	151	5	pathogenesis	pathogenesis	NOUN
dpc-3630	151	6	and	and	CCONJ
dpc-3630	151	7	classification	classification	NOUN
dpc-3630	151	8	of	of	ADP
dpc-3630	151	9	vitiligo	vitiligo	NOUN
dpc-3630	151	10	.	.	PUNCT
dpc-3630	152	1	j	j	PROPN
dpc-3630	152	2	am	be	AUX
dpc-3630	152	3	acad	acad	ADJ
dpc-3630	152	4	dermatol	dermatol	NOUN
dpc-3630	152	5	.	.	PUNCT
dpc-3630	153	1	2017;77(1):1	2017;77(1):1	NUM
dpc-3630	153	2	-	-	SYM
dpc-3630	153	3	13	13	NUM
dpc-3630	153	4	.	.	PUNCT
dpc-3630	154	1	doi	doi	NOUN
dpc-3630	154	2	:	:	PUNCT
dpc-3630	154	3	10.1016	10.1016	NUM
dpc-3630	154	4	/	/	SYM
dpc-3630	154	5	j.jaad.2016.10.048	j.jaad.2016.10.048	PROPN
dpc-3630	154	6	.	.	PUNCT
dpc-3630	155	1	pmid	pmid	NOUN
dpc-3630	155	2	:	:	PUNCT
dpc-3630	155	3	28619550	28619550	NUM
dpc-3630	155	4	.	.	PUNCT
dpc-3630	156	1	5	5	X
dpc-3630	156	2	.	.	X
dpc-3630	156	3	gill	gill	PROPN
dpc-3630	156	4	l	l	PROPN
dpc-3630	156	5	,	,	PUNCT
dpc-3630	156	6	zarbo	zarbo	X
dpc-3630	156	7	a	a	NOUN
dpc-3630	156	8	,	,	PUNCT
dpc-3630	156	9	isedeh	isedeh	PROPN
dpc-3630	156	10	p	p	NOUN
dpc-3630	156	11	,	,	PUNCT
dpc-3630	156	12	jacobsen	jacobsen	PROPN
dpc-3630	156	13	g	g	PROPN
dpc-3630	156	14	,	,	PUNCT
dpc-3630	156	15	lim	lim	PROPN
dpc-3630	156	16	hw	hw	PROPN
dpc-3630	156	17	,	,	PUNCT
dpc-3630	156	18	hamzavi	hamzavi	PROPN
dpc-3630	156	19	i.	i.	PROPN
dpc-3630	156	20	comorbid	comorbid	PROPN
dpc-3630	156	21	autoimmune	autoimmune	PROPN
dpc-3630	156	22	diseases	disease	NOUN
dpc-3630	156	23	in	in	ADP
dpc-3630	156	24	patients	patient	NOUN
dpc-3630	156	25	with	with	ADP
dpc-3630	156	26	vitiligo	vitiligo	NOUN
dpc-3630	156	27	:	:	PUNCT
dpc-3630	156	28	a	a	PRON
dpc-3630	156	29	among	among	ADP
dpc-3630	156	30	2886	2886	NUM
dpc-3630	156	31	first	first	ADJ
dpc-3630	156	32	-	-	PUNCT
dpc-3630	156	33	degree	degree	NOUN
dpc-3630	156	34	relatives	relative	NOUN
dpc-3630	156	35	of	of	ADP
dpc-3630	156	36	patients	patient	NOUN
dpc-3630	156	37	,	,	PUNCT
dpc-3630	156	38	10	10	NUM
dpc-3630	156	39	individuals	individual	NOUN
dpc-3630	156	40	(	(	PUNCT
dpc-3630	156	41	0.35	0.35	NUM
dpc-3630	156	42	%	%	NOUN
dpc-3630	156	43	,	,	PUNCT
dpc-3630	156	44	95	95	NUM
dpc-3630	156	45	%	%	NOUN
dpc-3630	156	46	ci:0.13%-0.56	ci:0.13%-0.56	NOUN
dpc-3630	156	47	%	%	NOUN
dpc-3630	156	48	)	)	PUNCT
dpc-3630	156	49	had	have	VERB
dpc-3630	156	50	ms	ms	NOUN
dpc-3630	156	51	.	.	PROPN
dpc-3630	156	52	although	although	SCONJ
dpc-3630	156	53	this	this	PRON
dpc-3630	156	54	was	be	AUX
dpc-3630	156	55	higher	high	ADJ
dpc-3630	156	56	than	than	ADP
dpc-3630	156	57	the	the	DET
dpc-3630	156	58	prevalence	prevalence	NOUN
dpc-3630	156	59	of	of	ADP
dpc-3630	156	60	ms	ms	NOUN
dpc-3630	156	61	in	in	ADP
dpc-3630	156	62	the	the	DET
dpc-3630	156	63	average	average	ADJ
dpc-3630	156	64	population	population	NOUN
dpc-3630	156	65	of	of	ADP
dpc-3630	156	66	tehran	tehran	PROPN
dpc-3630	157	1	[	[	X
dpc-3630	157	2	10	10	NUM
dpc-3630	157	3	]	]	PUNCT
dpc-3630	157	4	,	,	PUNCT
dpc-3630	157	5	this	this	DET
dpc-3630	157	6	difference	difference	NOUN
dpc-3630	157	7	was	be	AUX
dpc-3630	157	8	not	not	PART
dpc-3630	157	9	statistically	statistically	ADV
dpc-3630	157	10	significant	significant	ADJ
dpc-3630	157	11	(	(	PUNCT
dpc-3630	157	12	p	p	X
dpc-3630	157	13	=	=	NOUN
dpc-3630	157	14	0.0802	0.0802	NUM
dpc-3630	157	15	)	)	PUNCT
dpc-3630	157	16	.	.	PUNCT
dpc-3630	158	1	thus	thus	ADV
dpc-3630	158	2	,	,	PUNCT
dpc-3630	158	3	it	it	PRON
dpc-3630	158	4	seems	seem	VERB
dpc-3630	158	5	that	that	SCONJ
dpc-3630	158	6	the	the	DET
dpc-3630	158	7	history	history	NOUN
dpc-3630	158	8	of	of	ADP
dpc-3630	158	9	vitiligo	vitiligo	NOUN
dpc-3630	158	10	in	in	ADP
dpc-3630	158	11	patients	patient	NOUN
dpc-3630	158	12	does	do	AUX
dpc-3630	158	13	not	not	PART
dpc-3630	158	14	increase	increase	VERB
dpc-3630	158	15	the	the	DET
dpc-3630	158	16	risk	risk	NOUN
dpc-3630	158	17	of	of	ADP
dpc-3630	158	18	ms	ms	NOUN
dpc-3630	158	19	in	in	ADP
dpc-3630	158	20	their	their	PRON
dpc-3630	158	21	first	first	ADJ
dpc-3630	158	22	-	-	PUNCT
dpc-3630	158	23	degree	degree	NOUN
dpc-3630	158	24	relatives	relative	NOUN
dpc-3630	158	25	.	.	PUNCT
dpc-3630	159	1	according	accord	VERB
dpc-3630	159	2	to	to	ADP
dpc-3630	159	3	a	a	DET
dpc-3630	159	4	study	study	NOUN
dpc-3630	159	5	by	by	ADP
dpc-3630	159	6	al	al	PROPN
dpc-3630	159	7	khateeb	khateeb	PROPN
dpc-3630	159	8	et	et	PROPN
dpc-3630	159	9	al	al	PROPN
dpc-3630	159	10	,	,	PUNCT
dpc-3630	159	11	no	no	DET
dpc-3630	159	12	association	association	NOUN
dpc-3630	159	13	was	be	AUX
dpc-3630	159	14	observed	observe	VERB
dpc-3630	159	15	with	with	ADP
dpc-3630	159	16	the	the	DET
dpc-3630	159	17	frequency	frequency	NOUN
dpc-3630	159	18	of	of	ADP
dpc-3630	159	19	ms	ms	PROPN
dpc-3630	159	20	in	in	ADP
dpc-3630	159	21	first	first	ADJ
dpc-3630	159	22	-	-	PUNCT
dpc-3630	159	23	degree	degree	NOUN
dpc-3630	159	24	relatives	relative	NOUN
dpc-3630	159	25	of	of	ADP
dpc-3630	159	26	vitiligo	vitiligo	ADJ
dpc-3630	159	27	patients	patient	NOUN
dpc-3630	159	28	[	[	X
dpc-3630	159	29	2	2	NUM
dpc-3630	159	30	]	]	PUNCT
dpc-3630	159	31	.	.	PUNCT
dpc-3630	160	1	in	in	ADP
dpc-3630	160	2	recent	recent	ADJ
dpc-3630	160	3	studies	study	NOUN
dpc-3630	160	4	,	,	PUNCT
dpc-3630	160	5	ms	ms	PROPN
dpc-3630	160	6	is	be	AUX
dpc-3630	160	7	about	about	ADV
dpc-3630	160	8	three	three	NUM
dpc-3630	160	9	times	time	NOUN
dpc-3630	160	10	more	more	ADV
dpc-3630	160	11	common	common	ADJ
dpc-3630	160	12	in	in	ADP
dpc-3630	160	13	women	woman	NOUN
dpc-3630	160	14	than	than	ADP
dpc-3630	160	15	in	in	ADP
dpc-3630	160	16	men	man	NOUN
dpc-3630	160	17	[	[	PUNCT
dpc-3630	160	18	25	25	NUM
dpc-3630	160	19	-	-	SYM
dpc-3630	160	20	27	27	NUM
dpc-3630	160	21	]	]	PUNCT
dpc-3630	160	22	.	.	PUNCT
dpc-3630	161	1	interestingly	interestingly	ADV
dpc-3630	161	2	,	,	PUNCT
dpc-3630	161	3	ms	ms	PROPN
dpc-3630	161	4	is	be	AUX
dpc-3630	161	5	about	about	ADV
dpc-3630	161	6	four	four	NUM
dpc-3630	161	7	times	time	NOUN
dpc-3630	161	8	more	more	ADV
dpc-3630	161	9	common	common	ADJ
dpc-3630	161	10	in	in	ADP
dpc-3630	161	11	men	man	NOUN
dpc-3630	161	12	in	in	ADP
dpc-3630	161	13	our	our	PRON
dpc-3630	161	14	study	study	NOUN
dpc-3630	161	15	(	(	PUNCT
dpc-3630	161	16	p	p	X
dpc-3630	161	17	<	<	X
dpc-3630	161	18	0.001	0.001	NUM
dpc-3630	161	19	)	)	PUNCT
dpc-3630	161	20	.	.	PUNCT
dpc-3630	162	1	it	it	PRON
dpc-3630	162	2	is	be	AUX
dpc-3630	162	3	also	also	ADV
dpc-3630	162	4	inconsistent	inconsistent	ADJ
dpc-3630	162	5	with	with	ADP
dpc-3630	162	6	previous	previous	ADJ
dpc-3630	162	7	studies	study	NOUN
dpc-3630	162	8	showing	show	VERB
dpc-3630	162	9	that	that	SCONJ
dpc-3630	162	10	comorbid	comorbid	NOUN
dpc-3630	162	11	autoimmune	autoimmune	ADJ
dpc-3630	162	12	diseases	disease	NOUN
dpc-3630	162	13	are	be	AUX
dpc-3630	162	14	more	more	ADV
dpc-3630	162	15	common	common	ADJ
dpc-3630	162	16	in	in	ADP
dpc-3630	162	17	women	woman	NOUN
dpc-3630	162	18	[	[	X
dpc-3630	162	19	7	7	NUM
dpc-3630	162	20	]	]	PUNCT
dpc-3630	162	21	.	.	PUNCT
dpc-3630	163	1	although	although	SCONJ
dpc-3630	163	2	it	it	PRON
dpc-3630	163	3	can	can	AUX
dpc-3630	163	4	be	be	AUX
dpc-3630	163	5	suggested	suggest	VERB
dpc-3630	163	6	that	that	SCONJ
dpc-3630	163	7	male	male	ADJ
dpc-3630	163	8	gender	gender	NOUN
dpc-3630	163	9	is	be	AUX
dpc-3630	163	10	a	a	DET
dpc-3630	163	11	risk	risk	NOUN
dpc-3630	163	12	factor	factor	NOUN
dpc-3630	163	13	for	for	ADP
dpc-3630	163	14	ms	ms	NOUN
dpc-3630	163	15	in	in	ADP
dpc-3630	163	16	patients	patient	NOUN
dpc-3630	163	17	with	with	ADP
dpc-3630	163	18	vitiligo	vitiligo	PROPN
dpc-3630	163	19	,	,	PUNCT
dpc-3630	163	20	the	the	DET
dpc-3630	163	21	limited	limited	ADJ
dpc-3630	163	22	number	number	NOUN
dpc-3630	163	23	of	of	ADP
dpc-3630	163	24	cases	case	NOUN
dpc-3630	163	25	of	of	ADP
dpc-3630	163	26	ms	ms	NOUN
dpc-3630	163	27	prevents	prevent	VERB
dpc-3630	163	28	us	we	PRON
dpc-3630	163	29	from	from	ADP
dpc-3630	163	30	generalizing	generalize	VERB
dpc-3630	163	31	the	the	DET
dpc-3630	163	32	results	result	NOUN
dpc-3630	163	33	.	.	PUNCT
dpc-3630	164	1	in	in	ADP
dpc-3630	164	2	this	this	DET
dpc-3630	164	3	study	study	NOUN
dpc-3630	164	4	,	,	PUNCT
dpc-3630	164	5	a	a	DET
dpc-3630	164	6	comparison	comparison	NOUN
dpc-3630	164	7	was	be	AUX
dpc-3630	164	8	made	make	VERB
dpc-3630	164	9	between	between	ADP
dpc-3630	164	10	patients	patient	NOUN
dpc-3630	164	11	who	who	PRON
dpc-3630	164	12	had	have	VERB
dpc-3630	164	13	both	both	CCONJ
dpc-3630	164	14	ms	ms	NOUN
dpc-3630	164	15	and	and	CCONJ
dpc-3630	164	16	vitiligo	vitiligo	NOUN
dpc-3630	164	17	and	and	CCONJ
dpc-3630	164	18	those	those	PRON
dpc-3630	164	19	who	who	PRON
dpc-3630	164	20	had	have	AUX
dpc-3630	164	21	vitiligo	vitiligo	VERB
dpc-3630	164	22	only	only	ADV
dpc-3630	164	23	,	,	PUNCT
dpc-3630	164	24	and	and	CCONJ
dpc-3630	164	25	there	there	PRON
dpc-3630	164	26	were	be	VERB
dpc-3630	164	27	no	no	DET
dpc-3630	164	28	associations	association	NOUN
dpc-3630	164	29	between	between	ADP
dpc-3630	164	30	the	the	DET
dpc-3630	164	31	history	history	NOUN
dpc-3630	164	32	of	of	ADP
dpc-3630	164	33	ms	ms	NOUN
dpc-3630	164	34	and	and	CCONJ
dpc-3630	164	35	age	age	NOUN
dpc-3630	164	36	,	,	PUNCT
dpc-3630	164	37	age	age	NOUN
dpc-3630	164	38	of	of	ADP
dpc-3630	164	39	onset	onset	NOUN
dpc-3630	164	40	,	,	PUNCT
dpc-3630	164	41	duration	duration	NOUN
dpc-3630	164	42	of	of	ADP
dpc-3630	164	43	vitiligo	vitiligo	NOUN
dpc-3630	164	44	,	,	PUNCT
dpc-3630	164	45	and	and	CCONJ
dpc-3630	164	46	location	location	NOUN
dpc-3630	164	47	of	of	ADP
dpc-3630	164	48	the	the	DET
dpc-3630	164	49	depigmented	depigmented	ADJ
dpc-3630	164	50	lesions	lesion	NOUN
dpc-3630	164	51	.	.	PUNCT
dpc-3630	165	1	however	however	ADV
dpc-3630	165	2	,	,	PUNCT
dpc-3630	165	3	according	accord	VERB
dpc-3630	165	4	to	to	ADP
dpc-3630	165	5	elbuluk	elbuluk	PROPN
dpc-3630	165	6	et	et	PROPN
dpc-3630	165	7	al	al	PROPN
dpc-3630	165	8	,	,	PUNCT
dpc-3630	165	9	older	old	ADJ
dpc-3630	165	10	age	age	NOUN
dpc-3630	165	11	,	,	PUNCT
dpc-3630	165	12	older	old	ADJ
dpc-3630	165	13	age	age	NOUN
dpc-3630	165	14	at	at	ADP
dpc-3630	165	15	onset	onset	NOUN
dpc-3630	165	16	,	,	PUNCT
dpc-3630	165	17	and	and	CCONJ
dpc-3630	165	18	longer	long	ADJ
dpc-3630	165	19	duration	duration	NOUN
dpc-3630	165	20	of	of	ADP
dpc-3630	165	21	vitiligo	vitiligo	NOUN
dpc-3630	165	22	are	be	AUX
dpc-3630	165	23	associated	associate	VERB
dpc-3630	165	24	with	with	ADP
dpc-3630	165	25	the	the	DET
dpc-3630	165	26	development	development	NOUN
dpc-3630	165	27	of	of	ADP
dpc-3630	165	28	comorbid	comorbid	NOUN
dpc-3630	165	29	autoinflammatory	autoinflammatory	NOUN
dpc-3630	165	30	diseases	disease	NOUN
dpc-3630	165	31	in	in	ADP
dpc-3630	165	32	patients	patient	NOUN
dpc-3630	165	33	with	with	ADP
dpc-3630	165	34	vitiligo	vitiligo	PROPN
dpc-3630	165	35	[	[	X
dpc-3630	165	36	1	1	NUM
dpc-3630	165	37	]	]	PUNCT
dpc-3630	165	38	.	.	PUNCT
dpc-3630	166	1	according	accord	VERB
dpc-3630	166	2	to	to	ADP
dpc-3630	166	3	mokhtarpour	mokhtarpour	PROPN
dpc-3630	166	4	et	et	PROPN
dpc-3630	166	5	al	al	PROPN
dpc-3630	166	6	,	,	PUNCT
dpc-3630	166	7	patients	patient	NOUN
dpc-3630	166	8	in	in	ADP
dpc-3630	166	9	the	the	DET
dpc-3630	166	10	early	early	ADJ
dpc-3630	166	11	-	-	PUNCT
dpc-3630	166	12	onset	onset	NOUN
dpc-3630	166	13	group	group	NOUN
dpc-3630	166	14	are	be	AUX
dpc-3630	166	15	less	less	ADV
dpc-3630	166	16	likely	likely	ADJ
dpc-3630	166	17	to	to	PART
dpc-3630	166	18	develop	develop	VERB
dpc-3630	166	19	autoimmune	autoimmune	ADJ
dpc-3630	166	20	diseases	disease	NOUN
dpc-3630	166	21	[	[	X
dpc-3630	166	22	28	28	NUM
dpc-3630	166	23	]	]	PUNCT
dpc-3630	166	24	.	.	PUNCT
dpc-3630	167	1	we	we	PRON
dpc-3630	167	2	also	also	ADV
dpc-3630	167	3	evaluated	evaluate	VERB
dpc-3630	167	4	demographic	demographic	ADJ
dpc-3630	167	5	data	datum	NOUN
dpc-3630	167	6	.	.	PUNCT
dpc-3630	168	1	previous	previous	ADJ
dpc-3630	168	2	literature	literature	NOUN
dpc-3630	168	3	suggests	suggest	VERB
dpc-3630	168	4	that	that	SCONJ
dpc-3630	168	5	men	man	NOUN
dpc-3630	168	6	and	and	CCONJ
dpc-3630	168	7	women	woman	NOUN
dpc-3630	168	8	are	be	AUX
dpc-3630	168	9	equally	equally	ADV
dpc-3630	168	10	affected	affect	VERB
dpc-3630	168	11	by	by	ADP
dpc-3630	168	12	vitiligo	vitiligo	NOUN
dpc-3630	168	13	,	,	PUNCT
dpc-3630	168	14	with	with	ADP
dpc-3630	168	15	women	woman	NOUN
dpc-3630	168	16	more	more	ADV
dpc-3630	168	17	likely	likely	ADJ
dpc-3630	168	18	to	to	PART
dpc-3630	168	19	seek	seek	VERB
dpc-3630	168	20	treatment	treatment	NOUN
dpc-3630	168	21	,	,	PUNCT
dpc-3630	168	22	probably	probably	ADV
dpc-3630	168	23	because	because	SCONJ
dpc-3630	168	24	of	of	ADP
dpc-3630	168	25	the	the	DET
dpc-3630	168	26	greater	great	ADJ
dpc-3630	168	27	social	social	ADJ
dpc-3630	168	28	impact	impact	NOUN
dpc-3630	168	29	on	on	ADP
dpc-3630	168	30	them	they	PRON
dpc-3630	168	31	[	[	X
dpc-3630	168	32	29,30	29,30	NUM
dpc-3630	168	33	]	]	PUNCT
dpc-3630	168	34	.	.	PUNCT
dpc-3630	169	1	this	this	PRON
dpc-3630	169	2	contrasts	contrast	VERB
dpc-3630	169	3	with	with	ADP
dpc-3630	169	4	our	our	PRON
dpc-3630	169	5	findings	finding	NOUN
dpc-3630	169	6	that	that	SCONJ
dpc-3630	169	7	men	man	NOUN
dpc-3630	169	8	were	be	AUX
dpc-3630	169	9	slightly	slightly	ADV
dpc-3630	169	10	more	more	ADV
dpc-3630	169	11	likely	likely	ADJ
dpc-3630	169	12	to	to	PART
dpc-3630	169	13	be	be	AUX
dpc-3630	169	14	affected	affect	VERB
dpc-3630	169	15	,	,	PUNCT
dpc-3630	169	16	possibly	possibly	ADV
dpc-3630	169	17	because	because	SCONJ
dpc-3630	169	18	of	of	ADP
dpc-3630	169	19	cultural	cultural	ADJ
dpc-3630	169	20	issues	issue	NOUN
dpc-3630	169	21	.	.	PUNCT
dpc-3630	170	1	it	it	PRON
dpc-3630	170	2	should	should	AUX
dpc-3630	170	3	be	be	AUX
dpc-3630	170	4	mentioned	mention	VERB
dpc-3630	170	5	that	that	SCONJ
dpc-3630	170	6	women	woman	NOUN
dpc-3630	170	7	were	be	AUX
dpc-3630	170	8	more	more	ADV
dpc-3630	170	9	likely	likely	ADJ
dpc-3630	170	10	to	to	PART
dpc-3630	170	11	be	be	AUX
dpc-3630	170	12	affected	affect	VERB
dpc-3630	170	13	in	in	ADP
dpc-3630	170	14	the	the	DET
dpc-3630	170	15	early	early	ADJ
dpc-3630	170	16	-	-	PUNCT
dpc-3630	170	17	onset	onset	NOUN
dpc-3630	170	18	group	group	NOUN
dpc-3630	170	19	(	(	PUNCT
dpc-3630	170	20	≤	≤	NUM
dpc-3630	170	21	12	12	NUM
dpc-3630	170	22	years	year	NOUN
dpc-3630	170	23	old	old	ADJ
dpc-3630	170	24	)	)	PUNCT
dpc-3630	170	25	and	and	CCONJ
dpc-3630	170	26	men	man	NOUN
dpc-3630	170	27	were	be	AUX
dpc-3630	170	28	more	more	ADV
dpc-3630	170	29	frequently	frequently	ADV
dpc-3630	170	30	affected	affect	VERB
dpc-3630	170	31	in	in	ADP
dpc-3630	170	32	the	the	DET
dpc-3630	170	33	late	late	ADJ
dpc-3630	170	34	-	-	PUNCT
dpc-3630	170	35	onset	onset	NOUN
dpc-3630	170	36	group	group	NOUN
dpc-3630	170	37	(	(	PUNCT
dpc-3630	170	38	>	>	X
dpc-3630	170	39	12	12	NUM
dpc-3630	170	40	years	year	NOUN
dpc-3630	170	41	old	old	ADJ
dpc-3630	170	42	)	)	PUNCT
dpc-3630	170	43	,	,	PUNCT
dpc-3630	170	44	which	which	PRON
dpc-3630	170	45	is	be	AUX
dpc-3630	170	46	consistent	consistent	ADJ
dpc-3630	170	47	with	with	ADP
dpc-3630	170	48	previous	previous	ADJ
dpc-3630	170	49	studies	study	NOUN
dpc-3630	170	50	[	[	X
dpc-3630	170	51	28	28	NUM
dpc-3630	170	52	]	]	PUNCT
dpc-3630	170	53	.	.	PUNCT
dpc-3630	171	1	thus	thus	ADV
dpc-3630	171	2	,	,	PUNCT
dpc-3630	171	3	women	woman	NOUN
dpc-3630	171	4	are	be	AUX
dpc-3630	171	5	more	more	ADV
dpc-3630	171	6	likely	likely	ADJ
dpc-3630	171	7	to	to	PART
dpc-3630	171	8	develop	develop	VERB
dpc-3630	171	9	vitiligo	vitiligo	NOUN
dpc-3630	171	10	earlier	early	ADV
dpc-3630	171	11	than	than	ADP
dpc-3630	171	12	men	man	NOUN
dpc-3630	171	13	.	.	PUNCT
dpc-3630	172	1	considering	consider	VERB
dpc-3630	172	2	the	the	DET
dpc-3630	172	3	high	high	ADJ
dpc-3630	172	4	burden	burden	NOUN
dpc-3630	172	5	of	of	ADP
dpc-3630	172	6	ms	ms	NOUN
dpc-3630	172	7	and	and	CCONJ
dpc-3630	172	8	its	its	PRON
dpc-3630	172	9	increasing	increase	VERB
dpc-3630	172	10	prevalence	prevalence	NOUN
dpc-3630	172	11	worldwide	worldwide	ADV
dpc-3630	172	12	,	,	PUNCT
dpc-3630	172	13	(	(	PUNCT
dpc-3630	172	14	especially	especially	ADV
dpc-3630	172	15	in	in	ADP
dpc-3630	172	16	iran	iran	PROPN
dpc-3630	172	17	)	)	PUNCT
dpc-3630	172	18	,	,	PUNCT
dpc-3630	172	19	we	we	PRON
dpc-3630	172	20	suggest	suggest	AUX
dpc-3630	172	21	screening	screen	VERB
dpc-3630	172	22	vitiligo	vitiligo	ADJ
dpc-3630	172	23	patients	patient	NOUN
dpc-3630	172	24	and	and	CCONJ
dpc-3630	172	25	their	their	PRON
dpc-3630	172	26	first	first	ADJ
dpc-3630	172	27	-	-	PUNCT
dpc-3630	172	28	degree	degree	NOUN
dpc-3630	172	29	relatives	relative	NOUN
dpc-3630	172	30	for	for	ADP
dpc-3630	172	31	early	early	ADJ
dpc-3630	172	32	signs	sign	NOUN
dpc-3630	172	33	of	of	ADP
dpc-3630	172	34	ms	ms	NOUN
dpc-3630	172	35	,	,	PUNCT
dpc-3630	172	36	to	to	PART
dpc-3630	172	37	detect	detect	VERB
dpc-3630	172	38	the	the	DET
dpc-3630	172	39	disease	disease	NOUN
dpc-3630	172	40	at	at	ADP
dpc-3630	172	41	an	an	DET
dpc-3630	172	42	early	early	ADJ
dpc-3630	172	43	stage	stage	NOUN
dpc-3630	172	44	and	and	CCONJ
dpc-3630	172	45	treat	treat	VERB
dpc-3630	172	46	it	it	PRON
dpc-3630	172	47	efficiently	efficiently	ADV
dpc-3630	172	48	.	.	PUNCT
dpc-3630	173	1	conversely	conversely	ADV
dpc-3630	173	2	,	,	PUNCT
dpc-3630	173	3	we	we	PRON
dpc-3630	173	4	also	also	ADV
dpc-3630	173	5	recommend	recommend	VERB
dpc-3630	173	6	screening	screen	VERB
dpc-3630	173	7	patients	patient	NOUN
dpc-3630	173	8	with	with	ADP
dpc-3630	173	9	ms	ms	PROPN
dpc-3630	173	10	to	to	PART
dpc-3630	173	11	detect	detect	VERB
dpc-3630	173	12	early	early	ADJ
dpc-3630	173	13	signs	sign	NOUN
dpc-3630	173	14	of	of	ADP
dpc-3630	173	15	vitiligo	vitiligo	NOUN
dpc-3630	173	16	as	as	ADV
dpc-3630	173	17	soon	soon	ADV
dpc-3630	173	18	as	as	ADP
dpc-3630	173	19	possible	possible	ADJ
dpc-3630	173	20	.	.	PUNCT
dpc-3630	174	1	because	because	SCONJ
dpc-3630	174	2	of	of	ADP
dpc-3630	174	3	some	some	DET
dpc-3630	174	4	similarities	similarity	NOUN
dpc-3630	174	5	in	in	ADP
dpc-3630	174	6	the	the	DET
dpc-3630	174	7	pathological	pathological	ADJ
dpc-3630	174	8	pathways	pathway	NOUN
dpc-3630	174	9	of	of	ADP
dpc-3630	174	10	both	both	DET
dpc-3630	174	11	diseases	disease	NOUN
dpc-3630	174	12	,	,	PUNCT
dpc-3630	174	13	such	such	ADJ
dpc-3630	174	14	as	as	ADP
dpc-3630	174	15	the	the	DET
dpc-3630	174	16	role	role	NOUN
dpc-3630	174	17	of	of	ADP
dpc-3630	174	18	il15	il15	PROPN
dpc-3630	174	19	,	,	PUNCT
dpc-3630	174	20	some	some	DET
dpc-3630	174	21	current	current	ADJ
dpc-3630	174	22	or	or	CCONJ
dpc-3630	174	23	future	future	ADJ
dpc-3630	174	24	treatments	treatment	NOUN
dpc-3630	174	25	of	of	ADP
dpc-3630	174	26	one	one	NUM
dpc-3630	174	27	may	may	AUX
dpc-3630	174	28	have	have	VERB
dpc-3630	174	29	beneficial	beneficial	ADJ
dpc-3630	174	30	effects	effect	NOUN
dpc-3630	174	31	on	on	ADP
dpc-3630	174	32	the	the	DET
dpc-3630	174	33	other	other	ADJ
dpc-3630	174	34	,	,	PUNCT
dpc-3630	174	35	such	such	ADJ
dpc-3630	174	36	as	as	ADP
dpc-3630	174	37	targeting	target	VERB
dpc-3630	174	38	il15	il15	PROPN
dpc-3630	174	39	signaling	signal	VERB
dpc-3630	174	40	with	with	ADP
dpc-3630	174	41	anti	anti	ADJ
dpc-3630	174	42	-	-	ADJ
dpc-3630	174	43	cd	cd	ADJ
dpc-3630	174	44	122	122	NUM
dpc-3630	175	1	[	[	X
dpc-3630	175	2	20	20	NUM
dpc-3630	175	3	]	]	PUNCT
dpc-3630	175	4	.	.	PUNCT
dpc-3630	176	1	according	accord	VERB
dpc-3630	176	2	to	to	ADP
dpc-3630	176	3	a	a	DET
dpc-3630	176	4	review	review	NOUN
dpc-3630	176	5	by	by	ADP
dpc-3630	176	6	nociti	nociti	PROPN
dpc-3630	176	7	et	et	PROPN
dpc-3630	176	8	al	al	PROPN
dpc-3630	176	9	,	,	PUNCT
dpc-3630	176	10	patients	patient	NOUN
dpc-3630	176	11	with	with	ADP
dpc-3630	176	12	isolated	isolated	ADJ
dpc-3630	176	13	ms	ms	NOUN
dpc-3630	176	14	have	have	VERB
dpc-3630	176	15	a	a	DET
dpc-3630	176	16	more	more	ADV
dpc-3630	176	17	severe	severe	ADJ
dpc-3630	176	18	course	course	NOUN
dpc-3630	176	19	of	of	ADP
dpc-3630	176	20	the	the	DET
dpc-3630	176	21	disease	disease	NOUN
dpc-3630	176	22	and	and	CCONJ
dpc-3630	176	23	subsequently	subsequently	ADV
dpc-3630	176	24	more	more	ADJ
dpc-3630	176	25	disability	disability	NOUN
dpc-3630	176	26	compared	compare	VERB
dpc-3630	176	27	to	to	ADP
dpc-3630	176	28	ms	ms	NOUN
dpc-3630	176	29	patients	patient	NOUN
dpc-3630	176	30	with	with	ADP
dpc-3630	176	31	at	at	ADV
dpc-3630	176	32	least	least	ADV
dpc-3630	176	33	one	one	NUM
dpc-3630	176	34	autoimmune	autoimmune	ADJ
dpc-3630	176	35	comorbidity	comorbidity	NOUN
dpc-3630	176	36	[	[	X
dpc-3630	176	37	31	31	NUM
dpc-3630	176	38	]	]	PUNCT
dpc-3630	176	39	.	.	PUNCT
dpc-3630	177	1	on	on	ADP
dpc-3630	177	2	the	the	DET
dpc-3630	177	3	other	other	ADJ
dpc-3630	177	4	6	6	NUM
dpc-3630	177	5	original	original	ADJ
dpc-3630	177	6	article	article	NOUN
dpc-3630	177	7	|	|	ADV
dpc-3630	177	8	dermatol	dermatol	ADJ
dpc-3630	177	9	pract	pract	NOUN
dpc-3630	177	10	concept	concept	NOUN
dpc-3630	177	11	.	.	PUNCT
dpc-3630	178	1	2024;14(3):e2024103	2024;14(3):e2024103	NUM
dpc-3630	178	2	immunol	immunol	NOUN
dpc-3630	178	3	.	.	PUNCT
dpc-3630	179	1	2021;11:618897	2021;11:618897	NUM
dpc-3630	179	2	.	.	PUNCT
dpc-3630	179	3	doi	doi	NOUN
dpc-3630	179	4	:	:	PUNCT
dpc-3630	179	5	10.3389	10.3389	NUM
dpc-3630	179	6	/	/	SYM
dpc-3630	179	7	fimmu.2020.618897	fimmu.2020.618897	PROPN
dpc-3630	179	8	.	.	PUNCT
dpc-3630	180	1	pmid	pmid	NOUN
dpc-3630	180	2	:	:	PUNCT
dpc-3630	180	3	33633737	33633737	NUM
dpc-3630	180	4	.	.	PUNCT
dpc-3630	181	1	pmcid	pmcid	NOUN
dpc-3630	181	2	:	:	PUNCT
dpc-3630	181	3	pmc7901930	pmc7901930	NOUN
dpc-3630	181	4	.	.	PUNCT
dpc-3630	182	1	21	21	NUM
dpc-3630	182	2	.	.	X
dpc-3630	182	3	marrie	marrie	PROPN
dpc-3630	182	4	ra	ra	PROPN
dpc-3630	182	5	,	,	PUNCT
dpc-3630	182	6	reider	reider	NOUN
dpc-3630	182	7	n	n	CCONJ
dpc-3630	182	8	,	,	PUNCT
dpc-3630	182	9	cohen	cohen	PROPN
dpc-3630	182	10	j	j	PROPN
dpc-3630	182	11	,	,	PUNCT
dpc-3630	182	12	et	et	PROPN
dpc-3630	182	13	al	al	PROPN
dpc-3630	182	14	.	.	PUNCT
dpc-3630	183	1	a	a	DET
dpc-3630	183	2	systematic	systematic	ADJ
dpc-3630	183	3	review	review	NOUN
dpc-3630	183	4	of	of	ADP
dpc-3630	183	5	the	the	DET
dpc-3630	183	6	incidence	incidence	NOUN
dpc-3630	183	7	and	and	CCONJ
dpc-3630	183	8	prevalence	prevalence	NOUN
dpc-3630	183	9	of	of	ADP
dpc-3630	183	10	autoimmune	autoimmune	ADJ
dpc-3630	183	11	disease	disease	NOUN
dpc-3630	183	12	in	in	ADP
dpc-3630	183	13	multiple	multiple	ADJ
dpc-3630	183	14	sclerosis	sclerosis	NOUN
dpc-3630	183	15	.	.	PUNCT
dpc-3630	184	1	mult	mult	PROPN
dpc-3630	184	2	scler	scler	PROPN
dpc-3630	184	3	j.	j.	PROPN
dpc-3630	184	4	2015;21(3):282	2015;21(3):282	PROPN
dpc-3630	184	5	-	-	PUNCT
dpc-3630	184	6	293	293	NUM
dpc-3630	184	7	.	.	PUNCT
dpc-3630	185	1	doi	doi	NOUN
dpc-3630	185	2	:	:	PUNCT
dpc-3630	185	3	10.1177	10.1177	NUM
dpc-3630	185	4	/1352458514564490	/1352458514564490	NUM
dpc-3630	185	5	.	.	PUNCT
dpc-3630	186	1	pmid	pmid	NOUN
dpc-3630	186	2	:	:	PUNCT
dpc-3630	186	3	25533299	25533299	NUM
dpc-3630	186	4	.	.	PUNCT
dpc-3630	187	1	pmcid	pmcid	NOUN
dpc-3630	187	2	:	:	PUNCT
dpc-3630	187	3	pmc4429166	pmc4429166	NOUN
dpc-3630	187	4	.	.	PUNCT
dpc-3630	188	1	22	22	NUM
dpc-3630	188	2	.	.	PUNCT
dpc-3630	189	1	hart	hart	PROPN
dpc-3630	189	2	ph	ph	PROPN
dpc-3630	189	3	,	,	PUNCT
dpc-3630	189	4	norval	norval	NOUN
dpc-3630	189	5	m	m	PROPN
dpc-3630	189	6	,	,	PUNCT
dpc-3630	189	7	byrne	byrne	PROPN
dpc-3630	189	8	sn	sn	PROPN
dpc-3630	189	9	,	,	PUNCT
dpc-3630	189	10	rhodes	rhodes	PROPN
dpc-3630	189	11	le	le	PROPN
dpc-3630	189	12	.	.	PROPN
dpc-3630	189	13	exposure	exposure	NOUN
dpc-3630	189	14	to	to	ADP
dpc-3630	189	15	ultraviolet	ultraviolet	ADJ
dpc-3630	189	16	radiation	radiation	NOUN
dpc-3630	189	17	in	in	ADP
dpc-3630	189	18	the	the	DET
dpc-3630	189	19	modulation	modulation	NOUN
dpc-3630	189	20	of	of	ADP
dpc-3630	189	21	human	human	ADJ
dpc-3630	189	22	diseases	disease	NOUN
dpc-3630	189	23	.	.	PUNCT
dpc-3630	190	1	annu	annu	PROPN
dpc-3630	190	2	rev	rev	PROPN
dpc-3630	190	3	pathol	pathol	NOUN
dpc-3630	190	4	.	.	PUNCT
dpc-3630	191	1	2019;14:55	2019;14:55	NUM
dpc-3630	191	2	-	-	SYM
dpc-3630	191	3	81	81	NUM
dpc-3630	191	4	.	.	PUNCT
dpc-3630	192	1	doi	doi	NOUN
dpc-3630	192	2	:	:	PUNCT
dpc-3630	192	3	10.1146	10.1146	NUM
dpc-3630	192	4	/	/	SYM
dpc-3630	192	5	annurev	annurev	NOUN
dpc-3630	192	6	-	-	PUNCT
dpc-3630	192	7	pathmechdis-012418	pathmechdis-012418	NOUN
dpc-3630	192	8	-	-	PUNCT
dpc-3630	192	9	012809	012809	NUM
dpc-3630	192	10	.	.	PUNCT
dpc-3630	193	1	pmid	pmid	NOUN
dpc-3630	193	2	:	:	PUNCT
dpc-3630	193	3	30125148	30125148	NUM
dpc-3630	193	4	.	.	PUNCT
dpc-3630	194	1	23	23	NUM
dpc-3630	194	2	.	.	PUNCT
dpc-3630	195	1	silverberg	silverberg	PROPN
dpc-3630	195	2	ji	ji	PROPN
dpc-3630	195	3	,	,	PUNCT
dpc-3630	195	4	silverberg	silverberg	PROPN
dpc-3630	195	5	ai	ai	VERB
dpc-3630	195	6	,	,	PUNCT
dpc-3630	195	7	malka	malka	PROPN
dpc-3630	195	8	e	e	PROPN
dpc-3630	195	9	,	,	PUNCT
dpc-3630	195	10	silverberg	silverberg	PROPN
dpc-3630	195	11	nb	nb	PROPN
dpc-3630	195	12	.	.	PUNCT
dpc-3630	196	1	a	a	DET
dpc-3630	196	2	pilot	pilot	NOUN
dpc-3630	196	3	study	study	NOUN
dpc-3630	196	4	assessing	assess	VERB
dpc-3630	196	5	the	the	DET
dpc-3630	196	6	role	role	NOUN
dpc-3630	196	7	of	of	ADP
dpc-3630	196	8	25	25	NUM
dpc-3630	196	9	hydroxy	hydroxy	ADJ
dpc-3630	196	10	vitamin	vitamin	NOUN
dpc-3630	196	11	d	d	NOUN
dpc-3630	196	12	levels	level	NOUN
dpc-3630	196	13	in	in	ADP
dpc-3630	196	14	patients	patient	NOUN
dpc-3630	196	15	with	with	ADP
dpc-3630	196	16	vitiligo	vitiligo	NOUN
dpc-3630	196	17	vulgaris	vulgaris	NOUN
dpc-3630	196	18	.	.	PUNCT
dpc-3630	197	1	j	j	PROPN
dpc-3630	197	2	am	be	AUX
dpc-3630	197	3	acad	acad	ADJ
dpc-3630	197	4	dermatol	dermatol	NOUN
dpc-3630	197	5	.	.	PUNCT
dpc-3630	198	1	2010;62(6):937	2010;62(6):937	NUM
dpc-3630	198	2	-	-	SYM
dpc-3630	198	3	941	941	NUM
dpc-3630	198	4	.	.	PUNCT
dpc-3630	199	1	doi	doi	NOUN
dpc-3630	199	2	:	:	PUNCT
dpc-3630	199	3	10.1016	10.1016	NUM
dpc-3630	199	4	/	/	SYM
dpc-3630	199	5	j.jaad.2009.11.024	j.jaad.2009.11.024	PROPN
dpc-3630	199	6	.	.	PUNCT
dpc-3630	200	1	pmid	pmid	NOUN
dpc-3630	200	2	:	:	PUNCT
dpc-3630	200	3	20466170	20466170	NUM
dpc-3630	200	4	.	.	PUNCT
dpc-3630	201	1	24	24	NUM
dpc-3630	201	2	.	.	PUNCT
dpc-3630	202	1	lee	lee	PROPN
dpc-3630	202	2	h	h	PROPN
dpc-3630	202	3	,	,	PUNCT
dpc-3630	202	4	lee	lee	PROPN
dpc-3630	202	5	mh	mh	PROPN
dpc-3630	202	6	,	,	PUNCT
dpc-3630	202	7	lee	lee	PROPN
dpc-3630	202	8	dy	dy	PROPN
dpc-3630	202	9	,	,	PUNCT
dpc-3630	202	10	et	et	PROPN
dpc-3630	202	11	al	al	PROPN
dpc-3630	202	12	.	.	PUNCT
dpc-3630	203	1	prevalence	prevalence	NOUN
dpc-3630	203	2	of	of	ADP
dpc-3630	203	3	vitiligo	vitiligo	PROPN
dpc-3630	203	4	and	and	CCONJ
dpc-3630	203	5	associated	associated	ADJ
dpc-3630	203	6	comorbidities	comorbiditie	NOUN
dpc-3630	203	7	in	in	ADP
dpc-3630	203	8	korea	korea	PROPN
dpc-3630	203	9	.	.	PUNCT
dpc-3630	204	1	yonsei	yonsei	PROPN
dpc-3630	204	2	med	med	PROPN
dpc-3630	204	3	j.	j.	PROPN
dpc-3630	204	4	2015;56(3):719	2015;56(3):719	PROPN
dpc-3630	204	5	-	-	PUNCT
dpc-3630	204	6	725	725	PROPN
dpc-3630	204	7	.	.	PUNCT
dpc-3630	204	8	doi	doi	NOUN
dpc-3630	204	9	:	:	PUNCT
dpc-3630	204	10	10.3349	10.3349	NUM
dpc-3630	204	11	/	/	SYM
dpc-3630	204	12	ymj.2015.56.3.719	ymj.2015.56.3.719	PROPN
dpc-3630	204	13	.	.	PUNCT
dpc-3630	205	1	pmid	pmid	NOUN
dpc-3630	205	2	:	:	PUNCT
dpc-3630	205	3	25837178	25837178	NUM
dpc-3630	205	4	.	.	PUNCT
dpc-3630	206	1	pmcid	pmcid	NOUN
dpc-3630	206	2	:	:	PUNCT
dpc-3630	206	3	pmc4397442	pmc4397442	VERB
dpc-3630	206	4	.	.	PUNCT
dpc-3630	207	1	25	25	NUM
dpc-3630	207	2	.	.	PUNCT
dpc-3630	208	1	amiri	amiri	PROPN
dpc-3630	208	2	m.	m.	PROPN
dpc-3630	208	3	multiple	multiple	ADJ
dpc-3630	208	4	sclerosis	sclerosis	NOUN
dpc-3630	208	5	in	in	ADP
dpc-3630	208	6	iran	iran	PROPN
dpc-3630	208	7	:	:	PUNCT
dpc-3630	208	8	an	an	DET
dpc-3630	208	9	epidemiological	epidemiological	ADJ
dpc-3630	208	10	update	update	NOUN
dpc-3630	208	11	with	with	ADP
dpc-3630	208	12	focus	focus	NOUN
dpc-3630	208	13	on	on	ADP
dpc-3630	208	14	air	air	NOUN
dpc-3630	208	15	pollution	pollution	NOUN
dpc-3630	208	16	debate	debate	NOUN
dpc-3630	208	17	.	.	PUNCT
dpc-3630	209	1	j	j	PROPN
dpc-3630	209	2	clin	clin	PROPN
dpc-3630	209	3	transl	transl	PROPN
dpc-3630	209	4	res	res	PROPN
dpc-3630	209	5	.	.	PUNCT
dpc-3630	210	1	2021;7(1):49	2021;7(1):49	NUM
dpc-3630	210	2	.	.	PUNCT
dpc-3630	210	3	pmid	pmid	NOUN
dpc-3630	210	4	:	:	PUNCT
dpc-3630	210	5	34104808	34104808	NUM
dpc-3630	210	6	.	.	PUNCT
dpc-3630	211	1	pmcid	pmcid	NOUN
dpc-3630	211	2	:	:	PUNCT
dpc-3630	211	3	pmc8177027	pmc8177027	NOUN
dpc-3630	211	4	.	.	PUNCT
dpc-3630	212	1	26	26	NUM
dpc-3630	212	2	.	.	PUNCT
dpc-3630	213	1	eskandarieh	eskandarieh	PROPN
dpc-3630	213	2	s	s	PROPN
dpc-3630	213	3	,	,	PUNCT
dpc-3630	213	4	heydarpour	heydarpour	PROPN
dpc-3630	213	5	p	p	NOUN
dpc-3630	213	6	,	,	PUNCT
dpc-3630	213	7	elhami	elhami	PROPN
dpc-3630	213	8	sr	sr	PROPN
dpc-3630	213	9	,	,	PUNCT
dpc-3630	213	10	sahraian	sahraian	PROPN
dpc-3630	213	11	ma	ma	PROPN
dpc-3630	213	12	.	.	PROPN
dpc-3630	213	13	prevalence	prevalence	NOUN
dpc-3630	213	14	and	and	CCONJ
dpc-3630	213	15	incidence	incidence	NOUN
dpc-3630	213	16	of	of	ADP
dpc-3630	213	17	multiple	multiple	ADJ
dpc-3630	213	18	sclerosis	sclerosis	NOUN
dpc-3630	213	19	in	in	ADP
dpc-3630	213	20	tehran	tehran	PROPN
dpc-3630	213	21	,	,	PUNCT
dpc-3630	213	22	iran	iran	PROPN
dpc-3630	213	23	.	.	PUNCT
dpc-3630	214	1	iran	iran	PROPN
dpc-3630	214	2	j	j	PROPN
dpc-3630	214	3	public	public	ADJ
dpc-3630	214	4	health	health	NOUN
dpc-3630	214	5	.	.	PUNCT
dpc-3630	215	1	2017;46(5):699	2017;46(5):699	NUM
dpc-3630	215	2	.	.	PUNCT
dpc-3630	216	1	pmid	pmid	NOUN
dpc-3630	216	2	:	:	PUNCT
dpc-3630	216	3	28560202	28560202	NUM
dpc-3630	216	4	.	.	PUNCT
dpc-3630	217	1	pmcid	pmcid	ADJ
dpc-3630	217	2	:	:	PUNCT
dpc-3630	217	3	pmc5442284	pmc5442284	NOUN
dpc-3630	217	4	.	.	PUNCT
dpc-3630	218	1	27	27	NUM
dpc-3630	218	2	.	.	PUNCT
dpc-3630	219	1	hosseinzadeh	hosseinzadeh	PROPN
dpc-3630	219	2	a	a	PRON
dpc-3630	219	3	,	,	PUNCT
dpc-3630	219	4	sedighi	sedighi	PROPN
dpc-3630	219	5	b	b	PROPN
dpc-3630	219	6	,	,	PUNCT
dpc-3630	219	7	kermanchi	kermanchi	PROPN
dpc-3630	219	8	j	j	PROPN
dpc-3630	219	9	,	,	PUNCT
dpc-3630	219	10	heidari	heidari	PROPN
dpc-3630	219	11	m	m	PROPN
dpc-3630	219	12	,	,	PUNCT
dpc-3630	219	13	haghdoost	haghdoost	VERB
dpc-3630	219	14	aa	aa	NOUN
dpc-3630	219	15	.	.	PUNCT
dpc-3630	220	1	is	be	AUX
dpc-3630	220	2	the	the	DET
dpc-3630	220	3	sharp	sharp	ADJ
dpc-3630	220	4	increasing	increase	VERB
dpc-3630	220	5	trend	trend	NOUN
dpc-3630	220	6	of	of	ADP
dpc-3630	220	7	multiple	multiple	ADJ
dpc-3630	220	8	sclerosis	sclerosis	NOUN
dpc-3630	220	9	incidence	incidence	NOUN
dpc-3630	220	10	real	real	ADJ
dpc-3630	220	11	in	in	ADP
dpc-3630	220	12	iran	iran	PROPN
dpc-3630	220	13	?	?	PUNCT
dpc-3630	221	1	bmc	bmc	PROPN
dpc-3630	221	2	neurol	neurol	NOUN
dpc-3630	221	3	.	.	PUNCT
dpc-3630	222	1	2021;21(1):1	2021;21(1):1	NUM
dpc-3630	222	2	-	-	SYM
dpc-3630	222	3	5	5	NUM
dpc-3630	222	4	.	.	PUNCT
dpc-3630	222	5	doi	doi	NOUN
dpc-3630	222	6	:	:	PUNCT
dpc-3630	222	7	10.1186	10.1186	NUM
dpc-3630	222	8	/	/	SYM
dpc-3630	222	9	s12883	s12883	NOUN
dpc-3630	222	10	-	-	PUNCT
dpc-3630	222	11	020	020	NUM
dpc-3630	222	12	-	-	PUNCT
dpc-3630	222	13	02031	02031	NUM
dpc-3630	222	14	-	-	SYM
dpc-3630	222	15	5	5	NUM
dpc-3630	222	16	.	.	PUNCT
dpc-3630	223	1	pmid	pmid	NOUN
dpc-3630	223	2	:	:	PUNCT
dpc-3630	223	3	33407243	33407243	NUM
dpc-3630	223	4	.	.	PUNCT
dpc-3630	224	1	pmcid	pmcid	NOUN
dpc-3630	224	2	:	:	PUNCT
dpc-3630	224	3	pmc7789321	pmc7789321	PROPN
dpc-3630	224	4	.	.	PUNCT
dpc-3630	225	1	28	28	NUM
dpc-3630	225	2	.	.	PUNCT
dpc-3630	226	1	mokhtarpour	mokhtarpour	PROPN
dpc-3630	226	2	neilagh	neilagh	PROPN
dpc-3630	226	3	a	a	NOUN
dpc-3630	226	4	,	,	PUNCT
dpc-3630	226	5	alizadeh	alizadeh	NOUN
dpc-3630	226	6	f	f	PROPN
dpc-3630	226	7	,	,	PUNCT
dpc-3630	226	8	aghazadeh	aghazadeh	PROPN
dpc-3630	226	9	barenji	barenji	PROPN
dpc-3630	226	10	m	m	PROPN
dpc-3630	226	11	,	,	PUNCT
dpc-3630	226	12	behrouz	behrouz	VERB
dpc-3630	226	13	sharif	sharif	PROPN
dpc-3630	226	14	s	s	PROPN
dpc-3630	226	15	,	,	PUNCT
dpc-3630	226	16	sedokani	sedokani	ADJ
dpc-3630	226	17	a.	a.	NOUN
dpc-3630	226	18	different	different	ADJ
dpc-3630	226	19	characteristics	characteristic	NOUN
dpc-3630	226	20	of	of	ADP
dpc-3630	226	21	early	early	ADJ
dpc-3630	226	22	-	-	PUNCT
dpc-3630	226	23	onset	onset	NOUN
dpc-3630	226	24	vitiligo	vitiligo	NOUN
dpc-3630	226	25	versus	versus	ADP
dpc-3630	226	26	lateonset	lateonset	NOUN
dpc-3630	226	27	vitiligo	vitiligo	VERB
dpc-3630	226	28	.	.	PUNCT
dpc-3630	227	1	iran	iran	PROPN
dpc-3630	227	2	j	j	PROPN
dpc-3630	227	3	dermatology	dermatology	PROPN
dpc-3630	227	4	.	.	PUNCT
dpc-3630	228	1	2020;23(4):132	2020;23(4):132	NUM
dpc-3630	228	2	-	-	SYM
dpc-3630	228	3	136	136	NUM
dpc-3630	228	4	.	.	PUNCT
dpc-3630	229	1	doi	doi	NOUN
dpc-3630	229	2	:	:	PUNCT
dpc-3630	229	3	10.22034	10.22034	NUM
dpc-3630	229	4	/	/	SYM
dpc-3630	229	5	ijd.2020.223045	ijd.2020.223045	NUM
dpc-3630	229	6	.1044	.1044	PROPN
dpc-3630	229	7	.	.	PUNCT
dpc-3630	230	1	29	29	NUM
dpc-3630	230	2	.	.	PUNCT
dpc-3630	231	1	bergqvist	bergqvist	PROPN
dpc-3630	231	2	c	c	PROPN
dpc-3630	231	3	,	,	PUNCT
dpc-3630	231	4	ezzedine	ezzedine	PROPN
dpc-3630	231	5	k.	k.	PROPN
dpc-3630	231	6	vitiligo	vitiligo	PROPN
dpc-3630	231	7	:	:	PUNCT
dpc-3630	231	8	a	a	DET
dpc-3630	231	9	review	review	NOUN
dpc-3630	231	10	.	.	PUNCT
dpc-3630	232	1	dermatology	dermatology	NOUN
dpc-3630	232	2	.	.	PUNCT
dpc-3630	233	1	2020	2020	NUM
dpc-3630	233	2	;	;	PUNCT
dpc-3630	233	3	236(6):571	236(6):571	NUM
dpc-3630	233	4	-	-	SYM
dpc-3630	233	5	592	592	NUM
dpc-3630	233	6	.	.	PUNCT
dpc-3630	233	7	30	30	NUM
dpc-3630	233	8	.	.	PUNCT
dpc-3630	234	1	speeckaert	speeckaert	PROPN
dpc-3630	234	2	r	r	PROPN
dpc-3630	234	3	,	,	PUNCT
dpc-3630	234	4	van	van	PROPN
dpc-3630	234	5	geel	geel	PROPN
dpc-3630	234	6	n.	n.	NOUN
dpc-3630	234	7	distribution	distribution	NOUN
dpc-3630	234	8	patterns	pattern	NOUN
dpc-3630	234	9	in	in	ADP
dpc-3630	234	10	generalized	generalized	ADJ
dpc-3630	234	11	vitiligo	vitiligo	NOUN
dpc-3630	234	12	.	.	PUNCT
dpc-3630	235	1	j	j	PROPN
dpc-3630	235	2	eur	eur	PROPN
dpc-3630	235	3	acad	acad	PROPN
dpc-3630	235	4	dermatology	dermatology	NOUN
dpc-3630	235	5	venereol	venereol	NOUN
dpc-3630	235	6	.	.	PUNCT
dpc-3630	236	1	2014;28(6):755	2014;28(6):755	NUM
dpc-3630	236	2	-	-	SYM
dpc-3630	236	3	762	762	NUM
dpc-3630	236	4	.	.	PUNCT
dpc-3630	237	1	doi	doi	NOUN
dpc-3630	237	2	:	:	PUNCT
dpc-3630	237	3	10.1111	10.1111	NUM
dpc-3630	237	4	/	/	SYM
dpc-3630	237	5	jdv.12171	jdv.12171	NOUN
dpc-3630	237	6	.	.	PUNCT
dpc-3630	238	1	pmid	pmid	NOUN
dpc-3630	238	2	:	:	PUNCT
dpc-3630	238	3	23651011	23651011	NUM
dpc-3630	238	4	.	.	PUNCT
dpc-3630	239	1	31	31	NUM
dpc-3630	239	2	.	.	PUNCT
dpc-3630	240	1	nociti	nociti	ADV
dpc-3630	240	2	v	v	NOUN
dpc-3630	240	3	,	,	PUNCT
dpc-3630	240	4	romozzi	romozzi	NOUN
dpc-3630	240	5	m.	m.	NOUN
dpc-3630	240	6	multiple	multiple	ADJ
dpc-3630	240	7	sclerosis	sclerosis	NOUN
dpc-3630	240	8	and	and	CCONJ
dpc-3630	240	9	autoimmune	autoimmune	ADJ
dpc-3630	240	10	comorbidities	comorbiditie	NOUN
dpc-3630	240	11	.	.	PUNCT
dpc-3630	241	1	j	j	PROPN
dpc-3630	241	2	pers	per	NOUN
dpc-3630	241	3	med	me	VERB
dpc-3630	241	4	.	.	PUNCT
dpc-3630	241	5	2022;12(11	2022;12(11	NUM
dpc-3630	241	6	)	)	PUNCT
dpc-3630	241	7	.	.	PUNCT
dpc-3630	242	1	doi	doi	NOUN
dpc-3630	242	2	:	:	PUNCT
dpc-3630	242	3	10.3390	10.3390	NUM
dpc-3630	242	4	/jpm12111828	/jpm12111828	PUNCT
dpc-3630	242	5	.	.	PUNCT
dpc-3630	243	1	pmid	pmid	NOUN
dpc-3630	243	2	:	:	PUNCT
dpc-3630	243	3	36579555	36579555	NUM
dpc-3630	243	4	.	.	PUNCT
dpc-3630	244	1	pmcid	pmcid	NOUN
dpc-3630	244	2	:	:	PUNCT
dpc-3630	244	3	pmc9698878	pmc9698878	ADJ
dpc-3630	244	4	.	.	PUNCT
dpc-3630	245	1	32	32	NUM
dpc-3630	245	2	.	.	PUNCT
dpc-3630	246	1	marrie	marrie	PROPN
dpc-3630	246	2	ra	ra	PROPN
dpc-3630	246	3	,	,	PUNCT
dpc-3630	246	4	fisk	fisk	PROPN
dpc-3630	246	5	jd	jd	PROPN
dpc-3630	246	6	,	,	PUNCT
dpc-3630	246	7	fitzgerald	fitzgerald	PROPN
dpc-3630	246	8	k	k	PROPN
dpc-3630	246	9	,	,	PUNCT
dpc-3630	246	10	et	et	PROPN
dpc-3630	246	11	al	al	PROPN
dpc-3630	246	12	.	.	PROPN
dpc-3630	246	13	etiology	etiology	PROPN
dpc-3630	246	14	,	,	PUNCT
dpc-3630	246	15	effects	effect	NOUN
dpc-3630	246	16	and	and	CCONJ
dpc-3630	246	17	management	management	NOUN
dpc-3630	246	18	of	of	ADP
dpc-3630	246	19	comorbidities	comorbiditie	NOUN
dpc-3630	246	20	in	in	ADP
dpc-3630	246	21	multiple	multiple	ADJ
dpc-3630	246	22	sclerosis	sclerosis	NOUN
dpc-3630	246	23	:	:	PUNCT
dpc-3630	246	24	recent	recent	ADJ
dpc-3630	246	25	advances	advance	NOUN
dpc-3630	246	26	.	.	PUNCT
dpc-3630	247	1	front	front	ADJ
dpc-3630	247	2	immunol	immunol	NOUN
dpc-3630	247	3	.	.	PUNCT
dpc-3630	248	1	2023;14(may):1	2023;14(may):1	NUM
dpc-3630	248	2	-	-	SYM
dpc-3630	248	3	15	15	NUM
dpc-3630	248	4	.	.	PUNCT
dpc-3630	249	1	doi	doi	NOUN
dpc-3630	249	2	:	:	PUNCT
dpc-3630	249	3	10.3389	10.3389	NUM
dpc-3630	249	4	/fimmu.2023.1197195	/fimmu.2023.1197195	PUNCT
dpc-3630	249	5	pmid	pmid	NOUN
dpc-3630	249	6	:	:	PUNCT
dpc-3630	249	7	37325663	37325663	NUM
dpc-3630	249	8	.	.	PUNCT
dpc-3630	250	1	pmcid	pmcid	NOUN
dpc-3630	250	2	:	:	PUNCT
dpc-3630	250	3	pmc10266935	pmc10266935	ADJ
dpc-3630	250	4	.	.	PUNCT
dpc-3630	251	1	33	33	NUM
dpc-3630	251	2	.	.	PUNCT
dpc-3630	252	1	rato	rato	PROPN
dpc-3630	252	2	ml	ml	PROPN
dpc-3630	252	3	,	,	PUNCT
dpc-3630	252	4	santos	santos	PROPN
dpc-3630	252	5	m	m	PROPN
dpc-3630	252	6	,	,	PUNCT
dpc-3630	252	7	de	de	PROPN
dpc-3630	252	8	sá	sá	PROPN
dpc-3630	252	9	j	j	PROPN
dpc-3630	252	10	,	,	PUNCT
dpc-3630	252	11	ferreira	ferreira	PROPN
dpc-3630	252	12	j.	j.	PROPN
dpc-3630	252	13	comorbid	comorbid	PROPN
dpc-3630	252	14	autoimmune	autoimmune	ADJ
dpc-3630	252	15	disorders	disorder	NOUN
dpc-3630	252	16	in	in	ADP
dpc-3630	252	17	people	people	NOUN
dpc-3630	252	18	with	with	ADP
dpc-3630	252	19	multiple	multiple	ADJ
dpc-3630	252	20	sclerosis	sclerosis	NOUN
dpc-3630	252	21	:	:	PUNCT
dpc-3630	252	22	a	a	DET
dpc-3630	252	23	retrospective	retrospective	ADJ
dpc-3630	252	24	cohort	cohort	NOUN
dpc-3630	252	25	study	study	NOUN
dpc-3630	252	26	.	.	PUNCT
dpc-3630	253	1	j	j	PROPN
dpc-3630	253	2	neuroimmunol	neuroimmunol	PROPN
dpc-3630	253	3	.	.	PUNCT
dpc-3630	254	1	2023;385:578226	2023;385:578226	NUM
dpc-3630	254	2	.	.	PUNCT
dpc-3630	255	1	doi	doi	NOUN
dpc-3630	255	2	:	:	PUNCT
dpc-3630	255	3	10.1016	10.1016	NUM
dpc-3630	255	4	/j.jneuroim.2023.578226	/j.jneuroim.2023.578226	NOUN
dpc-3630	255	5	.	.	PUNCT
dpc-3630	256	1	pmid	pmid	NOUN
dpc-3630	256	2	:	:	PUNCT
dpc-3630	256	3	37918214	37918214	NUM
dpc-3630	256	4	.	.	PUNCT
dpc-3630	257	1	34	34	NUM
dpc-3630	257	2	.	.	X
dpc-3630	258	1	rauma	rauma	PROPN
dpc-3630	258	2	i	i	PRON
dpc-3630	258	3	,	,	PUNCT
dpc-3630	258	4	mustonen	mustonen	PROPN
dpc-3630	258	5	t	t	PROPN
dpc-3630	258	6	,	,	PUNCT
dpc-3630	258	7	seppä	seppä	VERB
dpc-3630	258	8	jm	jm	PROPN
dpc-3630	258	9	,	,	PUNCT
dpc-3630	258	10	et	et	PROPN
dpc-3630	258	11	al	al	PROPN
dpc-3630	258	12	.	.	PROPN
dpc-3630	258	13	safety	safety	NOUN
dpc-3630	258	14	of	of	ADP
dpc-3630	258	15	alemtuzumab	alemtuzumab	NOUN
dpc-3630	258	16	in	in	ADP
dpc-3630	258	17	a	a	DET
dpc-3630	258	18	nationwide	nationwide	ADJ
dpc-3630	258	19	cohort	cohort	NOUN
dpc-3630	258	20	of	of	ADP
dpc-3630	258	21	finnish	finnish	ADJ
dpc-3630	258	22	multiple	multiple	ADJ
dpc-3630	258	23	sclerosis	sclerosis	NOUN
dpc-3630	258	24	patients	patient	NOUN
dpc-3630	258	25	.	.	PUNCT
dpc-3630	259	1	j	j	PROPN
dpc-3630	259	2	neurol	neurol	PROPN
dpc-3630	259	3	.	.	PUNCT
dpc-3630	260	1	2022;269(2):824	2022;269(2):824	NUM
dpc-3630	260	2	-	-	SYM
dpc-3630	260	3	835	835	NUM
dpc-3630	260	4	.	.	PUNCT
dpc-3630	261	1	doi	doi	NOUN
dpc-3630	261	2	:	:	PUNCT
dpc-3630	261	3	10.1007	10.1007	NUM
dpc-3630	261	4	/	/	SYM
dpc-3630	261	5	s00415	s00415	NOUN
dpc-3630	261	6	-	-	PUNCT
dpc-3630	261	7	021	021	NUM
dpc-3630	261	8	-10664	-10664	PROPN
dpc-3630	261	9	-	-	PUNCT
dpc-3630	261	10	w.	w.	PROPN
dpc-3630	261	11	pmid	pmid	PROPN
dpc-3630	261	12	:	:	PUNCT
dpc-3630	261	13	34255182	34255182	NUM
dpc-3630	261	14	.	.	PUNCT
dpc-3630	262	1	pmcid	pmcid	NOUN
dpc-3630	262	2	:	:	PUNCT
dpc-3630	262	3	pmc8782800	pmc8782800	NOUN
dpc-3630	262	4	.	.	PUNCT
dpc-3630	263	1	35	35	NUM
dpc-3630	263	2	.	.	PUNCT
dpc-3630	264	1	kocer	kocer	PROPN
dpc-3630	264	2	b	b	PROPN
dpc-3630	264	3	,	,	PUNCT
dpc-3630	264	4	nazliel	nazliel	PROPN
dpc-3630	264	5	b	b	PROPN
dpc-3630	264	6	,	,	PUNCT
dpc-3630	264	7	oztas	oztas	PROPN
dpc-3630	264	8	m	m	PROPN
dpc-3630	264	9	,	,	PUNCT
dpc-3630	264	10	batur	batur	PROPN
dpc-3630	264	11	hz	hz	VERB
dpc-3630	264	12	.	.	PROPN
dpc-3630	264	13	vitiligo	vitiligo	PROPN
dpc-3630	264	14	and	and	CCONJ
dpc-3630	264	15	multiple	multiple	ADJ
dpc-3630	264	16	sclerosis	sclerosis	NOUN
dpc-3630	264	17	in	in	ADP
dpc-3630	264	18	a	a	DET
dpc-3630	264	19	patient	patient	NOUN
dpc-3630	264	20	treated	treat	VERB
dpc-3630	264	21	with	with	ADP
dpc-3630	264	22	interferon	interferon	ADJ
dpc-3630	264	23	beta-1a	beta-1a	NOUN
dpc-3630	264	24	:	:	PUNCT
dpc-3630	264	25	a	a	DET
dpc-3630	264	26	case	case	NOUN
dpc-3630	264	27	report	report	NOUN
dpc-3630	264	28	.	.	PUNCT
dpc-3630	265	1	eur	eur	PROPN
dpc-3630	265	2	j	j	PROPN
dpc-3630	265	3	neurol	neurol	PROPN
dpc-3630	265	4	.	.	PUNCT
dpc-3630	266	1	2009;16(4):e78	2009;16(4):e78	NUM
dpc-3630	266	2	-	-	SYM
dpc-3630	266	3	9	9	NUM
dpc-3630	266	4	.	.	PUNCT
dpc-3630	266	5	doi	doi	NOUN
dpc-3630	266	6	:	:	PUNCT
dpc-3630	266	7	10.1111	10.1111	NUM
dpc-3630	266	8	/	/	SYM
dpc-3630	266	9	j.1468	j.1468	NOUN
dpc-3630	266	10	-	-	PUNCT
dpc-3630	266	11	1331	1331	NUM
dpc-3630	266	12	.2009.02563.x	.2009.02563.x	PROPN
dpc-3630	266	13	.	.	PUNCT
dpc-3630	267	1	pmid	pmid	NOUN
dpc-3630	267	2	:	:	PUNCT
dpc-3630	267	3	19222549	19222549	NUM
dpc-3630	267	4	cross	cross	ADJ
dpc-3630	267	5	-	-	ADJ
dpc-3630	267	6	sectional	sectional	ADJ
dpc-3630	267	7	study	study	NOUN
dpc-3630	267	8	.	.	PUNCT
dpc-3630	268	1	j	j	PROPN
dpc-3630	268	2	am	be	AUX
dpc-3630	268	3	acad	acad	ADJ
dpc-3630	268	4	dermatol	dermatol	NOUN
dpc-3630	268	5	.	.	PUNCT
dpc-3630	269	1	2016;74(2):295	2016;74(2):295	NUM
dpc-3630	269	2	-	-	SYM
dpc-3630	269	3	302	302	NUM
dpc-3630	269	4	.	.	PUNCT
dpc-3630	270	1	doi	doi	NOUN
dpc-3630	270	2	:	:	PUNCT
dpc-3630	270	3	10.1016	10.1016	NUM
dpc-3630	270	4	/	/	SYM
dpc-3630	270	5	j.jaad.2015.08.063	j.jaad.2015.08.063	PROPN
dpc-3630	270	6	.	.	PUNCT
dpc-3630	271	1	pmid	pmid	NOUN
dpc-3630	271	2	:	:	PUNCT
dpc-3630	271	3	26518171	26518171	NUM
dpc-3630	271	4	.	.	PUNCT
dpc-3630	272	1	6	6	NUM
dpc-3630	272	2	.	.	X
dpc-3630	272	3	shen	shen	PROPN
dpc-3630	272	4	mh	mh	PROPN
dpc-3630	272	5	,	,	PUNCT
dpc-3630	272	6	ng	ng	PROPN
dpc-3630	272	7	cy	cy	PROPN
dpc-3630	272	8	,	,	PUNCT
dpc-3630	272	9	chang	chang	PROPN
dpc-3630	272	10	kh	kh	PROPN
dpc-3630	272	11	,	,	PUNCT
dpc-3630	272	12	chi	chi	PROPN
dpc-3630	272	13	cc	cc	PROPN
dpc-3630	272	14	.	.	PROPN
dpc-3630	272	15	association	association	NOUN
dpc-3630	272	16	of	of	ADP
dpc-3630	272	17	multiple	multiple	ADJ
dpc-3630	272	18	sclerosis	sclerosis	NOUN
dpc-3630	272	19	with	with	ADP
dpc-3630	272	20	vitiligo	vitiligo	NOUN
dpc-3630	272	21	:	:	PUNCT
dpc-3630	272	22	a	a	DET
dpc-3630	272	23	systematic	systematic	ADJ
dpc-3630	272	24	review	review	NOUN
dpc-3630	272	25	and	and	CCONJ
dpc-3630	272	26	meta	meta	ADJ
dpc-3630	272	27	-	-	PUNCT
dpc-3630	272	28	analysis	analysis	NOUN
dpc-3630	272	29	.	.	PUNCT
dpc-3630	273	1	sci	sci	PROPN
dpc-3630	273	2	rep	rep	PROPN
dpc-3630	273	3	.	.	PROPN
dpc-3630	273	4	2020;10(1):1	2020;10(1):1	NUM
dpc-3630	273	5	-	-	SYM
dpc-3630	273	6	7	7	NUM
dpc-3630	273	7	.	.	PUNCT
dpc-3630	273	8	doi	doi	NOUN
dpc-3630	273	9	:	:	PUNCT
dpc-3630	273	10	10.1038	10.1038	NUM
dpc-3630	273	11	/	/	SYM
dpc-3630	273	12	s41598	s41598	NOUN
dpc-3630	273	13	-	-	PUNCT
dpc-3630	273	14	020	020	NUM
dpc-3630	273	15	-	-	PUNCT
dpc-3630	273	16	74298	74298	NUM
dpc-3630	273	17	-	-	SYM
dpc-3630	273	18	0	0	NUM
dpc-3630	273	19	.	.	PUNCT
dpc-3630	274	1	pmid	pmid	NOUN
dpc-3630	274	2	:	:	PUNCT
dpc-3630	274	3	33082449	33082449	NUM
dpc-3630	274	4	.	.	PUNCT
dpc-3630	275	1	pmcid	pmcid	ADJ
dpc-3630	275	2	:	:	PUNCT
dpc-3630	275	3	pmc7575608	pmc7575608	NOUN
dpc-3630	275	4	.	.	PUNCT
dpc-3630	276	1	7	7	X
dpc-3630	276	2	.	.	X
dpc-3630	276	3	hadi	hadi	PROPN
dpc-3630	276	4	a	a	PROPN
dpc-3630	276	5	,	,	PUNCT
dpc-3630	276	6	wang	wang	PROPN
dpc-3630	276	7	jf	jf	PROPN
dpc-3630	276	8	,	,	PUNCT
dpc-3630	276	9	uppal	uppal	PROPN
dpc-3630	276	10	p	p	PROPN
dpc-3630	276	11	,	,	PUNCT
dpc-3630	276	12	penn	penn	PROPN
dpc-3630	276	13	la	la	PROPN
dpc-3630	276	14	,	,	PUNCT
dpc-3630	276	15	elbuluk	elbuluk	PROPN
dpc-3630	276	16	n.	n.	PROPN
dpc-3630	276	17	comorbid	comorbid	NOUN
dpc-3630	276	18	diseases	disease	NOUN
dpc-3630	276	19	of	of	ADP
dpc-3630	276	20	vitiligo	vitiligo	NOUN
dpc-3630	276	21	:	:	PUNCT
dpc-3630	276	22	a	a	DET
dpc-3630	276	23	10	10	NUM
dpc-3630	276	24	-	-	PUNCT
dpc-3630	276	25	year	year	NOUN
dpc-3630	276	26	cross	cross	ADJ
dpc-3630	276	27	-	-	ADJ
dpc-3630	276	28	sectional	sectional	ADJ
dpc-3630	276	29	retrospective	retrospective	ADJ
dpc-3630	276	30	study	study	NOUN
dpc-3630	276	31	of	of	ADP
dpc-3630	276	32	an	an	DET
dpc-3630	276	33	urban	urban	ADJ
dpc-3630	276	34	us	us	PROPN
dpc-3630	276	35	population	population	NOUN
dpc-3630	276	36	.	.	PUNCT
dpc-3630	277	1	j	j	PROPN
dpc-3630	277	2	am	be	AUX
dpc-3630	277	3	acad	acad	ADJ
dpc-3630	277	4	dermatol	dermatol	NOUN
dpc-3630	277	5	.	.	PUNCT
dpc-3630	278	1	2020;82(3	2020;82(3	NUM
dpc-3630	278	2	):	):	PUNCT
dpc-3630	278	3	628	628	NUM
dpc-3630	278	4	-	-	SYM
dpc-3630	278	5	633	633	NUM
dpc-3630	278	6	.	.	PUNCT
dpc-3630	279	1	doi	doi	NOUN
dpc-3630	279	2	:	:	PUNCT
dpc-3630	279	3	10.1016	10.1016	NUM
dpc-3630	279	4	/	/	SYM
dpc-3630	279	5	j.jaad.2019.07.036	j.jaad.2019.07.036	PROPN
dpc-3630	279	6	.	.	PUNCT
dpc-3630	280	1	pmid	pmid	NOUN
dpc-3630	280	2	:	:	PUNCT
dpc-3630	280	3	31325552	31325552	NUM
dpc-3630	280	4	.	.	PUNCT
dpc-3630	281	1	8	8	NUM
dpc-3630	281	2	.	.	X
dpc-3630	281	3	ruck	ruck	PROPN
dpc-3630	281	4	t	t	PROPN
dpc-3630	281	5	,	,	PUNCT
dpc-3630	281	6	pfeuffer	pfeuffer	NOUN
dpc-3630	281	7	s	s	PROPN
dpc-3630	281	8	,	,	PUNCT
dpc-3630	281	9	schulte	schulte	PROPN
dpc-3630	281	10	-	-	PUNCT
dpc-3630	281	11	mecklenbeck	mecklenbeck	PROPN
dpc-3630	281	12	a	a	PROPN
dpc-3630	281	13	,	,	PUNCT
dpc-3630	281	14	et	et	PROPN
dpc-3630	281	15	al	al	PROPN
dpc-3630	281	16	.	.	PROPN
dpc-3630	281	17	vitiligo	vitiligo	PROPN
dpc-3630	281	18	after	after	ADP
dpc-3630	281	19	alemtuzumab	alemtuzumab	NOUN
dpc-3630	281	20	treatment	treatment	NOUN
dpc-3630	281	21	:	:	PUNCT
dpc-3630	281	22	secondary	secondary	ADJ
dpc-3630	281	23	autoimmunity	autoimmunity	NOUN
dpc-3630	281	24	is	be	AUX
dpc-3630	281	25	not	not	PART
dpc-3630	281	26	all	all	ADV
dpc-3630	281	27	about	about	ADP
dpc-3630	281	28	b	b	NOUN
dpc-3630	281	29	cells	cell	NOUN
dpc-3630	281	30	.	.	PUNCT
dpc-3630	282	1	neurology	neurology	NOUN
dpc-3630	282	2	.	.	PUNCT
dpc-3630	283	1	2018;91(24):e2233	2018;91(24):e2233	PROPN
dpc-3630	283	2	-	-	PUNCT
dpc-3630	283	3	e2237	e2237	PROPN
dpc-3630	283	4	.	.	PUNCT
dpc-3630	283	5	doi	doi	PROPN
dpc-3630	283	6	:	:	PUNCT
dpc-3630	283	7	10.1212	10.1212	NUM
dpc-3630	283	8	/	/	SYM
dpc-3630	283	9	wnl.0000000000006648	wnl.0000000000006648	PROPN
dpc-3630	283	10	.	.	PUNCT
dpc-3630	284	1	pmid	pmid	NOUN
dpc-3630	284	2	:	:	PUNCT
dpc-3630	284	3	30404783	30404783	NUM
dpc-3630	284	4	.	.	PUNCT
dpc-3630	285	1	pmcid	pmcid	NOUN
dpc-3630	285	2	:	:	PUNCT
dpc-3630	285	3	pmc6329330	pmc6329330	PROPN
dpc-3630	285	4	.	.	PUNCT
dpc-3630	286	1	9	9	X
dpc-3630	286	2	.	.	X
dpc-3630	287	1	silverberg	silverberg	PROPN
dpc-3630	287	2	ji	ji	PROPN
dpc-3630	287	3	,	,	PUNCT
dpc-3630	287	4	silverberg	silverberg	PROPN
dpc-3630	287	5	nb	nb	PROPN
dpc-3630	287	6	.	.	PUNCT
dpc-3630	288	1	clinical	clinical	ADJ
dpc-3630	288	2	features	feature	NOUN
dpc-3630	288	3	of	of	ADP
dpc-3630	288	4	vitiligo	vitiligo	NOUN
dpc-3630	288	5	associated	associate	VERB
dpc-3630	288	6	with	with	ADP
dpc-3630	288	7	comorbid	comorbid	NOUN
dpc-3630	288	8	autoimmune	autoimmune	ADJ
dpc-3630	288	9	disease	disease	NOUN
dpc-3630	288	10	:	:	PUNCT
dpc-3630	288	11	a	a	DET
dpc-3630	288	12	prospective	prospective	ADJ
dpc-3630	288	13	survey	survey	NOUN
dpc-3630	288	14	.	.	PUNCT
dpc-3630	289	1	j	j	PROPN
dpc-3630	289	2	am	be	AUX
dpc-3630	289	3	acad	acad	ADJ
dpc-3630	289	4	dermatol	dermatol	NOUN
dpc-3630	289	5	.	.	PUNCT
dpc-3630	290	1	2013;69(5):824	2013;69(5):824	NUM
dpc-3630	290	2	-	-	PUNCT
dpc-3630	290	3	826	826	NUM
dpc-3630	290	4	.	.	PUNCT
dpc-3630	291	1	doi	doi	NOUN
dpc-3630	291	2	:	:	PUNCT
dpc-3630	291	3	10.1016	10.1016	NUM
dpc-3630	291	4	/	/	SYM
dpc-3630	291	5	j.jaad	j.jaad	PROPN
dpc-3630	291	6	.2013.04.050	.2013.04.050	PROPN
dpc-3630	291	7	.	.	PUNCT
dpc-3630	292	1	pmid	pmid	NOUN
dpc-3630	292	2	:	:	PUNCT
dpc-3630	292	3	24124820	24124820	NUM
dpc-3630	292	4	.	.	PUNCT
dpc-3630	293	1	10	10	NUM
dpc-3630	293	2	.	.	PUNCT
dpc-3630	293	3	amini	amini	PROPN
dpc-3630	293	4	p	p	PROPN
dpc-3630	293	5	,	,	PUNCT
dpc-3630	293	6	almasi	almasi	NOUN
dpc-3630	293	7	-	-	PUNCT
dpc-3630	293	8	hashiani	hashiani	NOUN
dpc-3630	293	9	a	a	NOUN
dpc-3630	293	10	,	,	PUNCT
dpc-3630	293	11	sahraian	sahraian	PROPN
dpc-3630	293	12	ma	ma	PROPN
dpc-3630	293	13	,	,	PUNCT
dpc-3630	293	14	najafi	najafi	PROPN
dpc-3630	293	15	m	m	PRON
dpc-3630	293	16	,	,	PUNCT
dpc-3630	293	17	eskandarieh	eskandarieh	PROPN
dpc-3630	293	18	s.	s.	PROPN
dpc-3630	293	19	multiple	multiple	PROPN
dpc-3630	293	20	sclerosis	sclerosis	NOUN
dpc-3630	293	21	projection	projection	NOUN
dpc-3630	293	22	in	in	ADP
dpc-3630	293	23	tehran	tehran	PROPN
dpc-3630	293	24	,	,	PUNCT
dpc-3630	293	25	iran	iran	PROPN
dpc-3630	293	26	using	use	VERB
dpc-3630	293	27	bayesian	bayesian	NOUN
dpc-3630	293	28	structural	structural	ADJ
dpc-3630	293	29	time	time	NOUN
dpc-3630	293	30	series	series	PROPN
dpc-3630	293	31	.	.	PUNCT
dpc-3630	294	1	bmc	bmc	PROPN
dpc-3630	294	2	neurol	neurol	NOUN
dpc-3630	294	3	.	.	PUNCT
dpc-3630	295	1	2021;21(1):1	2021;21(1):1	NUM
dpc-3630	295	2	-	-	PUNCT
dpc-3630	295	3	6	6	NUM
dpc-3630	295	4	.	.	PUNCT
dpc-3630	295	5	doi	doi	NOUN
dpc-3630	295	6	:	:	PUNCT
dpc-3630	295	7	10.1186	10.1186	NUM
dpc-3630	295	8	/	/	SYM
dpc-3630	295	9	s12883	s12883	NOUN
dpc-3630	295	10	-	-	PUNCT
dpc-3630	295	11	021	021	NUM
dpc-3630	295	12	-	-	PUNCT
dpc-3630	295	13	02281	02281	NUM
dpc-3630	295	14	-	-	PUNCT
dpc-3630	295	15	x.	x.	NOUN
dpc-3630	295	16	pmid	pmid	PROPN
dpc-3630	295	17	:	:	PUNCT
dpc-3630	295	18	34167483	34167483	NUM
dpc-3630	295	19	pmcid	pmcid	NOUN
dpc-3630	295	20	:	:	PUNCT
dpc-3630	295	21	pmc8223333	pmc8223333	NOUN
dpc-3630	295	22	.	.	PUNCT
dpc-3630	296	1	11	11	NUM
dpc-3630	296	2	.	.	X
dpc-3630	296	3	kundu	kundu	NOUN
dpc-3630	296	4	r	r	PROPN
dpc-3630	296	5	v	v	NOUN
dpc-3630	296	6	,	,	PUNCT
dpc-3630	296	7	mhlaba	mhlaba	PROPN
dpc-3630	296	8	jm	jm	PROPN
dpc-3630	296	9	,	,	PUNCT
dpc-3630	296	10	rangel	rangel	PROPN
dpc-3630	296	11	sm	sm	PROPN
dpc-3630	296	12	,	,	PUNCT
dpc-3630	296	13	le	le	PROPN
dpc-3630	296	14	poole	poole	PROPN
dpc-3630	296	15	ic	ic	PROPN
dpc-3630	296	16	.	.	PUNCT
dpc-3630	297	1	the	the	DET
dpc-3630	297	2	convergence	convergence	NOUN
dpc-3630	297	3	theory	theory	NOUN
dpc-3630	297	4	for	for	ADP
dpc-3630	297	5	vitiligo	vitiligo	NOUN
dpc-3630	297	6	:	:	PUNCT
dpc-3630	297	7	a	a	DET
dpc-3630	297	8	reappraisal	reappraisal	NOUN
dpc-3630	297	9	.	.	PUNCT
dpc-3630	298	1	exp	exp	NOUN
dpc-3630	298	2	dermatol	dermatol	NOUN
dpc-3630	298	3	.	.	PUNCT
dpc-3630	299	1	2019;28(6	2019;28(6	NUM
dpc-3630	299	2	):	):	PUNCT
dpc-3630	300	1	647	647	NUM
dpc-3630	300	2	-	-	SYM
dpc-3630	300	3	655	655	NUM
dpc-3630	300	4	.	.	PUNCT
dpc-3630	300	5	doi	doi	NOUN
dpc-3630	300	6	:	:	PUNCT
dpc-3630	300	7	10.1111	10.1111	NUM
dpc-3630	300	8	/	/	SYM
dpc-3630	300	9	exd.13677	exd.13677	PROPN
dpc-3630	300	10	.	.	PUNCT
dpc-3630	301	1	pmid	pmid	NOUN
dpc-3630	301	2	:	:	PUNCT
dpc-3630	301	3	29704874	29704874	NUM
dpc-3630	301	4	.	.	PUNCT
dpc-3630	302	1	pmcid	pmcid	ADJ
dpc-3630	302	2	:	:	PUNCT
dpc-3630	302	3	pmc6204319	pmc6204319	NOUN
dpc-3630	302	4	.	.	PUNCT
dpc-3630	303	1	12	12	NUM
dpc-3630	303	2	.	.	PUNCT
dpc-3630	304	1	al	al	PROPN
dpc-3630	304	2	abadie	abadie	PROPN
dpc-3630	304	3	ms	ms	PROPN
dpc-3630	304	4	,	,	PUNCT
dpc-3630	304	5	gawkrodger	gawkrodger	NOUN
dpc-3630	304	6	dj	dj	PROPN
dpc-3630	304	7	.	.	PUNCT
dpc-3630	305	1	integrating	integrate	VERB
dpc-3630	305	2	neuronal	neuronal	ADJ
dpc-3630	305	3	involvement	involvement	NOUN
dpc-3630	305	4	into	into	ADP
dpc-3630	305	5	the	the	DET
dpc-3630	305	6	immune	immune	ADJ
dpc-3630	305	7	and	and	CCONJ
dpc-3630	305	8	genetic	genetic	ADJ
dpc-3630	305	9	paradigm	paradigm	NOUN
dpc-3630	305	10	of	of	ADP
dpc-3630	305	11	vitiligo	vitiligo	PROPN
dpc-3630	305	12	.	.	PUNCT
dpc-3630	306	1	clin	clin	PROPN
dpc-3630	306	2	exp	exp	NOUN
dpc-3630	306	3	dermatol	dermatol	NOUN
dpc-3630	306	4	.	.	PUNCT
dpc-3630	307	1	2021;46(4):646	2021;46(4):646	NUM
dpc-3630	307	2	-	-	SYM
dpc-3630	307	3	650	650	NUM
dpc-3630	307	4	.	.	PUNCT
dpc-3630	308	1	doi	doi	NOUN
dpc-3630	308	2	:	:	PUNCT
dpc-3630	308	3	10.1111	10.1111	NUM
dpc-3630	308	4	/	/	SYM
dpc-3630	308	5	ced.14490	ced.14490	NUM
dpc-3630	308	6	.	.	PUNCT
dpc-3630	309	1	pmid	pmid	NOUN
dpc-3630	309	2	:	:	PUNCT
dpc-3630	309	3	33098692	33098692	NUM
dpc-3630	309	4	.	.	PUNCT
dpc-3630	310	1	13	13	NUM
dpc-3630	310	2	.	.	PUNCT
dpc-3630	310	3	lotti	lotti	PROPN
dpc-3630	310	4	t	t	PROPN
dpc-3630	310	5	,	,	PUNCT
dpc-3630	310	6	d’erme	d’erme	PROPN
dpc-3630	310	7	am	be	AUX
dpc-3630	310	8	,	,	PUNCT
dpc-3630	310	9	hercogová	hercogová	PROPN
dpc-3630	310	10	j.	j.	PROPN
dpc-3630	310	11	the	the	DET
dpc-3630	310	12	role	role	NOUN
dpc-3630	310	13	of	of	ADP
dpc-3630	310	14	neuropeptides	neuropeptide	NOUN
dpc-3630	310	15	in	in	ADP
dpc-3630	310	16	the	the	DET
dpc-3630	310	17	control	control	NOUN
dpc-3630	310	18	of	of	ADP
dpc-3630	310	19	regional	regional	ADJ
dpc-3630	310	20	immunity	immunity	NOUN
dpc-3630	310	21	.	.	PUNCT
dpc-3630	311	1	clin	clin	PROPN
dpc-3630	311	2	dermatol	dermatol	NOUN
dpc-3630	311	3	.	.	PUNCT
dpc-3630	312	1	2014;32(5):633	2014;32(5):633	NUM
dpc-3630	312	2	-	-	SYM
dpc-3630	312	3	645	645	NUM
dpc-3630	312	4	.	.	PUNCT
dpc-3630	313	1	doi	doi	NOUN
dpc-3630	313	2	:	:	PUNCT
dpc-3630	313	3	10.1016	10.1016	NUM
dpc-3630	313	4	/	/	SYM
dpc-3630	313	5	j.clindermatol.2014.04.011	j.clindermatol.2014.04.011	PROPN
dpc-3630	313	6	.	.	PUNCT
dpc-3630	314	1	pmid	pmid	NOUN
dpc-3630	314	2	:	:	PUNCT
dpc-3630	314	3	25160105	25160105	NUM
dpc-3630	314	4	.	.	PUNCT
dpc-3630	315	1	14	14	NUM
dpc-3630	315	2	.	.	PUNCT
dpc-3630	316	1	gauthier	gauthier	PROPN
dpc-3630	316	2	y	y	PROPN
dpc-3630	316	3	,	,	PUNCT
dpc-3630	316	4	benzekri	benzekri	PROPN
dpc-3630	316	5	l.	l.	PROPN
dpc-3630	316	6	the	the	DET
dpc-3630	316	7	neurogenic	neurogenic	ADJ
dpc-3630	316	8	hypothesis	hypothesis	NOUN
dpc-3630	316	9	in	in	ADP
dpc-3630	316	10	segmental	segmental	ADJ
dpc-3630	316	11	vitiligo	vitiligo	NOUN
dpc-3630	316	12	.	.	PUNCT
dpc-3630	317	1	in	in	ADP
dpc-3630	317	2	:	:	PUNCT
dpc-3630	317	3	vitiligo	vitiligo	VERB
dpc-3630	317	4	.	.	PUNCT
dpc-3630	317	5	springer	springer	NOUN
dpc-3630	317	6	;	;	PUNCT
dpc-3630	317	7	2010:302	2010:302	NUM
dpc-3630	317	8	-	-	SYM
dpc-3630	317	9	305	305	NUM
dpc-3630	317	10	.	.	PUNCT
dpc-3630	317	11	15	15	NUM
dpc-3630	317	12	.	.	PUNCT
dpc-3630	317	13	tegta	tegta	PROPN
dpc-3630	317	14	gr	gr	PROPN
dpc-3630	317	15	,	,	PUNCT
dpc-3630	317	16	thakur	thakur	PROPN
dpc-3630	317	17	s	s	PROPN
dpc-3630	317	18	,	,	PUNCT
dpc-3630	317	19	negi	negi	PROPN
dpc-3630	317	20	a	a	PROPN
dpc-3630	317	21	,	,	PUNCT
dpc-3630	317	22	verma	verma	PROPN
dpc-3630	317	23	g	g	PROPN
dpc-3630	317	24	,	,	PUNCT
dpc-3630	317	25	gupta	gupta	PROPN
dpc-3630	317	26	m	m	PROPN
dpc-3630	317	27	,	,	PUNCT
dpc-3630	317	28	verma	verma	PROPN
dpc-3630	317	29	k.	k.	PROPN
dpc-3630	317	30	von	von	PROPN
dpc-3630	317	31	recklinghausen	recklinghausen	PROPN
dpc-3630	317	32	disease	disease	NOUN
dpc-3630	317	33	with	with	ADP
dpc-3630	317	34	vitiligo	vitiligo	NOUN
dpc-3630	317	35	:	:	PUNCT
dpc-3630	317	36	a	a	DET
dpc-3630	317	37	rare	rare	ADJ
dpc-3630	317	38	association	association	NOUN
dpc-3630	317	39	.	.	PUNCT
dpc-3630	318	1	16	16	NUM
dpc-3630	318	2	.	.	PUNCT
dpc-3630	318	3	deretzi	deretzi	VERB
dpc-3630	318	4	g	g	NOUN
dpc-3630	318	5	,	,	PUNCT
dpc-3630	318	6	kountouras	kountouras	PROPN
dpc-3630	318	7	j	j	PROPN
dpc-3630	318	8	,	,	PUNCT
dpc-3630	318	9	polyzos	polyzos	PROPN
dpc-3630	318	10	sa	sa	PROPN
dpc-3630	318	11	,	,	PUNCT
dpc-3630	318	12	et	et	PROPN
dpc-3630	318	13	al	al	PROPN
dpc-3630	318	14	.	.	PROPN
dpc-3630	318	15	polyautoimmunity	polyautoimmunity	NOUN
dpc-3630	318	16	in	in	ADP
dpc-3630	318	17	a	a	DET
dpc-3630	318	18	greek	greek	ADJ
dpc-3630	318	19	cohort	cohort	NOUN
dpc-3630	318	20	of	of	ADP
dpc-3630	318	21	multiple	multiple	ADJ
dpc-3630	318	22	sclerosis	sclerosis	NOUN
dpc-3630	318	23	.	.	PUNCT
dpc-3630	319	1	acta	acta	PROPN
dpc-3630	319	2	neurol	neurol	PROPN
dpc-3630	319	3	scand	scand	PROPN
dpc-3630	319	4	.	.	PUNCT
dpc-3630	320	1	2015;131(4):225	2015;131(4):225	NUM
dpc-3630	320	2	-	-	SYM
dpc-3630	320	3	230	230	NUM
dpc-3630	320	4	.	.	PUNCT
dpc-3630	321	1	doi	doi	NOUN
dpc-3630	321	2	:	:	PUNCT
dpc-3630	321	3	10.1111	10.1111	NUM
dpc-3630	321	4	/	/	SYM
dpc-3630	321	5	ane.12308	ane.12308	PROPN
dpc-3630	321	6	.	.	PUNCT
dpc-3630	322	1	pmid	pmid	NOUN
dpc-3630	322	2	:	:	PUNCT
dpc-3630	322	3	25270060	25270060	NUM
dpc-3630	322	4	.	.	PUNCT
dpc-3630	323	1	17	17	NUM
dpc-3630	323	2	.	.	PUNCT
dpc-3630	323	3	kriegel	kriegel	PROPN
dpc-3630	323	4	ma	ma	PROPN
dpc-3630	323	5	,	,	PUNCT
dpc-3630	323	6	manson	manson	PROPN
dpc-3630	323	7	je	je	PROPN
dpc-3630	323	8	,	,	PUNCT
dpc-3630	323	9	costenbader	costenbader	PROPN
dpc-3630	323	10	kh	kh	PROPN
dpc-3630	323	11	.	.	PROPN
dpc-3630	323	12	does	do	AUX
dpc-3630	323	13	vitamin	vitamin	NOUN
dpc-3630	323	14	d	d	NOUN
dpc-3630	323	15	affect	affect	VERB
dpc-3630	323	16	risk	risk	NOUN
dpc-3630	323	17	of	of	ADP
dpc-3630	323	18	developing	develop	VERB
dpc-3630	323	19	autoimmune	autoimmune	ADJ
dpc-3630	323	20	disease	disease	NOUN
dpc-3630	323	21	?	?	PUNCT
dpc-3630	323	22	:	:	PUNCT
dpc-3630	323	23	a	a	DET
dpc-3630	323	24	systematic	systematic	ADJ
dpc-3630	323	25	review	review	NOUN
dpc-3630	323	26	.	.	PUNCT
dpc-3630	324	1	in	in	ADP
dpc-3630	324	2	:	:	PUNCT
dpc-3630	324	3	seminars	seminar	NOUN
dpc-3630	324	4	in	in	ADP
dpc-3630	324	5	arthritis	arthritis	NOUN
dpc-3630	324	6	and	and	CCONJ
dpc-3630	324	7	rheumatism	rheumatism	NOUN
dpc-3630	324	8	.	.	PUNCT
dpc-3630	325	1	vol	vol	NOUN
dpc-3630	325	2	40	40	NUM
dpc-3630	325	3	.	.	PUNCT
dpc-3630	326	1	elsevier	elsevier	NOUN
dpc-3630	326	2	;	;	PUNCT
dpc-3630	326	3	2011:512	2011:512	NUM
dpc-3630	326	4	-	-	SYM
dpc-3630	326	5	531	531	NUM
dpc-3630	326	6	.	.	PUNCT
dpc-3630	327	1	doi	doi	NOUN
dpc-3630	327	2	:	:	PUNCT
dpc-3630	327	3	10.1016	10.1016	NUM
dpc-3630	327	4	/	/	SYM
dpc-3630	327	5	j.semarthrit.2010.07.009	j.semarthrit.2010.07.009	PROPN
dpc-3630	327	6	.	.	PUNCT
dpc-3630	328	1	pmid	pmid	NOUN
dpc-3630	328	2	:	:	PUNCT
dpc-3630	328	3	21047669	21047669	NUM
dpc-3630	328	4	.	.	PUNCT
dpc-3630	329	1	pmcid	pmcid	NOUN
dpc-3630	329	2	:	:	PUNCT
dpc-3630	329	3	pmc3098920	pmc3098920	NOUN
dpc-3630	329	4	.	.	PUNCT
dpc-3630	330	1	18	18	NUM
dpc-3630	330	2	.	.	X
dpc-3630	330	3	harris	harris	PROPN
dpc-3630	330	4	je	je	PROPN
dpc-3630	330	5	.	.	PUNCT
dpc-3630	330	6	cellular	cellular	ADJ
dpc-3630	330	7	stress	stress	NOUN
dpc-3630	330	8	and	and	CCONJ
dpc-3630	330	9	innate	innate	ADJ
dpc-3630	330	10	inflammation	inflammation	NOUN
dpc-3630	330	11	in	in	ADP
dpc-3630	330	12	organ‐	organ‐	NOUN
dpc-3630	330	13	specific	specific	ADJ
dpc-3630	330	14	autoimmunity	autoimmunity	NOUN
dpc-3630	330	15	:	:	PUNCT
dpc-3630	330	16	lessons	lesson	NOUN
dpc-3630	330	17	learned	learn	VERB
dpc-3630	330	18	from	from	ADP
dpc-3630	330	19	vitiligo	vitiligo	PROPN
dpc-3630	330	20	.	.	PUNCT
dpc-3630	331	1	immunol	immunol	PROPN
dpc-3630	331	2	rev	rev	PROPN
dpc-3630	331	3	.	.	PROPN
dpc-3630	331	4	2016;269(1):11	2016;269(1):11	PROPN
dpc-3630	331	5	-	-	SYM
dpc-3630	331	6	25	25	NUM
dpc-3630	331	7	.	.	PUNCT
dpc-3630	332	1	doi	doi	NOUN
dpc-3630	332	2	:	:	PUNCT
dpc-3630	332	3	10.1111	10.1111	NUM
dpc-3630	332	4	/	/	SYM
dpc-3630	332	5	imr.12369	imr.12369	PROPN
dpc-3630	332	6	.	.	PUNCT
dpc-3630	333	1	pmid	pmid	NOUN
dpc-3630	333	2	:	:	PUNCT
dpc-3630	333	3	26683142	26683142	NUM
dpc-3630	333	4	.	.	PUNCT
dpc-3630	334	1	pmcid	pmcid	NOUN
dpc-3630	334	2	:	:	PUNCT
dpc-3630	334	3	pmc4685729	pmc4685729	VERB
dpc-3630	334	4	.	.	PUNCT
dpc-3630	335	1	19	19	NUM
dpc-3630	335	2	.	.	X
dpc-3630	335	3	zarobkiewicz	zarobkiewicz	PROPN
dpc-3630	335	4	mk	mk	PROPN
dpc-3630	335	5	,	,	PUNCT
dpc-3630	335	6	kowalska	kowalska	PROPN
dpc-3630	335	7	w	w	PROPN
dpc-3630	335	8	,	,	PUNCT
dpc-3630	335	9	morawska	morawska	PROPN
dpc-3630	335	10	i	i	PRON
dpc-3630	335	11	,	,	PUNCT
dpc-3630	335	12	halczuk	halczuk	PROPN
dpc-3630	335	13	p	p	NOUN
dpc-3630	335	14	,	,	PUNCT
dpc-3630	335	15	rejdak	rejdak	PROPN
dpc-3630	335	16	k	k	PROPN
dpc-3630	335	17	,	,	PUNCT
dpc-3630	335	18	bojarska	bojarska	PROPN
dpc-3630	335	19	-	-	PUNCT
dpc-3630	335	20	junak	junak	PROPN
dpc-3630	335	21	a.	a.	PROPN
dpc-3630	335	22	il-15	il-15	PUNCT
dpc-3630	335	23	is	be	AUX
dpc-3630	335	24	overexpressed	overexpresse	VERB
dpc-3630	335	25	in	in	ADP
dpc-3630	335	26	γδ	γδ	ADP
dpc-3630	335	27	t	t	NOUN
dpc-3630	335	28	cells	cell	NOUN
dpc-3630	335	29	and	and	CCONJ
dpc-3630	335	30	correlates	correlate	VERB
dpc-3630	335	31	with	with	ADP
dpc-3630	335	32	disease	disease	NOUN
dpc-3630	335	33	severity	severity	NOUN
dpc-3630	335	34	in	in	ADP
dpc-3630	335	35	relapsing	relapse	VERB
dpc-3630	335	36	-	-	PUNCT
dpc-3630	335	37	remitting	remit	VERB
dpc-3630	335	38	multiple	multiple	ADJ
dpc-3630	335	39	sclerosis	sclerosis	NOUN
dpc-3630	335	40	.	.	PUNCT
dpc-3630	336	1	j	j	PROPN
dpc-3630	336	2	clin	clin	PROPN
dpc-3630	336	3	med	med	PROPN
dpc-3630	336	4	.	.	PUNCT
dpc-3630	337	1	2021;10(18):4174	2021;10(18):4174	X
dpc-3630	337	2	.	.	PUNCT
dpc-3630	337	3	doi	doi	PROPN
dpc-3630	337	4	:	:	PUNCT
dpc-3630	337	5	10.3390/	10.3390/	NUM
dpc-3630	337	6	jcm10184174	jcm10184174	NOUN
dpc-3630	337	7	.	.	PUNCT
dpc-3630	338	1	pmid	pmid	NOUN
dpc-3630	338	2	:	:	PUNCT
dpc-3630	338	3	34575283	34575283	NUM
dpc-3630	338	4	.	.	PUNCT
dpc-3630	339	1	pmcid	pmcid	ADJ
dpc-3630	339	2	:	:	PUNCT
dpc-3630	339	3	pmc8467081	pmc8467081	NOUN
dpc-3630	339	4	.	.	PUNCT
dpc-3630	340	1	20	20	NUM
dpc-3630	340	2	.	.	PUNCT
dpc-3630	340	3	tokura	tokura	PROPN
dpc-3630	340	4	y	y	PROPN
dpc-3630	340	5	,	,	PUNCT
dpc-3630	340	6	phadungsaksawasdi	phadungsaksawasdi	NOUN
dpc-3630	340	7	p	p	X
dpc-3630	340	8	,	,	PUNCT
dpc-3630	340	9	kurihara	kurihara	ADJ
dpc-3630	340	10	k	k	X
dpc-3630	340	11	,	,	PUNCT
dpc-3630	340	12	fujiyama	fujiyama	PROPN
dpc-3630	340	13	t	t	PROPN
dpc-3630	340	14	,	,	PUNCT
dpc-3630	340	15	honda	honda	NOUN
dpc-3630	340	16	t.	t.	PROPN
dpc-3630	340	17	pathophysiology	pathophysiology	NOUN
dpc-3630	340	18	of	of	ADP
dpc-3630	340	19	skin	skin	NOUN
dpc-3630	340	20	resident	resident	NOUN
dpc-3630	340	21	memory	memory	NOUN
dpc-3630	340	22	t	t	PROPN
dpc-3630	340	23	cells	cell	NOUN
dpc-3630	340	24	.	.	PUNCT
dpc-3630	341	1	front	front	NOUN